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Chapter 1 
General introduction 
 
 
 
Part of the following chapter is intended for publication:  
 
Julia Christina Kasper, Wolfgang Friess 
Recent advances and further challenges in lyophilization, in preparation.   
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Abstract 
While entering a new century, lyophilization in the pharmaceutical field has 
been subjected to ongoing development and steady expansion. This chapter 
aims to highlight recent advances but also to discuss further challenges in 
lyophilization.  
At first, the three major steps of a typical lyophilization process, namely 
freezing, primary drying, and secondary drying, are described in brief. 
Additionally, a general description of the essential components and their 
function in a lyophilizer is given. 
With respect to recent advances in lyophilization, the expanded range of 
pharmaceutical applications based on lyophilization is summarized. Moreover, 
novel formulation aspects and novel container systems are discussed and the 
importance of the freezing step is outlined. Furthermore, the dogma of “ never 
lyophilizing above the glass transition temperature”  is argued and recent 
insights into novel stabilization concepts are provided. Process analytical 
technology (PAT) and quality by design (QbD) are now leading issues and the 
design of the lyophilization equipment might have to be reconsidered in the 
future.  
Nowadays, lyophilization has also gained importance for the preservation of 
nucleic acid based pharmaceuticals. In that context, a brief overview on the 
basic concepts of pDNA and siRNA delivery in gene therapy is given and the 
need for lyophilized long-term stable formulations is accentuated. Additionally, 
currently available literature on the lyophilization of nucleic acid nanoparticles is 
reviewed in brief.  
 
Keywords 
Lyophilization, freeze-drying, gene therapy, pDNA and siRNA delivery, nucleic 
acid nanoparticles 
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1 Lyophilization in brief 
In general, lyophilization is defined as a stabilizing process in which the sample 
is frozen followed by a reduction of the solvent content by sublimation and then 
by desorption to values that will no longer allow biological growth or chemical 
reactions [1].  
The first evidence on freeze-drying of food products is traced back over 
thousand years when ancient South Americans living in the Andes used a 
primitive freeze-drying method to preserve potatoes [2]. In 1890, it was reported 
the first time that biological specimens can be preserved by drying under 
vacuum conditions and at temperature below 0 °C [3]. The emergence of 
modern, industrial freeze-drying of pharmaceutical products towards the middle 
part of the last century is related to the demand for large-scale production of 
preserved blood plasma [3]. Several years later, the interest in freeze-drying, 
now often called lyophilization, drastically increased with the growing numbers 
of antibiotics and other sensitive pharmaceuticals [4]. At the end the of the past 
century, lyophilization has evolved to a well-established technology for 
preservation of biopharmaceuticals products [2]. During that time, fundamental 
concepts with regard to process design and formulation development have 
been established.  
 
1.1 The lyophilization process 
A typical lyophilization process can be divided into three stages: freezing, 
primary drying, and secondary drying. Figure 1-1 displays a schematic 
illustration of a typical lyophilization cycle. 
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Figure 1-1: Schematic illustration of a typical lyophilization cycle. The solid black line represents 
the temperature course and the dashed black line represents the pressure course during the 
different stages of a lyophilization process: 1) freezing, 2) primary drying, and 3) secondary 
drying. 
The freezing step is initiated by cooling the shelves, on which the samples are 
placed, to the desired freezing temperature and holding the temperature 
constant for equilibration [5]. In this context, the sample is first cooled until ice 
nucleation occurs several degrees below the equilibrium freezing point of the 
sample, referred to as “supercooling” [6]. After ice nucleation, ice crystals start 
to grow resulting in freeze-concentration of the sample [7]. At this point, two 
phases are present, i.e. ice and freeze-concentrated solution, and the 
composition of the sample is determined via the equilibrium freezing curve of 
water in the presence of the solute [8]. For crystalline excipients, solute 
crystallization occurs when the product temperature falls below the eutectic 
temperature (Teu) [9]. However, for amorphous excipients, freeze-concentration 
continues until the viscosity exceeds a critical value at which glass formation 
occurs. This temperature, at which maximal freeze-concentration is observed, is 
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referred to as the glass transition temperature (Tg`) [9]. Thus, in order to ensure 
complete solidification of the sample, the sample has to be frozen below Tg` if it 
is in the amorphous state or below Teu if it is in the crystalline state [10]. As 
upon completion of freezing the majority of the water has been separated from 
the solute, the freezing step is the major dehydration step in lyophilization [11]. 
In general, the freezing step in lyophilization is of paramount importance as it 
considerably impacts lyophilization performance and product quality [11]. 
Therefore, physico-chemical fundamentals of freezing, currently available 
freezing methods, and consequences of the freezing step on process 
performance and product quality will be discussed in detail in Chapter 2.  
After the completion of freezing, an optional annealing step, during which 
product temperature is hold 10 to 20 °C above Tg`, can be applied in order to 
allow for complete crystallization of the excipients and/ or to increase the size of 
ice crystals [10, 12].  
Primary drying, wherein the majority of the water is removed from the product 
by sublimation, is initiated by introducing vacuum in the product chamber [5]. 
The chamber pressure has to be reduced below the saturated vapor pressure of 
ice at the frozen product temperature in order to allow for sublimation. The real 
driving force for sublimation is provided by the water vapor pressure difference 
between the product ice interface and the condenser surface [8]. Thus, different 
chamber pressures below the saturated vapor pressure of ice affect the rate of 
sublimation but do not affect the driving force in general [8]. The mass transfer 
of water vapor from the product to the condenser (dm/dt) is largely determined 
by the dry layer resistance of the product (Rp) but also by the stopper 
resistance (Rs) and can be described by: 
sp
cice
RR
PP
dt
dm
+
−
=            (1-1) 
where Pice is the equilibrium vapor pressure of ice at the sublimation interface 
temperature and Pc is the chamber pressure [10]. At a given product 
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temperature (i.e. a given ice vapor pressure), the smallest chamber pressure 
gives the highest ice sublimation rate [10]. However, too low pressures are also 
counterproductive for fast sublimation rates by limiting the rate of heat transfer 
to the product [10]. As the sublimation of water vapor from the frozen sample is 
an endothermic reaction, with a heat of sublimation ∆Hs of approximately 
650 cal/g, the energy for continuing sublimation of ice needs to be supplied from 
the shelves by heating to increased shelf temperatures [12]. In general, heat 
transfer to the product is based on three components namely radiation from 
“warm” surfaces, direct conduction within and between solid phases, and gas 
conduction (convection) within vapor phases by Brownian diffusion and 
molecular collision [8]. The heat transfer rate (dQ/dt) to a product in vials can be 
described by: 
)( psvv TTKAdt
dQ
−⋅⋅=          (1-2) 
where Q is the energy received by each vial from the shelf, Av is the outer area 
of the vial bottom, Kv is the heat transfer coefficient of the vial, Ts is the shelf 
temperature, and Tp is the product temperature [10, 12]. During steady state of 
primary drying, the rate of heat input into the product (equation 1-2) is in 
equilibrium with the rate of heat output by sublimation of ice (equation 1-1) [12]. 
Thus in order to maximize the sublimation rate, the combination of the highest 
allowable product temperature, which is in general below Tg` or Teu, and the 
lowest possible chamber pressure should be used. The complex relationship 
between chamber pressure, shelf temperature, and product temperature, and 
its impact on the sublimation rate is illustrated in Figure 1-2. 
For instance, at a constant shelf-temperature, the sublimation rate could be 
decreased (A to B) or increased (A to C) by altering the chamber pressure. 
However, an increase in chamber pressure results in an increase in product 
temperature, at the same time [9]. Thus, in order to achieve a safe increase in 
the sublimation rate at a constant product temperature a reduction of the 
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chamber pressure with a simultaneous increase in the shelf temperature 
(A to D) would be required [9].  
 
Figure 1-2: The relationship between chamber pressure, shelf temperature, product 
temperature, and sublimation rate. Redrawn from reference [9]. 
Primary drying is complete when all frozen bulk water is removed via 
sublimation [5]. At this point, the product still contains some bound unfrozen 
water that has to be removed by desorption at higher temperatures during 
secondary drying [8]. Therefore, shelf temperature is slowly increased, in order 
to avoid product collapse, to temperatures between 20 °C and 40 °C and 
maintained at that temperature until the residual moisture content reaches its 
targeted level of usually less than 1% [10]. The secondary drying rate is mainly 
determined by the diffusion rate of water from the bulk to the surface and the 
influence of desorption rates from the surface into the vapor state can in 
practice almost be neglected [1]. Thus, final moisture levels are only dependent 
on the shelf temperature and the specific surface area of the cake, but 
independent of the chamber pressure or the height of the dried product 
thickness [13].  
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1.2 The lyophilization equipment 
The environmental conditions necessary for the lyophilization process, 
subambient temperatures and subatmospheric pressures, are achieved by the  
lyophilization equipment. The following gives a general description of the 
essential components and their function in a lyophilizer. The general design of a 
common lyophilizer is displayed in Figure 1-3.  
 
Figure 1-3: General design of a common lyophilizer: 1) product chamber, 2) temperature-
controlled shelves, 3) heat transfer system, 4) condenser chamber, 5) ice condenser, 6) 
refrigeration system, 7) vacuum pump, 8) hydraulic system to move the shelves, 9) connection 
for temperature probes, 10) capacitance manometer, and 11) pirani gauge.  
The freeze-drying chamber or product chamber is a vacuum vessel, generally 
constructed from stainless steel, that can be accessed by a hinged door [1, 5]. 
The chamber door is either made from clear acrylic material or stainless steal 
and is fitted with an elastomer gasket to form a vacuum seal with the product 
chamber [1, 5].  
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The product chamber houses one unusable shelf, which serves as a radiation 
shelf for the top shelf, and the usable shelves, on which the product is placed 
during lyophilization [1, 5]. The shelves are a hollow construction and contain 
circulating heat transfer fluid for temperature control. The shelves either remove 
heat from or supply heat to the product, depending on the step in the 
lyophilization process (freezing or drying). The shelves can be moved vertically 
by the aid of a hydraulic system and then serve as stoppering platens to force 
the slotted stoppers to their final position into the vial [5]. 
The condenser chamber houses the condenser which operates as a trap to 
collect solvent vapor by condensing the solvent. The condenser has an 
enormous pumping capacity in order to efficiently remove a larger vapor volume 
and to allow the system to achieve lower pressures [5]. In order to be effective, 
the temperature of the condenser plates has to be at minimum 20 °C lower than 
the product temperature during primary drying [1]. In contrast to the shelves, 
which are chilled by heat-transfer fluid, the condenser is generally refrigerated 
by direct expansion of a refrigerant [1]. 
The vacuum pumping system in combination with the condenser provides the 
subambient pressures that are necessary for the primary and secondary drying 
process [1]. The vacuum pump removes any non-condensable gases that pass 
through the system, e.g. gases that are introduced into the system through 
leaks or outgassing, or inert gases, such as nitrogen, that are used for pressure 
control during drying [1, 5].  
Moreover, the lyophilization unit comprises basic instrumentation for process 
control and monitoring. Shelf temperature is most commonly measured and 
controlled as the temperature of the circulating heat transfer fluid through the 
shelf [5]. Chamber pressure is usually measured and controlled with a 
capacitance manometer. In combination with a conductivity gauge (Pirani 
gauge), these two pressure measures can be used for manometric endpoint 
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determination. Here, the endpoint of primary drying is reached when the 
pressure difference between the Pirani gauge and the capacitance manometer 
decreases and approaches zero [10]. Finally, product temperature, which 
depends on the shelf temperature and the chamber pressure, is most 
commonly monitored by T-type copper-constantan thermocouples (TCs) or 
100-ohm platinum resistance temperature detectors (RTDs). Nowadays, with 
the increasing demand on process analytical technology (PAT), several other 
tools have been introduced for lyophilization process monitoring and control 
(see section 2.9). Other recent advances and further challenges in lyophilization 
will be addressed in the following section. 
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2 Recent advances and further challenges in 
lyophilization 
Entering a new century, scientists strive for new applications of lyophilization, 
the technology is subject of ongoing development and even well-accepted 
dogmas have been challenged. The aim of the following section is to highlight 
recent advances and to discuss existing and future challenges in lyophilization.  
2.1 Lyophilization beyond drying of pharmaceutical proteins 
Most current literature in the field of pharmaceutical lyophilization is available on 
drying of protein drugs for parenteral application. However, research also 
started to investigate the use of lyophilization for several other pharmaceutical 
applications. With respect to parenteral, but also non-parenteral, application, 
substantial effort has been spent to develop lyophilization into a promising 
approach in order to achieve long-term stable vaccine formulations [14]. 
Moreover, lyophilization of cells, e.g. red blood cells, is a desirable goal [15], for 
which however, a complete success has not been reported yet. Additionally, 
different nanoparticulate systems, employing lyophilization to overcome 
physical and/or chemical instabilities, have been developed for efficient drug 
delivery of small molecules, proteins or peptides [16]. With the rapid progress in 
gene therapy, lyophilization also gained importance for the preservation of 
nucleic acid based pharmaceuticals (see section 3). Successful gene therapy 
requires complex nanoparticulate carriers that protect and efficiently deliver 
their nucleic acid payload. Lyophilization has the capability to both stabilize the 
nucleic acid against degradation and to preserve the nanoparticle 
structures [17]. It is important to note that stabilization mechanism and 
excipients that were established for proteins do not necessarily apply to 
nanoparticles. 
12                                                                                                           Chapter 1 
 
Lyophilized biological reference standards are a new expansion of the 
traditional field of lyophilization. These biological standards are often derived 
from a single large-batch of well-characterized biological material and here, 
lyophilization, often performed in ampoules instead of vials, guarantees long-
term stability and ease of distribution [18]. Additionally, as many new chemical 
entities suffer from poor solubility, the preparation of amorphous solid 
dispersions by lyophilization, especially from co-solvents systems, is a 
promising alternative to achieve stable systems with increased bioavailability 
and a low tendency to recrystallization or particle size increase [19]. 
2.2 Pharmaceutical applications of lyophilisates in the solid state 
The most common use of lyophilization is the manufacturing of parenterals 
which are reconstituted prior to application. But several other applications of 
solid lyophilisates have emerged. They take advantage of the unique properties 
of the highly porous structures. First of all, orally disintegrating tablets (ODTs), 
which have gained popularity, can be manufactured by lyophilization based 
technologies such as the ZydisTM (R.P. Scherer, UK), LyocTM (Farmalyoc, 
France) or QuicksolvTM (Janssen Pharmaceutica, USA) technology [20]. ODTs 
prepared by lyophilization have a unique porosity that guarantees rapid 
dissolution in the saliva, but may show limited mechanical strength and storage 
stability. But the gentle preparation method could have high potential for oral 
vaccine ODTs [21]. Lyophilized three-dimensional scaffolds, for which the 
porosity can be controlled by varying the freezing conditions, are well-
established for wound healing and tissue engineering [22]. Moreover, it is also 
reported that lyophilized wafers are promising systems for drug delivery via the 
buccal mucosa [23]. A new interesting approach is “partial lyophilization” with 
the bulking agent partially suspended at higher concentration in the aqueous 
liquid which is lyophilized [24-25]. This approach, known as the LyopanTM 
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technology, consumes less time and energy than previous methods to produce 
fast-disintegrating tablets, thus making it more economical.  
Additionally, lyophilization can also be utilized as the first step to produce dry 
powder inhalation systems [26-27]. Previously, the lyophilized powder were 
reduced to respirable powders in a subsequent milling step [26]. Similarly, 
lyophilized dry powder vaccines for nasal delivery can be prepared [28]. 
Recently Claus et al. [29] introduced a promising new dry powder inhalation 
technology based on the direct dispersion of lyophilisates by an air impact. This 
approach allowed to overcome the disadvantages associated with milling and 
enabled high fine particle fractions. 
2.3 Novel formulation aspects 
Good freeze drying practice typically entails minimizing the amount of buffer or 
salt in order to keep the glass transition temperature (Tg`) of the formulation 
high [30]. However, it was shown that the addition of a plasticizer like glycerol or 
sorbitol leads to an improved protein stability despite lowering of Tg` which was 
explained by decreased fast glass dynamics (see section 2.8) [31-32].  
The expansion of the excipient spectrum by high molecular weight compounds, 
e.g. dextran, hydroxyethylstarch, polyvinylpyrrolidone, polyethylenglycol might 
allow for accelerated drying processes and for better storage stability at higher 
temperatures due to the increased Tg` and Tg. But when using these excipients 
possible phase separation negatively influencing protein stability has to be 
taken into account [33]. Recently, Padilla and Pikal [34], introduced Raman 
mapping as a new tool for studying amorphous phase separation in lyophilized 
protein formulations. Moreover, when using dextran or hydroxyethylstarch in 
protein formulation, optimal storage stability could only be achieved in 
combination with disaccharides [35-36]. Thus, the possible benefit of high 
molecular weight excipients in protein formulation needs to be further evaluated 
in the future. In contrast, oligosaccharides such as low-molecular weight 
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dextrans [37] or inulin [38] are clearly beneficial to provide sufficient stabilization 
of nanoparticles at low osmolalities when a high mass ratio of stabilizer to 
nanoparticle is required.  
NCEs often cannot be lyophilized from aqueous solution due to their poor 
solubility. One option is the use of non-aqueous co-solvents, mainly tertiary 
butyl alcohol (TBA), that offers several advantages (e.g. increased drug 
solubility, acceleration of sublimation rates, decreased reconstitution time, and 
improved product stability) [39-40]. But limitations, e.g. special equipment 
requirements, residual solvent levels, toxicity of residual solvents, over-all cost 
disadvantage, and increased regulatory issues, have to be considered, as well 
[39-40]. The addition of TBA has recently been shown to constitute a promising 
approach to incorporate lipophilic drugs in sugar glasses [41] or to improve 
primary drying rates and product quality of a concentrated formulation with high 
fill depth [42]. 
2.4 Importance of the freezing step in lyophilization 
Recently, researchers began to stress the importance of the freezing step in 
lyophilization. A comprehensive review on the freezing step in lyophilization will 
be given in Chapter 2. In brief, the freezing process is shown to impact intra-vial 
and inter-vial uniformity [42], primary and secondary drying performance 
[43-44], the physical state of the sample [45], residual moisture content [46], or 
reconstitution time [47]. Moreover, there are several studies available that 
demonstrate the effect of the freezing process on protein stability [46, 48]. 
However, some of the results on protein stability are contradictory and thus, 
further investigations are necessary. Recently, it was demonstrated that the ice 
nucleation temperature during freezing inversely correlated with the recovery of 
protein activity [49]. Furthermore, the stability of nanoparticulate structures 
[50-52] is also affected by the freezing step. However, comprehensive studies 
are still lacking (see Chapter 6).  
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In order to encounter the up-scaling challenge with regard to the bias in ice 
nucleation, methods that allow for direct control of ice nucleation are essential 
[53]. Recently introduced methods, include electro-freezing [54], ultrasound-
controlled ice nucleation [55], ice fog technique [56], or depressurization 
technique [57], among which, ice fog technique and depressurization technique 
appear to be the most promising with regard to operational handling or 
applicability in manufacturing scale freeze-drying. 
2.5 Lyophilization above Tg`  
According to the widespread opinion, collapse, defined as loss of the cake 
structure caused by viscous flow of the freeze-concentrate during drying [58], is 
considered detrimental due to the loss of the pharmaceutically elegant cake, 
high residual moisture levels, prolonged reconstitution times, and the negative 
impact on protein stability [10]. Hence, good pharmaceutical freeze-drying 
practice entails keeping the product temperature below the glass transition 
temperature (Tg`) or the slightly higher collapse temperature (Tc) of the product 
during primary drying, even though drying at higher temperatures would highly 
accelerate the cost-intensive drying process [10]. Interestingly, there is 
experimental evidence that collapse itself does not necessarily negatively affect 
product quality. For instance, it was shown that primary drying above Tg` did not 
negatively impact the stability of recombinant Factor VIII (rFVIII) or α-amylase 
[59], lactate dehydrogenase (LDH) [59], and two proteinous toxins [60]. 
Recently, Schersch et al. [61] showed that protein stability of a monoclonal IgG 
antibody, a tissue-type plasminogen activator, and LDH in collapsed samples 
were not negatively affected, but in some cases even slightly improved in 
comparison to non-collapsed samples. Additionally, no effect on residual 
moisture levels or reconstitution times was observed. Moreover, the occurrence 
of collapse had no negative but sometimes even a positive effect on the storage 
stability of several proteins [58, 62].  
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In general, if product collapse does not diminish protein stability, still 
macroscopic collapse has to be prevented to guarantee a pharmaceutically 
acceptable product. This can be achieved by inclusion of a crystalline bulking 
agent which provides macroscopic support for the collapsing amorphous phase 
leading only to macroscopically invisible “small-scale” or micro collapse [10]. In 
this context, the weight ratio of amorphous excipient to crystalline bulking agent 
is critical, as an excess of amorphous component can inhibit crystallization of 
the bulking agent, which actually leads to a lowered Tg`. Promising results were 
reported for glycine/raffinose or glycine/trehalose mixtures [59], 
mannitol/sucrose mixtures [61] and lately, for phenylalanine/sucrose or 
phenylalanine/trehalose mixtures [63]. 
High-concentration protein formulations represent a special case and might be 
lyophilized above Tg` without considering the aforementioned limitations due to 
their pronounced difference between Tg` and Tc as a result of the highly viscous 
freeze-concentrated phase. Colandene et al. [64] reported for a high-
concentration monoclonal antibody formulation lacking a crystalline bulking 
agent that the difference between Tc and Tg` and also the difference between 
the onset temperature of collapse and the complete collapse progressively went 
up as protein concentration increased. Thus, these formulations can be 
lyophilized above Tg` but below Tc with no detrimental effect on protein stability 
or cake appearance [64-65]. In this case it is essential to accurately determine 
Tc, usually by freeze-drying microscopy (FDM) [66]. As an alternative optical 
coherence tomography based FDM was introduced in order to allow for the 
measurement of Tc during freeze-drying in a vial [67]. 
2.6 Stabilization by thermal treatment/ high secondary drying 
temperatures  
Recently, the concept of physical aging of an amorphous sample by thermal 
treatment to improve API stability was addressed in lyophilization 
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development [68]. During this temper process a glass will approach the 
“equilibrium glassy state” asymptotically leading to a change in the physical 
properties of the glass such as enthalpy, entropy, and volume [69]. Thereby, 
structural relaxation times are increased and global mobility is decreased. 
Consequently, as structural relaxation and reactivity are coupled, reaction rates 
should be minimized upon physical aging [68]. Although it is not assured that 
the underlying stabilization mechanism in amorphous solids can be fully 
correlated to structural relaxation dynamics (see section 2.8), there are several 
studies that support the concept of “stabilization by thermal treatment”. For 
instance, the chemical stability of maxolactam disodium improved over storage 
as temper temperatures and times post-lyophilization increased, although a 
greater initial degradation due to the temper phase was observed [68]. 
Moreover, post-lyophilization annealing also decelerated bimolecular 
degradation of sodium ethacrynate [70] and limited aggregation of an IgG1 
fusion protein [71] during storage. The optimal treatment temperature can be 
identified by DSC experiments analyzing the maximum value in enthalpy 
recovery [70]. Beside these promising results for post-lyophilization tempering, it 
is also reported that the stability of maxolactam disodium was improved when 
secondary drying was performed at 60 °C rather than just 40 °C despite 
identical residual moisture [72]. In conclusion, performing secondary drying at 
increased temperatures does not only accelerate the final drying phase but 
might also improve storage stability. 
2.7 Individual factors contributing to protein stability during 
lyophilization 
It is well established, that freezing and drying induce different stresses that 
impact protein stability during lyophilization. Recently, the contribution of 
individual stress factors was scrutinized. Bhatnagar et al. [73] found that ice 
formation is the critical factor for LDH stability during freezing by separately 
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investigating the effect of temperature, ice formation, and freeze-concentration 
using a temperature-step approach. Moreover, Tang and Pikal [74] proved that 
proteins can be lyophilized well above Tg` without the need for vitrification, as 
protein unfolding kinetics are highly coupled with system viscosity and thus, 
protein unfolding is very slow on the time scale of lyophilization, even at 
temperatures well above Tg`. Luthra et al. [75] found that secondary drying is a 
critical step for LDH stability by differentiating between primary and secondary-
drying stresses using a mini freeze-dryer. A more detailed study on the stresses 
during secondary drying established that both direct excipient interaction and 
vitrification are required for complete LDH stabilization [76]. In general, although 
these findings might not fully apply to other proteins, the described procedural 
methods are useful in order to investigate the factors contributing to the stability 
of one’s protein formulation.  
2.8 Enhanced understanding of stabilization mechanisms in the 
solid state 
The stabilization of proteins in a sugar-glass matrix has been attributed to a 
thermodynamic mechanism according to which sugar molecules stabilized the 
native protein confirmation via “water replacement” [77], or to a kinetic 
mechanism, which is based on the fact that degradation mechanisms in the 
vitrificated, rigid sugar matrix will be limited [78]. The latter mechanisms, the 
“vitrification hypothesis”, coupled the stability of proteins or chemical 
compounds to the global mobility of the sugar glass matrix, often referred to as 
structural relaxation or α-relaxation [79]. There is much experimental evidence 
for the two hypotheses, but neither of both was capable to universally explain 
and predict stabilization in the glassy solid state [80-82]. 
Recently, it was shown that local dynamics in sugar glasses, in the term of 
β-relaxation, correlate strongly with protein or other drug 
stability [31-32, 68, 81-82]. In an up-to-date publication, Cicerone and 
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Douglas [83] argued that protein or drug stability is directly linked to high 
frequency β-relaxation processes of the sugar matrix as these β-relaxations are 
directly linked to local protein motions and to diffusion of small molecule 
reactive species in the glass. Moreover, they also showed that the enhanced 
protein conformational stability in sugar matrixes via “water replacement” does 
not have a significant impact on the degradation rate of the proteins. In addition, 
they also reported that protein stability increases continuously with the addition 
of anti-plasticizing compounds such as glycerol or sorbitol as β-relaxation time 
is prolonged whereas simultaneously glass transition temperature and 
α-relaxation time of the sugar matrix are decreased. Thus, the development of 
formulations or processes that allow for the modification of β-relaxation appears 
to be a highly interesting approach to improve the stability of drugs in 
amorphous lyophilisates. 
2.9 Quality by design and process analytical technology in 
lyophilization 
With the beginning of the 21st century the FDA started the initiative to shift from 
traditional rigorous testing of the final product to a “risk based approach” 
[84-85]. The aim is to design quality into the product (Quality by Design (QbD)) 
rather than to test quality into the product [86]. Thus, key factors for QbD are 
identification, understanding, and control of critical process and product 
parameters [86]. The development of a “design space” and a “control strategy” 
is required to ensure the production of a product of constant quality, promoting 
real-time release [86]. The measuring and control of critical process parameters 
requires the implementation of Process Analytical Technology (PAT) [85]. As 
these regulatory changes are increasingly adopted in pharmaceutical industry, 
QbD and PAT form leading issues in lyophilization development. This led to the 
development of a number of single vial or batch technologies in order to monitor 
critical product and process parameters. 
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Traditionally, thermocouples (TCs) or resistance temperature detectors (RTDs) 
have been utilized to measure product temperature in a few selected vials [88]. 
Recently, wireless temperatures sensors have been developed in order to allow 
for automatic loading in manufacturing scale freeze-drying [88]. But there is still 
need for more sensitive or non-invasive monitoring tools. Moreover, the three-
dimensional monitoring of the lyophilization process in a vial would be highly 
beneficial (see Chapter 8). 
A well-established method to determine the endpoint of primary drying is 
comparative pressure measurements using a capacitance manometer and a 
Pirani gauge The technique was just recently shown to be the best choice 
among several endpoint determination methods [89]. Manometric temperature 
measurement (MTM), which is based on pressure rise data obtained by a Pirani 
gauge, was introduced as a non-invasive batch method to predict the average 
product temperature at the sublimation interface [90-91]. This method has also 
been used for the analysis of heat and mass transfer parameters [92] and dry 
layer resistance measurements [92]. Tang et al. [93] used MTM in combination 
with additional algorithms for the design of the SMARTTM freeze-drier which 
allows for automatic optimization and control of the drying process. Likewise, 
Barresi and coworkers used a dynamic parameters estimation (DPE) approach 
in order to estimate several process data [94]. This approach, together with 
another mathematical model constitutes the basis for the LyoDriverTM 
technology [95].  
Just recently, tunable diode laser absorption spectroscopy (TDLAS), which 
allows the in-line quantification of the water vapor flux from the chamber to the 
condenser, was introduced as PAT tool in lyophilization [96]. TDLAS was 
applied for primary drying endpoint determination [89], non-invasive product 
temperature measurements [97], vial heat transfer parameter determination 
[98], process optimization simplification [99], choked flow detection [100], 
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residual moisture monitoring during secondary drying [101], or for product mass 
transfer resistance determination, which can be used to estimate the effective 
pore radius of the dry layer [102]. Overall, TDLAS has great potential to support 
scale-up of lyophilization processes. 
Moreover, near infrared (NIR) or Raman spectroscopy have gained attention as 
process analytical and process understanding tools in lyophilization despite the 
fact these two methods represent single-vial approaches with possible sensor 
placement problems. In combination these two techniques are capable to 
monitor the solid state of crystallizing excipients through the entire process, the 
onset of ice nucleation, and the onset and endpoint of ice sublimation [68-70]. In 
combination with an experimental design approach, these tools were also used 
for formulation and process optimization of a pharmaceutical product [103]. Just 
recently, NIR spectroscopy was utilized for in-line monitoring of protein 
unfolding and protein excipient interactions [104]. 
Several studies on the application of design space in lyophilization processes 
have been already published. At first, the design space was obtained by 
extensive experimental studies [105]. Later on, experimental work was reduced 
by the use of in-line measurements [106-107]. In a second step, process 
simulation instead of experimental testing was proposed, as this can 
significantly shorten the time for design space development [108-111]. 
Moreover, there are several methods available that consider parameter 
uncertainty, leading to “shrinkage” of the design space [108-109, 111]. 
Recently, Fissore et al. [112] described a method that considers changes in the 
design space with time and Bogner [113] presented a new approach to take 
vial-to-vial variations into account. 
2.10 Novel container systems 
As a response to the increasing market of high price biotech products, glass 
vials have become available that were especially developed for the 
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requirements of lyophilization. For instance, Schott forma vitrum AG introduced 
the TopLyoTM tubing vials, which have a customized geometry and carry a 
hydrophobic inner layer to maximize strength and minimize breakage and to 
improve heat transfer [114-115]. Furthermore, experiments with the TopLyoTM 
vials showed less disruption of the lyo cake, less dry material pulling up from 
the edge, improved cake aesthetics and reduced residual volume, and higher 
yield of reconstituted product [115]. Additionally, SGD S.A. introduced 
EasyLyoTM, molded vials that are intended to improve heat transfer through the 
flattened vial bottom and the lighter vial mass [116]. Recently, Hibler et al. [117] 
compared the TopLyoTM  and the EasyLyoTM vials with standard serum tubing 
and molded vials and found comparable heat transfer coefficients for all vials 
which is in contrast to traditional theories. However, for a polymer vial 
(TopPacTM) a loss of ~30% in heat transfer was observed. 
The development of cyclic olefin polymers (COP) and copolymers (COC) 
induced the trend to replace glass by break-resistant and surface inert plastic 
containers [118]. It has been found that lyophilization in the plastic containers 
led to improved uniformity within the lyophilisate [118]. However, the distinct 
advantages of break-resistance and low weight of plastic containers might not 
compensate for their high moisture permeability and new multilayer vials with an 
additional moisture barrier are approaching the market. Whatever container 
system different from a glass vial is to be used, such vials from new materials, 
syringes or cartridges, LyoguardTM trays or containers, or 96-well plates, they 
represent new challenges in process development, as a process optimized for 
standard glass vials has to be reevaluated. The understanding of heat and 
mass transfer in these container system will help in the development of a robust 
lyophilization process, as currently reviewed by Patel and Pikal [119]. 
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2.11 Scale-up, equipment issues and the dream of continuous 
processing 
One of the main sources of scale-up difficulties is the difference of ice 
nucleation in laboratory-scale and manufacturing-scale freeze-drying [53]. This 
issue is to be addressed by the aforementioned introduction of technologies for 
controlled ice nucleation. Other critical aspects are differences in shelf-surface 
temperature distribution, differences in dryer load, differences in heat and mass 
transfer performance, differences in the contribution of radiative heat, and 
differences in chamber pressure [119-120]. Recently, the effect of dryer load on 
critical process parameters was studied on lab scale, pilot scale, and a clinical 
scale dryer [87]. Here, radiative heat effects, which were decreased for a full 
dryer load as the fraction of edge vials decreased, were the predominant factor. 
In general, the effect of radiative heat may be minimized by using trays that 
have no tray sides and by controlling chamber wall temperatures [121]. 
Moreover, freeze drying cycle conditions that are developed on a small scale 
dryer can lead to water vapor flux conditions that the full-scale equipment 
cannot handle (“choked flow”), resulting in loss of the ability to control chamber 
pressure [100].  
Furthermore, several procedures that use a combination of experimental testing 
and numerical modeling have been described to facilitate scale-up [122-125]. 
Modeling of fluid dynamics was also performed to simulate pressure and 
pressure gradients or the velocity of flow at variable shelf separation distances 
[124, 126], to illustrate the influence of a sterilization pipe or of the isolation 
valve in the connection duct on flow velocity [126-127], to quantify the 
contribution of different heat transfer components at variable pressure and vial 
separation [128], or to predict 3D unsteady ice accumulation on the condenser 
[128]. These results might be very useful to reconsider the traditional design of 
the freeze-drier hardware.  
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The general problem of batch non-uniformity could be sorted out by switching to 
a continuous lyophilization process as it has already been established in the 
food industry, e.g. like the ConradTM continuous freeze drying plant [129-130]. 
Here, the frozen product, most often in granular form, is deposited on trays, that 
enter the cabinet through a specially designed airlock system [130]. The trays 
are then pushed on heating plates through the various subsequent drying 
zones. Moreover, the cabinet is equipped with a number of vapor condensers 
that allow continuous de-icing. In this case, drying times fall in the order of 
minutes instead of hours or days [129]. Recently, the Meridion Technology 
GmbH introduced a continuous process line for pharmaceutical applications that 
combines a spray technology for the production of frozen microspheres with a 
dynamic bulk lyophilization technology [131]. However, this dream of switching 
form historical batch-type to continuous processing in pharmaceutical 
application would also require a fundamental change in mind. 
2.12 Conclusion and outlook 
In conclusion, the expanding range of pharmaceutical applications and the new 
approaches to understand and control the combination of formulation and 
process highlight the high importance of the lyophilization process. Moreover, 
by extending the formulation spectrum, introducing novel container systems, 
providing a more comprehensive understanding of stabilization mechanisms, 
and addressing the demands of QbD and PAT, the development of improved 
formulations and the design of optimized processes is highly facilitated, 
resulting in an increased product quality. This also includes that we can leave 
behind some traditional ways of thinking, like “never lyophilizing above the glass 
transition temperature”  or traditional designs of containers and equipment. 
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3 Lyophilization of nucleic acid nanoparticles  
With the rapid progress in gene therapy, lyophilization has gained importance 
for the preservation of nucleic acid based pharmaceuticals. In the following 
section, a brief overview on the basic concepts of pDNA and siRNA delivery in 
gene therapy will be given and the need for long-term stable formulations will be 
accentuated. Additionally, currently available scientific literature dealing with 
lyophilization of nucleic acid nanoparticles will be reviewed in brief. 
3.1 pDNA and siRNA delivery in gene therapy and the need for 
long-term stable formulations 
Gene therapy using nucleic acids (i.e. plasmid DNA, oligonucleotides or short 
interfering RNA) offers significant promise to cure, treat or prevent various 
incurable diseases [132-133] such as cardiovascular [134], neurological [135-
136] and infectious disorders [137], severe combined immunodeficiency [138], 
cystic fibrosis [139-140], and an alternative method to traditional chemotherapy 
in tumor treatment [141-142].  
In traditional gene therapy, gene substitutes (e.g. pDNA), which are 
transcriptionally fully competent genes, are introduced into the target cells to 
replace or substitute a specific gene resulting in the recovered production of a 
specific protein [133].  
Since Fire et al. [143] discovered RNA interference (RNAi) in 1998, this 
technology has evolved to a promising tool for gene silencing in therapeutic 
applications [144]. Here, gene inhibitors (e.g. siRNA) are used in order to 
silence defective genes at the mRNA level [133]. There are two approaches for 
bringing siRNA to its effect: the stable expression of siRNA precusors or the 
direct delivery of stabilized synthetic siRNAs [145]. The mechanism of siRNA 
mediated RNA interference is schematically displayed in Figure 1-4. After 
entering the cytoplasma of the targeted cell, siRNA duplexes are incorporated 
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into the RNA-induced silencing complex (RISC). Argonaute 2, a multifunctional 
protein contained within RISC, unwinds the siRNA and the sense strand of the 
siRNA is cleaved [145-146]. Then, the activated RISC, which contains the 
antisense strand of the siRNA, selectively triggers cleavage of mRNA that is 
complementary to this the antisense strand [145-146]. 
 
Figure 1-4: The mechanism of siRNA mediated RNA interference: siRNA is incorporated into 
the RNA-induced silencing complex (RISC) and the sense strand is cleaved by argonaute 2 
(AGO2). The activated RISC-siRNA complex binds to and cleaves complementary mRNA and 
can then be recycled to further destruct identical mRNA targets. Redrawn from reference [145].  
However, as unprotected nucleic acids are degraded in plasma within minutes, 
in vivo gene therapy necessitates gene delivery vectors that ideally protect their 
nucleic acid payload against nucleases and deliver the drug efficiently and 
selectively to the target site [147].  
The most commonly used gene transfer systems applied in clinical trials are 
viral vectors due to their high gene transfer efficiency [148]. The limitations of 
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viral vectors in particular concerns about their safety, including immune and 
toxic reactions, the potential for viral recombination, low transgene loading 
capabilities, and high costs, render non-viral gene delivery systems a promising 
alternative [149]. Non-viral vectors are attractive because of their compound 
stability, easy preparation and purification at low cost, high flexibility, high 
loading capacity for DNA and as they have been proven safe, non-pathogenic 
and non-immunogenic in clinical trials [149-150]. Non-viral delivery vectors can 
be divided into two major classes: cationic lipids or cationic polymers, which 
interact electrostatically with the negatively charged nucleic acids and form 
condensed complexes (i.e. lipoplexes or polyplexes) [151-152].  
Among the cationic polymers, linear polyethylenimine (LPEI) is the “golden 
standard” as very efficient gene expression both in vitro and in vivo has been 
observed [150, 153-154]. Here, the nano-scaled, positively charged polyplexes, 
formed between PEI and DNA molecules, enter the cells after cell adhesion by 
endocytosis and escape from the endo-lysosomal compartment by the so called 
“proton sponge effect” [155]. However, PEI exhibits polydispersity, significant 
toxicity, and limited degradability [152], and shows only modest delivery 
efficiency in the case of siRNA transfer [156-157]. Thus, for efficient and safe 
clinical siRNA delivery the development of modified polymers, which preferably 
allow for the establishement of structure activity relationships, is required [158-
159]. Currently, a library of more than 300 sequence-defined, precise oligomers 
has been created by solid-phase assisted synthesis, among which a number of 
oligomers was highly efficient in siRNA transfer [160]. 
However, the major drawback of synthetic systems is the low pDNA or siRNA 
delivery efficiency compared to viral vectors particularly after in vivo application 
and the high instability in aqueous suspensions [161]. To date, the predominant 
focus has been on the development of more efficient polymers but other crucial 
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pharmaceutical aspects including quality control, long-term stability, and 
practicability in clinical trials have been rather ignored [152, 162-163].  
A limiting factor for the clinical practicability of synthetic vectors is the 
requirement for freshly mixing nucleic acid solution with the carrier solution prior 
to administration because of the high instability or the nanoparticles in liquid 
environment resulting in particle aggregation, which is known to correlate with a 
loss of transfection efficiency [17, 52, 164]. The day-to-day preparation poses 
the risk of batch-to-batch variations, which is afflicted with safety concerns, and 
the inability to perform extensive quality control prior to the actual 
administration, due to time constraints [165-167]. Thus, the reproducible 
production of large standardized and long-term stable batches of pDNA or 
siRNA nanoparticulate complexes is a desirable goal. 
3.2 The current status on lyophilization of nucleic acid nanoparticles 
Lyophilization is a highly attractive way to achieve dried pharmaceuticals in 
general [8, 10] and nucleic acid-based formulations in particular [17]. The 
advantages of lyophilized formulations are their long-term storage stability at 
room temperature and their easy handling during shipping and storage [10]. 
Moreover, lyophilized formulations are ready to use after a simple reconstitution 
step [17, 161]. 
One essential prerequisite for the successful development of lyophilized nucleic 
acid complex formulations is the availability of nanoparticles at a constant and 
defined quality. The standard preparation of non-viral vectors is performed by 
mixing the nucleic acid solution with the cationic agent solution (i.e. lipid or 
polymer) via pipetting, which is restricted to relatively small batches (~ 250µL) 
[161]. This poorly defined and difficult to control preparation method is highly 
dependent on the operator and can result in the formation of highly 
heterogeneous complexes with a broad range in size and charge [168-169]. 
Therefore, the development of an up-scalable, controllable, and reproducible 
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method for the preparation of large, standardized batches of well-defined 
polyplexes is a necessary prerequisite for lyophilization development (see 
Chapter 4).  
The lyophilization process involves two stresses, freezing and drying, that are 
known to be damaging to macromolecules and nanoparticles, unless 
appropriate stabilizers are used [161]. Table 1-1 provides an overview on 
excipients that are described in literature for the stabilization of nucleic acid 
nanoparticles.  
Table 1-1: Overview on excipients that are described in literature for the stabilization of nucleic 
acid nanoparticles upon lyophilization.  
 
Several mechanisms how cryoprotectants and lyoprotectans may stabilize 
nucleic acid nanoparticles during freezing and drying have been described but 
are still not fully understood [17, 178]. For cryoprotection during freezing 
“preferential exlusion”, “vitrification”, and “particle isolation” have been 
Cationic agent Nucleic acid Excipient Reference 
DOTAP/DOPE pDNA 0.5 M sucrose or trehalose [170] 
DAC-30TM pDNA 250 mM sucrose or 220 mM mannitol with 29 mM sucrose [165] 
DMRIE-C pDNA 1% to 5% PEG, HES, mannitol, sucrose, trehalose, lactose, glucose [171] 
DOTAP/DOPE/ 
DSPE-PEG pDNA 12.6% sucrose, trehalose, inulin, dextran [38] 
Transferrin-PEI pDNA 10% sucrose [172] 
PDMAEMA pDNA > 2.5% or 10% sucrose [164, 173] 
Branched-PEI pDNA 1% Dextran 3000 [37] 
PEI ODN or pDNA 10 to 50 µg/mL trehalose, mannitol,or sucrose [174] 
Chitosan or 
TransIT-TKO siRNA 10% sucrose [175] 
DOTAP/DOPE siRNA 278 mM sucrose, trehalose, glucose, lactose [176] 
PEI F25 siRNA 5% glucose [177] 
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discussed [17]. According to the “preferential exclusion hypothesis”, established 
for protein stabilization, solutes are preferentially excluded from the surface 
resulting in the formation of a stabilizing solvent layer [17, 178-179]. However, it 
is questionable if this hypothesis can be adapted to nucleic acid nanoparticles, 
as the relatively high amounts of cryoprotectants required point to a nonspecific 
bulk stabilization [17, 178-179]. Based on the “glass formation or vitrification 
hypothesis”, nucleic acid nanoparticles are entrapped in the amorphous gassy 
matrix when the sample is cooled below the glass transition temperature (Tg`) 
limiting particle mobility and thus, preventing particle aggregation [17, 178]. As 
some sugars were able to preserve particle size at temperatures well above Tg` 
vitrification cannot be the only stabilization mechanism [180]. The “particle 
isolation hypothesis” states that particles have to be sufficiently separated in the 
freeze-concentrate in order to inhibit particle aggregation, which is observed 
above a critical excipient to complex ratio [180]. However, these three 
mechanisms are not suitable to solely explain the stabilization of nucleic acid 
nanoparticles during freezing. Thus, the influence of freezing on nucleic acid 
nanoparticles and underlying stabilization mechanisms during freezing will be 
addressed in detail in Chapter 6.  
 
Among synthetic delivery systems most literature is available on lyophilization of 
lipid DNA complexes or complexes based on polymers like 
poly(2-dimethlyamino)ethyl methacrylate (PDMAEMA). In a very first study, 
Anchordoquy et al. [170] showed that pDNA-DOTAP/DOEP lipoplexes had to 
be lyophilized in the presence of quite high amounts of sucrose or trehalose 
(0.5 M) in order to maintain transfection activity and particle size. Similarly, 
Clement et al. [165] were able to successfully lyophilize pDNA lipoplexes in the 
presence of sucrose or mannitol sucrose mixtures (250 mM). Moreover, Cherng 
et al. [164] reported that a sucrose concentration ≥ 2.5% was required to 
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maintain transfection efficiency and particle size of PDMAEMA polyplexes upon 
freeze-thawing and lyophilization. In a follow on study, they proved the long-
term stability of these formulations at 4 °C and 20 °C for 10 months, but when 
stored at 40 °C for 2 months or longer PDMAEMA polyplexes aggregated and 
lost their transfection efficiency [173]. Besides the use of disaccharides, 
Hinrichs et al. [39] introduced oligosaccharides such as inulin or dextran as 
stabilizers for the lyophilization of pDNA-DOTAP/DOPE or -DOTAP/DOPE/ 
DSPE-PEG lipoplexes. In this case, dextran was not suitable for sufficient 
protection of PEGylated lipoplexes. Allison et al. [171] used a variety of different 
stabilizers (PEG, HES, mannitol, sucrose, trehalose, lactose, glucose) in order 
to investigate their protective mechanism during lyophilization of cationic lipid-
DNA complexes. They found that large polymeric sugars, such as HES, did 
completely fail to protect lipoplexes upon lyophilization and that excipients that 
crystallize during lyophilization, such as mannitol, are also less effective 
compared to disaccharides.  
However, only little is reported in literature on the lyophilization of PEI-based 
polyplexes. Talsma et al. showed that 10% sucrose was required in order to 
reasonably maintain gene delivery efficient (~ 5fold decrease), whereas in the 
absence of sucrose the transfection efficiency dropped by a factor of 
100-1000 [172]. Moreover, Anchordoquy et al. [37], introduced low molecular 
weight dextrans for the stabilization of pDNA-bPEI polyplexes at low 
osmolalities during lyophilization, which then could be concentrated tenfold 
upon rehydration in reduced volumes. However, in this context, particle integrity 
was only evaluated based on turbidity values. The only study on lyophilization of 
PEI based polyplexes that also investigated particle size, in addition to 
transfection efficiency or turbidity, was published by Brus et al. [174]. They 
observed only marginal changes in size and transfection efficiency for 
complexes of short oligodeoxynucleatides (ODN) and PEI after lyophilization in 
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the presence of low amounts of stabilizers (50 µg/mL). In contrast, pDNA-PEI 
complexes were found to drastically aggregate and biological activity 
decreased.  
With regard to lyophilization of siRNA nanoparticles, only limited information is 
available, as well. Wu et al. [181] reported that siRNA-loaded lipid particles 
could be prepared by hydration of a stable freeze-dried matrix, containing 
siRNA and lipids. But here, only this preparation method was compared to an 
established direct preparation procedure and the influence of the lyophilization 
process itself on particle size and biological activity was not studied. Kundu et 
al. [183] evaluated the storage stability of lyophilized lipid-based siRNA 
nanosome formulations, but also did not investigate the influence of the 
lyophilization process. Moreover, Andersen et al. [175] described lyophilized 
chitosan or lipid siRNA formulations that are coated on cell culture plates as 
high-throughput screening tool and reported that 10% sucrose was required to 
sufficiently preserve particle size and gene silencing activity. Additionally, 
Yadava et al. [176] reported that siRNA lipoplexes could only be lyophilized with 
maintenance of transfection efficacy and with only a slight increase in particle 
size in the presence of stabilizers, such as glucose or sucrose. Similar results 
were published by Werth et al. [177], who showed that 5% glucose was 
required to preserve the transfection efficacy of low molecular weight 
polyethylenimine based siRNA polyplexes, but atomic force microscopy 
demonstrated a broadening of the polyplex particle size.  
In conclusion, this brief overview on the current status of lyophilization of nucleic 
acid nanoparticles illustrates that until now neither plasmid DNA/ LPEI 
polyplexes (see Chapter 5) nor siRNA polyplexes (see Chapter 7) could be 
perfectly stabilized by lyophilization. Moreover, besides the preservation of 
transfection efficiency, crucial quality control parameters, such as retention of 
particle size, number of subvisible particles in a formulation, or relevant 
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characteristics of the lyophilisates, such as physical state, glass transition 
temperature or residual moisture content, have been rather ignored in the past. 
However, the possibility to produce long-term stable, transfection efficient pDNA 
or siRNA polyplexes with a defined pharmaceutical quality would be an 
important step closer from promising technology to application. 
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Abstract 
Lyophilization is a common, but cost-intensive, drying process to achieve 
protein formulations with long-term stability. In the past, typical process 
optimization has focused on the drying steps and the freezing step was rather 
ignored. However, the freezing step is an equally important step in 
lyophilization, as it impacts both process performance and product quality. 
While simple in concept, the freezing step is presumably the most complex step 
in lyophilization. Therefore, in order to get a more comprehensive 
understanding of the processes that occur during freezing, the physico-chemical 
fundamentals of freezing are first summarized. The available techniques that 
can be used to manipulate or directly control the freezing process in 
lyophilization are also reviewed. In addition, the consequences of the freezing 
step on quality attributes, such as sample morphology, physical state of the 
product, residual moisture content, reconstitution time, and performance of the 
primary and secondary drying phase, are discussed. A special focus is given to 
the impact of the freezing process on protein stability. 
This review aims to provide the reader with an awareness of not only the 
importance but also the complexity of the freezing step in lyophilization and its 
impact on quality attributes of biopharmaceuticals and process performance. 
With a deeper understanding of freezing and the possibility to directly control or 
at least manipulate the freezing behavior, more efficient lyophilization cycles 
can be developed, and the quality and stability of lyophilized 
biopharmaceuticals can be improved. 
 
Keywords 
Lyophilization, freeze-drying, modifications of the freezing step, influence on 
process performance, influence on product quality, influence on protein stability 
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1 Introduction 
Lyophilization also known as freeze-drying is an important and well-established 
process to improve the long-term stability of labile drugs, especially therapeutic 
proteins [1]. About 50% of the currently marketed biopharmaceuticals are 
lyophilized, representing the most common formulation strategy [2]. In the 
freeze-dried solid state, chemical or physical degradation reactions are inhibited 
or sufficiently decelerated, resulting in an improved long-term stability [3]. 
Besides the advantage of better stability, lyophilized formulations also provide 
easy handling during shipping and storage [1].  
A traditional lyophilization cycle consists of three steps; freezing, primary drying, 
and secondary drying [1]. During the freezing step, the liquid formulation is 
cooled until ice starts to nucleate, which is followed by ice growth. This results 
in the separation of most of the water into ice crystals from a matrix of glassy 
and/or crystalline solutes [4,5]. During primary drying, the crystalline ice formed 
during freezing is removed by sublimation. Therefore, the chamber pressure is 
reduced well below the vapor pressure of ice, and the shelf temperature is 
raised to supply the heat removed by ice sublimation [6]. At the completion of 
primary drying, the product can still contain approximately 15–20% of unfrozen 
water, which is then desorbed during the secondary drying stage, usually at 
elevated temperature and low pressure, to finally allow the desired low moisture 
content to be achieved [7].  
In general, lyophilization is a very time- and energy-intensive drying process [8]. 
Freezing is typically over within a few hours, while drying often requires days. 
Within the drying phase, however, secondary drying is relatively short (~hours) 
compared to primary drying (~days) [1,4]. For that reason, lyophilization cycle 
development has typically focused on optimizing the primary drying step, i.e. 
shortening the primary drying time by adjusting the shelf temperature and/or 
chamber pressure without influencing product quality [5,9]. Although freezing is 
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one of the most critical stages during lyophilization, the importance of the 
freezing process has rather been neglected in the past [10]. 
The freezing step is of paramount importance. Freezing itself is the major 
dehydration step in lyophilization [6]. Solvent water is removed from the liquid 
formulation in the form of a pure solid ice phase, leading to a dramatic 
concentration of the solutes [11,12]. Moreover, the kinetics of ice nucleation and 
crystal growth determine the physical state and morphology of the frozen cake 
and consequently the final properties of the freeze-dried product [11-13]. Ice 
morphology is directly correlated with the rate of sublimation in primary and 
secondary drying [14]. In addition, freezing is a critical step with regards to the 
biological activity and stability of the active pharmaceutical ingredients (API), 
especially pharmaceutical proteins [1]. 
While simple in concept, the freezing process is presumably the most complex 
but also the most important step in the lyophilization process [10]. To meet this 
challenge, a thorough understanding of the physico-chemical processes that 
occur during freezing is required. Moreover, in order to optimize the freeze-
drying process and product quality, it is vital to control the freezing step. But the 
random nature of ice nucleation makes this challenging. However, several 
approaches have been developed to trigger ice nucleation during freezing. 
The purpose of this review is to provide the reader with an awareness of the 
importance and complexity of the physico-chemical processes that occur during 
freezing. Furthermore, currently available freezing techniques are summarized, 
and an attempt is made to address the consequences of the freezing procedure 
on process performance and product quality. A special focus is given to the 
critical factors that influence protein stability. Understanding and controlling the 
freezing step in lyophilization will lead to optimized, more efficient lyophilization 
cycles as well as products with an improved stability. 
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2 Physico-chemical fundamentals of freezing 
In general, freezing is defined as the process of ice crystallization from 
supercooled water [15]. The freezing process first involves the cooling of the 
solution until ice nucleation occurs. Ice crystals begin to grow at a certain rate, 
resulting in freeze-concentration of the solution, a process that can result in 
both crystalline and amorphous solids, or in mixtures [11]. The following 
sections (2.1–2.3) summarize the physico-chemical fundamentals of freezing. 
First, the distinction between cooling rate and freezing rate should be 
emphasized. The cooling rate is defined as the rate at which a solution is 
cooled. The freezing rate is the rate of post-nucleation ice crystal growth, which 
is largely determined by the amount of supercooling prior to nucleation [16,17]. 
Therefore, the freezing rate of a formulation is not necessarily related to its 
cooling rate [18]. 
2.1 Freezing phenomena: supercooling, ice nucleation and ice 
crystal formation 
In order to review the physico-chemical processes that occur during freezing of 
pure water, the relationship between time and temperature during freezing is 
displayed in Figure 2-1. When pure water is cooled at atmospheric pressure, it 
does not freeze spontaneously at its equilibrium freezing point (0 °C) [19]. The 
retention of the liquid state below the equilibrium freezing point of the solution is 
termed as ‘‘supercooling’’ [19]. Supercooling (represented by line A) always 
occurs during freezing, often in the range of 10–15 °C or more [12,18]. The 
degree of supercooling depends on the solution properties and process 
conditions and is defined as the difference between the equilibrium ice 
formation temperature and the actual temperature at which ice crystals first 
form [1,6,11,20]. As discussed later, it is necessary to distinguish between 
‘‘global supercooling’’, in which the entire liquid volume exhibits a similar level of 
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supercooling, and ‘‘local supercooling’’, in which only a small volume of the 
liquid is supercooled [14]. Supercooling is a non-equilibrium, meta-stable state, 
which is similar to an activation energy necessary for the nucleation 
process [21]. Due to density fluctuations from Brownian motion in the 
supercooled liquid water, water molecules form clusters with relatively long-
living hydrogen bonds [22] with similar molecular arrangements as in ice 
crystals [11,15]. Because this process is energetically unfavorable, these 
clusters break up rapidly [15]. The probability for these nuclei to grow in both 
number and size is more pronounced at lowered temperatures [15]. Once the 
critical mass of nuclei is reached, ice crystallization occurs rapidly in the entire 
system (point B) [15,21,22].  
 
Figure 2-1: Temperature profile measured with a thermocouple for a pure water sample during 
shelf-ramped freezing at -1 °C/min. The figure was created from own data by the authors. 
The limiting nucleation temperature of water, referred to as the ‘‘homogeneous 
nucleation temperature’’, appears to be at about -40 °C. At this temperature, the 
pure water sample will contain at least one spontaneously formed active water 
nucleus, capable of initiating ice crystal growth [11]. However, in all 
pharmaceutical solutions and even in sterile-filtered water for injection, the 
nucleation observed is ‘‘heterogeneous nucleation’’. Meaning that ice-like 
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clusters are formed via adsorption of layers of water on ‘‘foreign 
impurities’’ [6,11]. Such ‘‘foreign impurities’’ may be the surface of the container, 
particulate contaminants present in the water, or even sites on large molecules 
such as proteins [23–25].  
Once stable ice crystals are formed, their growth proceeds by the addition of 
molecules to the interface [22]. However, only a fraction of the freezable water 
freezes immediately, as the supercooled water can absorb only 15 cal/g of the 
79 cal/g of heat given off by the exothermic ice formation [12,22]. Therefore, 
once crystallization begins, the product temperature rises rapidly to near the 
equilibrium freezing point [12,26]. After the initial ice network has formed (point 
C), additional heat is removed from the solution by further cooling, and the 
remaining water freezes when the previously formed ice crystals grow [12]. Ice 
crystal growth is controlled by the latent heat release and the cooling rate which 
the sample is exposed to [22]. The freezing time is the time taken from the 
completed ice nucleation to the time of removal of latent heat (from point C to 
point D). The temperature drops when the freezing of the sample is completed 
(point E) [21].  
The number of ice nuclei formed, the rate of ice growth, and the ice crystals’ 
size depend on the degree of supercooling [14,20]. The higher the degree of 
supercooling, the higher the rate of nucleation and the faster the effective rate 
of freezing. This results in a high number of small ice crystals. In contrast, at a 
lower degree of supercooling, one observes a lower number of large ice 
crystals [14,19]. The rate of ice crystal growth can be expressed as a function of 
the degree of supercooling [23]. For example, for water for injection showing a 
degree of supercooling of 10 ± 3 °C, an ice crystal growth rate of about 5.2 cm/s 
results [23]. In general, a slower cooling rate leads to a faster freezing rate and 
vice versa. Thus, in case of cooling rate versus freezing rate, it has to be kept in 
mind ‘‘slow is fast and fast is slow’’.  
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Nevertheless, one has to distinguish between the two basic freezing 
mechanisms; global supercooling and directional solidification. When global 
supercooling occurs, which is typically the case for shelf-ramped freezing, the 
entire liquid volume achieves a similar level of supercooling and solidification 
progresses through the already nucleated volume [12,14]. In contrast, 
directional solidification occurs when a small volume is supercooled, which is 
the case for high cooling rates, e.g., with nitrogen immersion. Here, the 
nucleation and solidification front are in close proximity in space and time and 
move further into non-nucleated solution. In this case, a faster cooling rate will 
lead to a faster freezing rate [12,14].  
However, ice nucleation in general is a stochastically event [6,18]. Ice 
nucleation and, in consequence, ice crystal size distribution will differ from 
vial-to-vial, resulting in a large sample heterogeneity within one batch [6,14,27]. 
During freezing, the growth of ice crystals within one vial can also be 
heterogeneous, influencing intra-vial uniformity [5].  
So far 10 polymorphic forms of ice have been described. However, at 
temperatures and pressures typical for lyophilization, the stable crystal structure 
of ice is limited to the hexagonal type, in which each oxygen atom is 
tetrahedrally surrounded by four other oxygen atoms [23]. The fact that the ice 
crystal morphology is a unique function of the nucleation temperature was first 
reported by Tammann in 1925 [28]. In general, three different types of growth of 
ice crystals around nuclei can be observed in solution [15]. (i) If the water 
molecules are given sufficient time, they arrange themselves regularly into 
hexagonal crystals, called dendrites; (ii) if the water molecules are incorporated 
randomly into the crystal at a fast rate, ‘‘irregular dendrites’’ or axial columns 
that originate from the center of crystallization are formed; (iii) at higher cooling 
rates, many ice spears can originate from the center of crystallization without 
side branches, referred to as spherulites. However, the ice morphology 
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depends not only on the degree of supercooling but also on the freezing 
mechanism. It is reported that ‘‘global solidification’’ creates spherulitic ice 
crystals, whereas ‘‘directional solidification’’ results in directional lamellar 
morphologies with connected pores [12,14]. While some solutes will have 
almost no effect on ice structure, other solutes can affect not only the ice 
structure but also its physical properties [19]. Based on Raoults’s Law, the 
presence of solutes at high concentrations will result in a depression of the 
freezing point of the solution and in a faster ice nucleation because of the 
promotion of heterogeneous nucleation. This leads to a enormously lowered 
degree of supercooling [21]. 
2.2 Crystallization and vitrification of solutes 
The hexagonal structure of ice is of great importance in the lyophilization of 
pharmaceutical formulations, while most solutes cannot fit in the dense 
structure of the hexagonal ice as it forms [23]. Consequently, the concentration 
of the solute constituents of the formulation is increased in the interstitial region 
between the growing ice crystals. This is referred to as 
‘‘cryoconcentration’’ [11,12]. If this separation does not occur, a solid solution is 
formed with a greatly reduced vapor pressure and the formulation cannot be 
lyophilized [23]. The total solute concentration increases rapidly and is only a 
function of the temperature and independent of the initial concentration [4]. For 
example, for an isotonic saline solution a 20-fold concentration increase is 
reported when cooled to -10 °C, and all other components in a mixture show 
similar concentration increases [4]. Upon further cooling, the solution will 
increase to a critical concentration, above which the concentrated solution will 
either undergo eutectic freezing or vitrification [7].  
An eutectic mixture is formed by the simple crystallization of solutes from 
cryoconcentrated solution [19]. For example, mannitol, glycine, sodium chloride, 
and phosphate buffers are known to crystallize upon freezing, if present as the 
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major component [12]. When such a solution is cooled, pure ice crystals will 
form first. Two phases are present, ice and freeze-concentrated solution. The 
composition is determined via the equilibrium freezing curve of water in the 
presence of the solute (Figure 2-2).  
 
Figure 2-2: State diagram for a water (w)/solute (s) system. Tm (w) and Tm (s): melting 
temperatures of water and solute, Teu: eutectic temperature, Tg (w) and Tg (s): glass transition 
temperature of water and solute and Tg`: glass transition temperature of the maximally freeze-
concentrated solution. Crystallization (black drawings) of a solute occurs below Teu. In the case 
of vitrification (gray drawings), the solute does not crystallize at Teu, freeze-concentration 
proceeds and transits into a glass state at Tg`. The figure was modified from Ref. [18] 
The system will then follow the specific equilibrium freezing curve, as the solute 
content increases as more pure water is removed via ice formation. The lowest 
temperature at which the solute remains a liquid is the eutectic melting 
temperature (Teu). As the solution reaches Teu and a certain solute 
concentration (Ceu), the freezing curve will meet the solubility curve. Here, the 
freeze-concentrate is saturated and eutectic freezing, which means solute 
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crystallization, will occur [7,19]. Only below Teu, the system can be completely 
solidified [19]. The Teu and Ceu are independent of the initial concentration of 
the solution [7]. In general, the lower the solubility of a given solute in water, the 
higher the Teu [19]. A general rule for multi-component systems is that the 
crystallization of any component is influenced, i.e. hindered, by other 
components [11]. In practice, similar to the supercooling of water, only a few 
solutes will spontaneously crystallize at Teu [11]. Such delayed crystallization of 
solutes from a freezing solution is termed supersaturation and can lead to an 
even more extreme freeze-concentration [11]. Moreover, supersaturation can 
inhibit complete crystallization, leading to a meta-stable glass formation 
(e.g., mannitol) [12,23]. It is also possible that crystalline states exist in a 
mixture of different polymorphs or as hydrates [11]. For example, mannitol can 
exist in the form of several polymorphs (α, β and δ), and under certain 
processing conditions, it can crystallize as a monohydrate [11].  
The phase behavior is extremely different for polyhydroxy compounds, like 
sucrose, which do not crystallize at all from a freezing solution in real time [11]. 
The fact that sucrose does not crystallize during freeze-concentration is an 
indication of its extremely complex crystal structure [11]. The interactions 
between sugar -OH groups and those between sugar -OH groups and water 
molecules are closely similar in energy and configuration, resulting in very low 
nucleation probabilities [11]. In this case, water continues to freeze beyond the 
eutectic melting temperature, and the solution becomes increasingly 
supersaturated and viscous [11]. The increasing viscosity slows down ice 
crystallization until at some characteristic temperature no further freezing 
occurs [11]. This is called glassification or vitrification [18]. The temperature at 
which the maximal freeze-concentration (Cg`) occurs is referred to as the glass 
transition temperature (Tg`) [11,29]. This is the intersection of the freezing point 
depression curve and the glass transition or isoviscosity curve, shown in the 
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‘‘supplemented phase diagram’’ [30] or ‘‘state diagram’’ (Figure 2-2) [11]. Tg` is 
the point on the glass transition curve, representing a reversible change 
between a viscous, rubber-like liquid and a rigid glass system [19]. In the region 
of the glass transition, the viscosity of the freeze-concentrate changes about 
four orders of magnitude over a temperature range of a few degrees [19]. Tg` 
depends on the composition of the solution, but is independent of the initial 
concentration [4,11,27]. For example, the maximal freeze-concentration of 
sucrose is a concentration of 72–73% [31]. In addition to Tg`, the collapse 
temperature (Tc) of a product is used to define more precisely the temperature 
at which a structural loss of the product will occur. In general, Tc is several 
degrees higher than Tg` as the high viscosity of the sample close to Tg` will 
prevent viscous flow [10]. The glassy state is a solid solution of concentrated 
solutes and unfrozen, amorphous water. It is thermodynamically unstable with 
respect to the crystal form, but the viscosity is high enough, in the order of 
1014 Pa s, so that any motion is in the order of mm/year [4,11,29].  
The important difference between eutectic crystallization and vitrification is that 
the interstitial between the ice crystal matrices in crystalline material consists of 
an intimate mixture of small crystals of ice and solute, whereas the interstitial 
region in amorphous solutes consists of solid solution and unfrozen, amorphous 
water [19,23]. Therefore, in crystalline material, nearly all water is frozen and 
can easily be removed during primary drying without requiring secondary 
drying [19]. However, in amorphous solutes, about 20% of unfrozen water is 
associated with the solid solution, which must be removed by a diffusion 
process during secondary drying [19]. Moreover, the Teu for crystalline material 
and the Tg`, respectively Tc, for amorphous material define the maximum 
allowable product temperature during primary drying [19]. Eutectic melting 
temperatures are relatively high compared to glass transition temperatures, 
allowing a higher product temperature during primary drying and resulting in 
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more efficient drying processes [19]. If the product temperature exceeds this 
critical temperature, crystalline melting or amorphous collapse will occur. This 
loss of structure in the freeze-dried products is termed ‘‘cake collapse’’ [11,19]. 
2.3 Phase separation and other types of freezing behavior 
A property characteristic of multi-component aqueous solutions (particularly 
those containing at least one polymer component) is the liquid–liquid phase 
separation during freezing into two liquid equilibrium phases, which are 
enriched in one component [11,19]. This phase separation behavior has been 
reported for aqueous solutions of polymers such as PEG/dextran or 
PVP/dextran but is also reported for proteins and excipients [32,33]. When a 
critical concentration of the solutes is reached, the enthalpically unfavorable 
interactions between the solutes exceed the favorable  entropy of a solution 
with complete miscibility [34]. Another proposed explanation is that solutes have 
different effects on the structure of water, leading to phase separation [35].  
Besides the separation into two amorphous phases, two other types of phase 
separation are stated in literature; crystallization of amorphous solids and 
amorphization from crystalline solids [18]. Crystallization of amorphous solids 
often occurs when meta-stable glasses are formed during freezing. Upon 
extremely fast cooling, a compound that normally would crystallize during 
slower freezing is entrapped as an amorphous, meta-stable glass in the freeze-
concentrate [12,23]. However, with subsequent heating above Tg`, it will 
undergo crystallization, which is the basis for annealing during freeze-drying 
(see Section 3.3) [19]. Without annealing, the meta-stable glass can crystallize 
spontaneously out of the amorphous phase during drying or storage [18]. 
Amorphization from crystalline solids, that can be buffer components or 
stabilizers, predominantly occurs during the drying step and not during the 
freezing step [18,36].  
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Additionally, lyotropic liquid crystals, which have the degree of order between 
amorphous and crystalline, are reported to form as a result of freeze-
concentration. However, their influence on critical quality attributes of the 
lyophilized product is not clarified [19]. Clathrates, also termed gas hydrates, 
are also known to form, especially in the presence of non-aqueous co-solvents, 
when the solute alters the structure of the water [23]. 
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3 Modifications of the freezing step 
As aforementioned, the ice nucleation temperature defines the size, number, 
and morphology of the ice crystals formed during freezing. Therefore, the 
statistical nature of ice nucleation poses a major challenge for process control 
during lyophilization. This highlights the importance of a controlled, reproducible 
and homogeneous freezing process. Several methods have already been 
developed in order to control and optimize the freezing step. Some only tend to 
influence ice nucleation by modifying the cooling rate, and some just statistically 
increase the mean nucleation temperature. Few others allow a true control of 
the nucleation at the desired nucleation temperature. 
3.1 Shelf-ramped freezing 
Shelf-ramped freezing is a conventional freezing condition that is most often 
employed in lyophilization [37]. Here, the filled vials are placed on the shelves of 
the lyophilizer, and the shelf temperature is then decreased linearly (0.1 °C/min 
up to 5 °C/min, depending on the capacity of the lyophilizer) with time [37,38]. 
Both water and ice have low thermal conductivities and large heat capacities. 
The thermal conductivity between vials and shelf is limited; thus, the shelf-
ramped cooling rate is inherently slow [11]. In order to ensure the complete 
solidification of the samples, they must be cooled below Tg` for amorphous 
material and, respectively, below Teu for crystalline material. Traditionally, 
many lyophilization cycles use a final shelf temperature of -50 °C or lower as 
this was the maximal cooling temperature of the freeze-drier [7]. It is now 
suggested to use a final shelf temperature of -40 °C if the Tg` or Teu is higher 
than -38 °C, or to use a temperature 2 °C less than the Tg` and Teu [1]. 
Complete solidification also requires a significant amount of time [11]. The time 
for complete solidification generally depends on the fill volume. The larger the 
fill volume, the more time is required for complete solidification [11]. Tang et 
al. [1] suggest that the final shelf temperature should be held for 1 h for samples 
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with a fill depth of less than or equal to 1 cm or 2 h for samples with a fill depth 
of greater than 1 cm. Fill depths greater than 2 cm should be avoided. However, 
the holding time should be increased proportionately when such high depths are 
required.  
To obtain a more homogeneous freezing, the vials are often equilibrated for 
about 15-30 min at a lowered shelf temperature (5-10 °C) before the shelf 
temperature is linearly decreased [1]. The vials are either directly loaded on the 
cooled shelves or loaded at ambient temperatures, and the shelf temperature is 
then decreased to the hold temperature [1,5,9]. 
Two-step freezing is another modification of the shelf-ramped freezing process, 
where a ‘‘supercooling holding’’ is applied. Here, the shelf temperature is 
decreased from either room temperature or the preset lowered shelf 
temperature, to about -5 to -10 °C and held for 30-60 min. This leads to a more 
homogenous supercooling state across the total fill volume [1,5]. When the shelf 
temperature is then further decreased, relatively homogeneous ice formation is 
observed [5].  
Although shelf-ramped frozen samples show a high degree of supercooling, ice 
crystal growth proceeds extremely fast when the nucleation temperature is 
reached and results in many small ice crystals [9,39]. The ice nucleation cannot 
be directly controlled when shelf-ramped freezing is applied and is therefore 
quite random [4]. It is not practical to manipulate the ice nucleation temperature 
as the cooling rates are limited inside the lyophilizer and the degree of 
supercooling might not change within such a small range [1,14]. A drawback of 
shelf-ramped freezing is the fact that different vials may become subject to 
different degrees of supercooling, typically about ±3 °C from the mean [4]. This 
results in a great variability in product quality and process performance [4]. 
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3.2 Pre-cooled shelf method 
When applying the pre-cooled shelf method, the vials are placed on the 
lyophilizer shelf that has already cooled to the desired final shelf temperature, 
e.g. -40 °C or -45 °C [1,13,14]. It is reported that the placement of samples on a 
pre-cooled shelf results in higher nucleation temperatures (-9.5 °C) compared to 
the conventional shelf-ramped freezing (-13.4 °C) [14]. Moreover, the freezing 
rate after ice nucleation is actually slower compared to shelf-ramped freezing 
due to the lowered degree of supercooling and more limited time for thermal 
equilibration throughout the fill volume [40]. A large heterogeneity in 
supercooling between vials is also observed with this method [14]. A distinct 
influence of the loading shelf temperature on the nucleation temperature is 
described in literature [13,14]. Searles et al. [14] found that the nucleation 
temperatures for samples placed on a shelf at -44 °C were several degrees 
higher than for samples placed on a -40 °C shelf. Thus, the shelf temperature 
should be chosen with care when using this method. 
3.3 Annealing 
Annealing is a hold step at a temperature above the glass transition 
temperature [12]. Annealing is generally performed to allow for complete 
crystallization of crystalline compounds and to improve inter-vial heterogeneity 
and drying rates [1,19]. Tang et al. [1] proposed the following annealing 
protocol: When the final shelf temperature is reached after the freezing step, the 
product temperature is increased to 10-20 °C above Tg` but well below Teu and 
held for several hours. The shelf temperature is then decreased and held at the 
final shelf temperature. Annealing has a rigorous effect on the ice crystal size 
distribution [17,41] and can eliminate the interdependence between the ice 
nucleation temperature and ice crystal size and morphology. If the sample 
temperature exceeds Tg`, the system follows the equilibrium freezing curve and 
some of the ice melts [12,41]. The raised water content and the increased 
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temperature enhance the mobility of the amorphous phase and all species in 
that phase [12]. Increased mobility of the amorphous phase enables the 
relaxation into physical states of lower free energy [12]. According to the Kelvin 
equation, ice crystals with smaller radii of curvature will melt preferentially due 
to their higher free energy compared to larger ice crystals [12,37,41]. Ostwald 
ripening (recrystallization) results in the growth of dispersed crystals larger than 
a critical size at the expense of smaller ones and is a consequence of these 
chemical potential driving forces [12,41]. Small ice crystals do not reform upon 
refreezing of the annealed samples, as the present large ice crystals serve as 
nucleation sites for addition crystallization [41]. The mean ice crystal radius 
rises with time1/3 during annealing [37,41]. As a consequence of that time 
dependency, the inter-vial heterogeneity in ice crystal size distribution is 
reduced with increasing annealing time. Meaning, vials comprised of smaller ice 
crystals ‘‘catch up’’ with the vials that contained larger ice crystals at the start of 
annealing [12,17,37,41]. Searles et al. [41] found that when annealing multiple 
sheets of lamellar ice crystals with a high surface area merged to form pseudo-
cylindrical shapes with a lower interfacial area. In addition to the increased ice 
crystal size, it was also observed that annealing opened up holes on the surface 
of the lyophilized cake. The hole formation is explained by the diffusion of water 
from melted ice crystals through the frozen matrix at the increased annealing 
temperature. And in the case of meta-stable glass formation of crystalline 
compounds, annealing facilitates complete crystallization [42]. Above Tg`, the 
meta-stable glass is re-liquefied and crystallization occurs when enough time is 
provided. Furthermore, annealing can also promote the completion of freeze-
concentration (devitrification), as it allows amorphous water to crystallize [41]. 
This is of importance when samples are frozen too fast, and water capable of 
crystallization was entrapped as amorphous water in the glassy matrix. The 
phenomenon of annealing also becomes relevant when samples are optimally 
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frozen, but then kept at suboptimal conditions in the lyophilizer or in a freezer 
before lyophilization is performed [11] 
3.4 Quench freezing 
Quench freezing, also referred to as vial immersion, is the process of immersing 
vials into either liquid nitrogen or liquid propane (ca. -200 °C) or a dry 
ice/acetone or dry ice/ethanol bath (ca. -80 °C), long enough for complete 
solidification. The vials are then placed on a pre-cooled shelf [9,16]. In this 
case, ice crystal formation begins on both the vial wall and bottom, where the 
heat transfer media has contact [10]. This freezing method results in a lowered 
degree of supercooling, as well as a high freezing rate. Because the sample 
temperature is decreased quickly, small ice crystals are formed. Liquid nitrogen 
immersion has been said to induce less supercooling than slower 
methods [9,37,39]. However, this faster cooling method actually induces 
supercooling only in a small sample volume before nucleation starts and 
freezes by directional solidification [12,14]. While it is reported that external 
quench freezing might be advantageous for some applications [39], this 
uncontrolled freezing method promotes heterogeneous ice crystal formation and 
is not applicable in large-scale manufacturing [7]. 
3.5 Directional freezing 
Directional or vertical freezing can be performed in order to generate straight, 
vertical ice crystallization. Ice nucleation is induced at the bottom of the vial by 
contact with dry ice and followed by slow freezing on a pre-cooled shelf [9]. In 
this case, the ice propagation is vertical, and lamellar ice crystals are 
formed [9]. 
Unidirectional solidification is a similar approach described by Schoof et al. [43] 
as the solidification through a gradient freezing stage which is based on the 
Power Down principle. Homogenous ice crystal morphology here occurs with a 
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temperature gradient between the upper and the lower cooling stage of 
50 K/cm. 
3.6 Ice fog technique 
In 1990, Rowe [44] described an ice fog technique for the controlled ice 
nucleation during freezing. After the vials are cooled to the desired nucleation 
temperature, on the lyophilizer shelf, a flow of cold nitrogen is released into the 
chamber. The high humidity of the chamber generates an ice fog, a vapor 
suspension of small ice particles. The ice fog penetrates into the vials, where it 
initiates ice nucleation at the solution surface [45]. Rambhatla et al. [20] 
successfully implemented this technique for temperature controlled nucleation, 
in the range of -1 °C to -11 °C, in laboratory scale lyophilizers. The challenge in 
this study was the induction of ice nucleation in all vials at the same time. 
Because the small particle of the ice fog does not reach all the vials 
simultaneously, intervial heterogeneity occurs [20]. Therefore, Patel et al. 
introduced a variation in the ice fog method, in which a reduced pressure in the 
chamber was applied to enable a faster and more uniform freezing [45]. With 
this modification, a rapid ice nucleation within one minute and a uniform ice 
crystal structure in all vials were observed. Although it is a promising technique 
to control ice nucleation inside the lyophilizers, it is not yet implemented in 
largescale, commercial lyophilization [20]. 
3.7 Electrofreezing 
Electrofreezing (EF) is another method to control ice nucleation. In this method, 
a high voltage pulse is applied to generate an ice nucleus on a platinum 
electrode, which initiates ice crystallization [46,47]. The capability of high 
voltage to induce ice nucleation in supercooled water was first reported by 
Rau [48] in 1951. There are still, however, discussions about the basic 
mechanisms of EF, including the influence on molecular dynamics [46], bubble 
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formation and breakdown [48], and electrolytic formation of hydrated metal-ion 
complexes [49]. For this external freezing method, samples are first cooled to 
the desired temperature. Ice nucleation is then induced by EF, and samples are 
further cooled. For direct EF, a simple and disposable electrode setup 
composed of a gold wire can be used to allow the ice nucleation of many 
samples at the same time (Figure 2-3a) [47]. However, the presence of high 
amounts of excipients, especially salts, inhibits ice nucleation [46,47]. Special 
electrode caps (Figure 2-3b), called indirect EF, were developed as a result, to 
achieve ice nuclei generation independent form the sample composition [47]. In 
these caps, the ice nucleus is formed on the platinum electrode in a separate 
small volume of water. It then grows through a narrow cannula and PTFE-tube 
into the sample [47].  
 
 
Figure 2-3: Schematic drawing of the electrodes used for (a) direct and (b) indirect 
electrofreezing, adapted from Ref. [47]. 
This method only allows the parallel freezing of eight samples under identical 
conditions [46]. The ice nucleation temperature can be induced at the desired 
temperature by electrofreezing (-1.5 to -8.5 °C for indirect EF and -4.5 to -8.5 °C 
for direct EF) [47]. Small spherical ice crystals grow when the ice nucleation 
temperature is low and large plate-like ice crystals form at higher ice nucleation 
temperatures [47]. However, this freezing method has only been applied in 
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modified cryotubes, and the need for individual electrodes for each sample 
diminishes the applicability in manufacturing. 
3.8 Ultrasound-controlled ice nucleation 
Nucleation can be induced by ultrasonic vibration. This was first applied in the 
food science field, e.g. for manufacturing of ice cream [15]. Inada et al. [50] 
reported that the phase change from supercooled water to ice, by ultrasonic 
vibration, can be actively controlled at the desired freezing temperature. The 
mechanisms of sono-nucleation are still being discussed [51–53]. Acoustic 
cavitation, which results in the formation of air bubbles in the liquid, is a key 
factor. In addition, during the final stage of collapse of a cavitating bubble, the 
equilibrium freezing temperature of water increases due to very high pressures. 
This results in an increased supercooling level, which is the driving force for ice 
nucleation.  
Nakagawa et al. [54] introduced ultrasound-controlled nucleation for 
lyophilization of pharmaceutical proteins. An ultrasound transducer, which is 
connected to an ultrasound generator, is attached to an aluminum plate, which 
is combined with a cooling stage to cool the vials (Figure 2-4). Ice nucleation is 
triggered with an ultrasound wave once the vials have reached a desired 
temperature. Samples are then continually cooled down to the final temperature 
to allow for complete solidification.  
 
 
Figure 2-4: Cooling stage with ultrasound system proposed by Nakagawa et al. [54]. 
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Larger and directional ice crystals of the dendrite type were found when the 
sample was nucleated at higher temperatures, while smaller and 
heterogeneous ice crystals were formed at lower nucleation temperatures. It 
was also observed that ice crystal initiated by ultrasound started at the bottom 
of the vial and progressed to the top, resulting in the possible formation of a 
cryoconcentrated solution layer at the top of the sample. In comparison with the 
samples nucleated at the same nucleation temperature without ultrasound, no 
significant differences in ice morphology were observed. This indicates that the 
ice morphology depends only on the nucleation temperature, and not on the 
mode of nucleation. In a follow-up study, Hottot et al. [55] investigated the effect 
of ultrasound-controlled nucleation on structural and morphological properties of 
freeze-dried mannitol solutions. They found that a compromise between 
nucleation temperature level and ultrasound pulse power is necessary to get the 
most stable mannitol polymorph with a highly permeable cake structure [55]. 
Saclier et al. [53,56] found in a theoretical model and also experimentally that 
the size and circularity of the ice crystals depends on both supercooling and the 
acoustic power used. In the aforementioned studies, the controlled ice 
nucleation during freezing was always performed externally. Passot et al. [57] 
used a prototype freeze-dryer, in which one of the shelves is equipped with the 
ultrasound technology. In accordance, they found that the controlled nucleation 
by ultrasound was possible at a nucleation temperature close to the equilibrium 
freezing point and that the homogeneity of the whole batch (100 vials) could be 
improved.  
A significant intra-vial heterogeneity of ice crystal distribution with smaller ice 
crystals at the vial bottom compared to larger ice crystals at the top was 
observed by applying ultrasound-induced ice nucleation [54]. Thus, Nakagawa 
et al. [54] applied an additional annealing step to reduce the intra-vial 
heterogeneity. A good mechanical and thermal contact between the more or 
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less curved vial bottoms and the plate surface is another challenge for 
successful implementation [54]. However, an advantage of ultrasound-
controlled nucleation is the ability to be applied without the need for direct 
contact with the product and is thus chemically non-invasive [15]. 
3.9 Vacuum-induced surface freezing 
At low pressure, evaporation of water is favored. Known as self-cooling, the 
associated enthalpy of evaporation reduces the local temperature in the water 
surface, such that the water surface freezes, and a thin film of ice is 
formed [58,59]. Based on this concept, Kramer et al. [59] introduced a ‘‘vacuum-
induced surface freezing’’ technique. The vials were placed onto the pre-cooled 
shelves (+10 °C) of the freeze-drier, and the pressure was reduced to 1 mbar 
(equal to 750 mTorr). After 5 min under these conditions, a 1-3 mm thick layer 
of ice was formed on the surface of the sample. In order to prevent further water 
loss by boiling and inhibit melting of the ice film on the surface, the chamber 
pressure was released to atmospheric pressure as fast as possible, and the 
shelf temperature was simultaneously decreased to 3-4 °C below the eutectic 
melting temperature of the formulation. This temperature was held for 1 h, and 
the shelf temperature was subsequently decreased to -40 °C. The release of 
the vacuum and reduction in the shelf temperature lead to the growth of 
dendritic ice crystals, resulting in the formation of long, chimney-like, extremely 
large ice crystals.  
It is still unclear whether this technique can be scaled up for commercial 
applications. Moreover, this method has high risks of uncontrolled boiling, which 
can result in a ‘‘puff off’’ [5] when the unfrozen portion in the vial boils and blows 
up the frozen surface. This can influence the concentration of the sample [10] 
and could also influence the API. Therefore, Liu et al. [5] modified this method 
as follows: The temperature was held at -10 °C for equilibration before pulling a 
vacuum to 600 mTorr to induce freezing. In parallel, the shelf temperature was 
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rapidly (>1 °C/min) decreased to -45 °C. They showed that the lowered initial 
shelf temperature is necessary because when performed at higher 
temperatures ice is only formed at the top of the vial. The heat uptake by 
evaporation is not enough to lower the temperature of the whole fill volume and 
therefore results in a two-layer solidification (the first from vacuum-induced 
freezing, the second from shelf cooling). 
3.10  High-pressure shift freezing or depressurization technique 
‘‘High-pressure assisted freezing’’ was the first freezing method in which 
increased pressures were applied to promote freezing [15,60]. Under high 
pressure, the freezing point of water is lowered and a large number of small ice 
crystals are formed [61]. This method also generates smaller ice crystals 
compared to other conventional rapid freezing methods, such as liquid nitrogen 
immersion [62]. So far, this method was only applied in food science.  
Later, researchers from the same group investigated a ‘‘high-pressure shift 
freezing’’ method [63,64] where the pressure is released slowly or quickly. The 
phase transition from liquid to solid occurs as a result of the pressure change, 
and instantaneous ice formation is promoted. In 2007, Gasteyer et al. [65] 
introduced an analogous method, referred to as ‘‘depressurization method’’, for 
the controlled ice nucleation in samples intended for lyophilization. The samples 
are initially cooled to the equilibrium freezing temperature in a pressurized gas 
atmosphere, which is subsequently de-pressurized to induce ice nucleation.  
This freezing method involves several steps. The freeze-dryer is loaded, and air 
within the chamber is purged with a pressurization gas, e.g. argon or nitrogen. 
The chamber is pressurized up to less than 50 psig (approximately 2600 Torr or 
3.5 bar), and the samples are cooled to and equilibrated at the desired 
nucleation temperature. The samples are then nucleated by depressurizing the 
freeze-drying chamber. After the nucleation, the samples are further cooled to 
the final shelf temperature. The detailed construction of a freeze-dryer, that is 
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applicable for that purpose, is described in more detail in a follow-up patent by 
Rampersad et al. [66]. The system consists of a freeze-drying chamber, a gas 
circuit to pressurize the freeze-drying chamber, and a separate circuit for 
depressurization.  
Bursac et al. [67] demonstrated that this freezing method could be applied in 
both laboratory and small commercial-scale freeze-dryers for a wide range of 
formulations and containers. They showed that the nucleation of aqueous 
samples could be well controlled within 1 °C of the equilibrium freezing point. 
One main advantage of this technique is that the samples are only contacted by 
inert gas, which is removed from the vials during lyophilization [67]. The 
technique can be implemented with minor additions to equipment on freeze-
dryers that are designed to withstand pressures, i.e. during steam 
sterilization [66,67]. However, in the presence of a capacitance manometer, or if 
the product chamber is not intended and approved for such high pressures, the 
adaptation of this technique will be very cost-intensive. This required equipment 
has now been integrated in commercially available freeze-dryers with the 
‘‘ControLyo™ nucleation on demand technology’’ [68]. 
3.11  Addition of ice nucleating agents 
In general, all insoluble impurities have the potential to serve as ice nucleating 
agent (INA) [15]. INAs promote a heterogeneous ice nucleation process that 
occurs at higher temperatures compared to samples that do not contain 
INAs [15]. The most studied nonbiogenic INA is silver iodine (AgI), which is also 
used for cloudseeding and snow-making [15,69]. AgI enhances ice nucleation 
not only because of crystal structure’s similarity to ice [70] but also because of 
an electric field mechanism [71]. Among the biogenic INAs, six different species 
of ice nucleation bacteria have been studied in food science, of which 
Pseudomonas syringae is most widely used [15,69]. These biogenic INAs favor 
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ice nucleation, because their structure is similar to that of the ice crystal lattice, 
lacks surface charge and is of high hydrophobicity [15,72,73].  
Searles et al. [14] used P. syringae (0.001% w/v) and AgI (1 mg/ml) to alter the 
ice nucleation temperature during freezing of a 10% HES solution. The addition 
of P. syringae reduced supercooling (nucleation at -1.8 °C compared to -13.4 °C 
for control samples) and directional solidification with complete lamellar ice 
crystal structure [14]. Samples seeded with AgI nucleated in a temperature 
range between -5 °C and -7.5 °C in the center of the meniscus, where most of 
the AgI was concentrated and a mixture between spheroidal and lamellar ice 
crystal structures was formed [14]. Liu et al. [5] found in the case of high fill 
depth, AgI (0.1 mg per vial) limited supercooling (about -2 °C). However, this 
study also showed that ice grew from the bottom to the top of the vial and 
dendritic ice crystals were observed. Nucleation efficiency for P. syringae 
depends on the INA concentration [69]. This also seems to be the case for AgI. 
Searles et al. [14] also showed that vials with high particulate contamination 
from drying the open vials after washing in an uncontrolled laboratory 
environment also slightly decreased the degree of supercooling to -11.4 °C 
compared to -13.4 °C in conventional shelf-ramped freezing. Overall, the 
presence of INAs increases the average nucleation temperature but does not 
allow controlled nucleation, and individual vials may show a great 
heterogeneity. Moreover, the addition of ice nucleating agents is not of practical 
use for FDA-regulated and approved pharmaceutical products. 
3.12  Non-aqueous co-solvents 
Teagarden and Baker [74] published a comprehensive review on the potential 
of non-aqueous co-solvents in lyophilization. The use of non-aqueous co-
solvents has both advantages and disadvantages [74]. The advantages include 
increased sublimation rate leading to a decreased drying time, potentially 
increased wettability, improved reconstitution characteristics, increased 
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solubility and stability of some drugs in solution, and enhanced sterility 
assurance [74]. Operator safety concerns due to high degree of flammability or 
explosion potential is one disadvantage. Toxicity and regulatory issues because 
of residual solvent levels can also arise [74]. The most extensively used co-
solvent in lyophilization is tertiary butyl alcohol, tert-butanol (TBA). This is due to 
the fact that it is 100% miscible in water shows a high freezing point (24 °C) and 
a high vapor pressure (26.8 mm Hg at 20 °C) [74]. Other co-solvents that do not 
freeze completely in commercial freeze-driers are very difficult to use and often 
result in unacceptable freeze-dried cakes [74]. In general, the specific effect of 
TBA is related to the modification of the ice crystal habit which leads to the 
growth of needle-shaped crystals [11]. However, the water–TBA mixture shows 
an extremely complex series of eutectic, peritectic, and hydration 
phenomena [11]. Kasraian et al. [75] suggested a phase diagram for TBA-water 
systems, which can be described as side-by-side placement of two simple 
eutectic phase diagrams: one for water-TBA hydrate with Teu at 20% TBA and 
one for TBA hydrate-TBA with Teu at 90% TBA. Depending on the 
concentration of TBA used, ice, solid TBA hydrate, or solid TBA will separate 
upon cooling. At concentrations lower than 20%, pure ice will form and leads to 
increasingly concentrated TBA solutions. TBA crystallizes as TBA hydrate when 
the concentration is increased to 20% TBA.  
The size and morphology of the ice crystals depends on the amount of TBA 
present. In the presence of 1% TBA, the ice crystal morphology does not differ 
from pure water [75]. At a concentration of 3% larger, dendritic ice crystals form. 
Above this concentration, but still below the eutectic concentration of 20%, 
needle-shaped ice crystals form [75]. In accordance, Liu et al. [5] found that with 
the presence of 5% TBA, large needle-like ice crystals were formed and grew 
faster than the ice crystals in the control. It is also reported that the freezing rate 
also influences the size of the ice crystals with the presence of TBA. Smaller ice 
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crystals for fast freezing and bigger ice crystals for slower freezing [76]. 
Moreover, the collapse temperature of e.g. sucrose, is not influenced by TBA 
addition (3-10% w/v) [77].  
The level of residual solvent in the final product can be critical when TBA is 
added to the samples. It is influenced by the initial TBA concentration, the 
freezing rate, and the physical state of the solute [76]. In general, crystalline 
samples contain very low levels of residual TBA. With the presence of an 
amorphous solid, the removal of TBA is hindered when used at low initial 
concentrations (<2%), as TBA does not crystallize but is dispersed in the 
amorphous phase. Complete crystallization is inhibited during fast freezing, 
resulting in high residual TBA levels. Annealing, which promotes TBA 
crystallization, lowers residual TBA levels [78]. An additional critical point is the 
time between filling the highly volatile solvent and freezing of the solution. 
During this time, some dissolved substances can be carried along the 
evaporating stream and recondense near the top of the vial. This time span 
should kept as short as possible in order to avoid dry powder spots near the 
neck of the vial after drying. This will also avoid reduced cake heights [74]. 
3.13  Others 
Vial pretreatment by scoring, scratching, or roughening can also be applied to 
lower the degree of supercooling during freezing. Searles et al. [14] used 
scored vials, scratched at the bottom interior surface with a metal scribe. The 
produced surface defects or scraped glass particles were supposed to catalyze 
ice nucleation. However, only a marginal increase in ice nucleation temperature 
to -13.1 °C, compared to -13.4 °C for shelf-ramped frozen samples, was 
observed. With regard to particle contamination, this method is undesirable for 
pharmaceuticals. Randolph et al. [37] suggested the incorporation of ice 
nucleation chemistry into the vial interior. However, no successful 
implementation has been demonstrated yet. 
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4 Consequences of the freezing step on general quality 
attributes of biopharmaceuticals and process 
performance 
As aforementioned, the freezing process directly influences number, size, and 
shape of ice crystal formation. The ice crystal properties are set early in the 
freezing process by the ice nucleation temperature. The properties are also 
influenced by the freezing rate and the time required for complete solidification 
and directly impact several quality attributes of the biopharmaceutical such as 
morphology, product uniformity, physical state, residual moisture content, or 
reconstitution time and also primary and secondary drying performance, as 
summarized in Table 2-1. However, the quality attributes of the 
biopharmaceutical and process performances are not influenced only by the 
process conditions. It should also be emphasized that the quality attributes are 
also influenced by factors such as formulation composition, fill volume and fill 
depth or properties of the glass vials. 
4.1 Intra-vial and inter-vial uniformity 
The growth of ice crystals during freezing as well as the distribution of solutes 
across the vial can be heterogeneous. Both are reflected by intra-vial 
uniformity [5]. Intra-vial heterogeneity results in unpredictable changes in 
sublimation rate during drying and, in the most extreme case unacceptable 
quality of the biopharmaceutical [5]. The lower the temperature equilibration in 
the sample, the more heterogeneous ice crystals form across the vial. For 
example, ice crystal distribution is more homogeneous in the two-step shelf-
ramped frozen samples when compared to those in shelf-ramped freezing 
without a holding step [5]. More time is available with a slower freezing rate for 
the solute to concentrate ahead of the advancing freezing front.  
  
Table 2-1: Summary of the various freezing methods, which allow or do not allow nucleation control (NC), and their impact on ice nucleation 
temperature (INT), freezing rate (FR), freezing type (global supercooling versus directional solidification), ice crystal morphology (ICM), specific surface 
area (SSA), dry layer resistance (DLR), and drying time (DT). Percentages are referred to the values obtained for shelf-ramped freezing. All trends are 
estimated to best knowledge. ↑↑↑ or ↓↓↓: extremely high or low, ↑↑ or ↓↓: very high or low, ↑ or ↓: high or low. 
 
a For annealing not the freezing rate but the long time provided for ice crystal growth is indicated. 
Freezing Method Description NC INT FR FT ICM SSA DLR DT Examples 
Shelf-ramped freezing Shelf temperature is decreased 
linearly with 0.1 to 5°C/min 
No ↓↓ ↑↑ global very small, 
spherulitic 
↑↑ ↑↑ ↑↑ [14] 10% HES: INT -13.4°C                    
[57] 5% sucrose: INT -7.3°C Two-/three-step freezing Like shelf-ramped freezing but 
with holding step at approx. -
No ↓ ↑ global small, 
spherulitic 
↑ ↑ ↑ [5]: 15% SBECD: DT -3% 
Precooled shelf method Vials are placed on a pre-cooled 
shelf at -40 to -45°C 
No ↑ ↓ global/ 
direction
mixed 
small to 
↓ ↓ ↓ [14] 10% HES: INT -9.5°C, DT -
14%   Annealing Holding step above Tg` No  ↓↓↓a global* 
very large, 
spherulitic 
↓↓ ↓↓ ↓↓ [41] 10% HES: DT up to -350% 
Quench freezing Immersion of the vials in liquid 
nitrogen or dry ice/alcohol bath 
No ↑ ↑↑↑ direction
al 
very small, 
lamellar 
↑↑↑ ↑↑↑ ↑↑↑ [108] buffer with NaCl: SSA 
+65% Vertical freezing Nucleation at vial bottom with 
dry ice, then cooled by shelf-
No ↑ ↓↓ direction
al 
large, 
lamellar 
↓↓ ↓↓ ↓↓ [9] DT -28% 
Ice-fog technique Ice fog generates small ice 
particles as nucleating agents 
Yes ↑↑ ↓↓ direction
al 
large ↓↓ ↓↓ ↓↓ [20] HES 5%: INT -1.5°C, DT -
8%, SSA -11%  Electrical High voltage generates ice 
nucleus at electrode 
Yes ↑↑ ↓↓ direction
al 
large, 
chimney-
↓↓ ↓↓ ↓↓ [47] 10% HES: INT -2°C, DT -
6% Ultrasound Ultrasound triggered nucleation  Yes ↑↑ ↓↓ global large, 
chimney-
↓↓ ↓↓ ↓↓ [54] 10% mannitol: INT -1°C, 
DT -10%  Vaccuum induced freezing Self-cooling of the sample on the 
surface due to the enthalpy of 
Yes ↑↑ ↓↓ direction
al 
large, 
chimney-
↓↓ ↓ ↓ [5] 15% SBECD: -9% DT                      
[25] 2% mannitol, DT -25% Depressurization 
technique 
Ice nucleation as a result of 
pressure change 
Yes ↑↑ ↓↓ direction
al 
large ↓↓ ↓↓ ↓↓ [9] 5% sucrose: SSA -50%, DT 
-27%, PS +140%, INT -3°C AgI Ice nucleating agent acts as "ice 
nucleus" 
No ↑ ↓ global/ 
direction
lamellar/ 
spherulitic 
↓ ↓ ↓ [5] 15% SBECD: DT -6%                      
[14] 10% HES: INT -6.1°C, DT -P. syringae  Ice nucleating agent acts as "ice 
nucleus" 
No ↑ ↓ global large, 
lamellar 
↓ ↓ ↓ [14] 10% HES: INT -1.8°C, DT -
60%   Non-aqueous cosolvent: 
TBA 
Ice crystal habit is altered No   global large, 
needle-
↓↓ ↓↓ ↓↓ [5] 15% SBECD: DT -24%                     
[29] 5% sucrose: DT - 90% 
Scored vial Surface defects catalyze ice 
nucleation 
No ↓ ↓ global small, 
spherulitic 
↑ ↑ ↑ [77] 10% HES: INT -13.1°C, DT 
-8% 
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For shelf-ramped freezing, high heterogeneity in solute distribution across the 
vial is reported, especially at high fill volumes [5]. Patapoff et al. [9] concluded 
when the sample was frozen by shelf-ramping with a first fast and later slower 
increase in dry layer resistance that the structure of the dried cake varied in the 
vertical direction. Liu et al. [5] determined the vertical heterogeneity by three-
section weight analysis. In shelf-ramped freezing, a highly concentrated core 
was found in the middle. In this study, the best intra-vial uniformity resulted from 
shelf-ramped two-step freezing or by addition of TBA. If the controlling 
parameters are not sufficiently adjusted, vacuum-induced freezing often results 
in two-layer solidification: one from vacuum-induced freezing and one from shelf 
cooling [5]. Annealing is suggested to improve intra-vial and also inter-vial 
heterogeneity [20,41,54]. During annealing, larger ice crystals grow at the 
expense of smaller ones, leading to a large and more uniform ice crystal size 
that is no longer dependent on ice nucleation temperature.  
Inter-vial or batch uniformity is a consequence of the stochastic phenomenon of 
nucleation. Thus, all the vials in a batch do not  have the same nucleation 
temperature and will not behave equally during drying [56]. Passot et al. [57] 
found that the ultrasound and pre-cooled shelf method allowed a significant 
increase in inter-vial uniformity when compared to shelf-ramped freezing. The 
optimal batch uniformity was obtained by the addition of a nucleating agent. 
Annealing also has an inter-vial homogenization effect [41]. Webb et al. [79] 
demonstrated that the variations in primary drying endpoints were three to four 
times larger for non-annealed versus annealed samples. Bursac et al. [67] 
showed that the depressurization technique improved batch homogeneity with a 
60% decrease in standard variations between vials. Although ice nucleating 
agents can also improve inter-vial uniformity, the best way to produce a 
homogeneous batch is to directly control the ice nucleation temperature in all 
vials of a batch during freezing. 
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4.2 Sample morphology 
Sublimation of the ice crystals leaves pores in the solute matrix. The texture and 
porosity of the final, dried biopharmaceutical product are directly fixed by the 
details of ice growth in the freezing process. It is proposed that the cake texture 
changes from a homogeneous, sponge-like structure for samples with a high 
degree of supercooling to a lamellar structure with a degree of orientation for 
samples with a low degree of supercooling. In addition to the degree of 
supercooling, freezing rate and time required for complete solidification also 
determine ice crystal morphology. In general, freezing methods where 
supercooling exceeds 5 °C freeze by global supercooling and result in a 
dispersed spherulitic morphology. The size of the spheroidal pores correlates 
directly with the degree of supercooling. Directional solidification is often 
observed at very high cooling rates, or when ice nucleation is induced close to 
the equilibrium freezing point. This directional solidification shows lamellar plate 
morphology, and the interface velocity is a major determinant [12,14].  
High freezing rate after slow cooling via shelf-ramped freezing results in very 
small spherulitic pores, approximately 100 µm in diameter, and a sponge-like 
matrix [14]. In the two-step freezing process, the samples are first equilibrated 
in a super-cooled state across the whole sample volume [5]. Thus, when shelf 
temperature is further increased, rapid and homogeneous freezing occurs and 
results in small, uniform, spherulitic pores. In the pre-cooled shelf method, a 
lower and less consistent degree of supercooling is observed [14]. As the time 
for temperature equilibration is limited, an enormous temperature gradient can 
be observed inside the sample. This leads to smaller pores at the bottom and 
large pores near the top. Liquid nitrogen immersion freezes by directional 
solidification in combination with a high freezing rate, resulting in small lamellar-
oriented pores [80]. In comparison with the pre-cooled shelf method, the 
temperature gradient during vertical freezing is more pronounced. This forms 
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chimney-like large lamellar structures [9]. The addition of an annealing step 
promotes the formation of large spherulitic pores due to Ostwald ripening [41]. 
Freezing by directional solidification is assumed in all methods that allow 
controlled nucleation at a temperature close to the equilibrium temperature and 
could result in large chimney-like pores. Vacuum-induced freezing leads to long 
parallel chimney-like pores with a diameter of approximately 200 µm [59]. The 
controlled nucleation via depressurization of a 5% sucrose solution resulted in 
an increased pore diameter of 120 µm compared to 50 µm in shelf-ramped 
freezing [67]. Large chimney-like pores at the top and smaller lamellar pores at 
the bottom were observed in samples frozen by ultrasound-induced 
nucleation [54]. Large lamellar, highly oriented pores were detected when 
electrofreezing at high nucleation temperatures [47]. In the presence of AgI, a 
mixed morphology of the cake is produced. A trend of dominating lamellar 
structures appears at the top where ice nucleation starts, while spheroidal 
structures appear at the bottom [14]. Supercooling is almost eliminated with the 
addition of P. syringae and thus enables a directional solidification with total 
lamellar morphology [14]. TBA influences the ice crystal habit and promotes the 
formation of large, needle-shaped pores stretching from the top to the 
bottom [5]. 
4.3 Primary and secondary drying performance 
The primary drying rate or the sublimation during primary drying can be 
expressed by the following equation [6]: 
RsRp
PcPo
dt
dm
+
−
=            (2-1) 
The mass transfer rate for the water vapor is represented by dm/dt. Po is the 
equilibrium vapor pressure over ice at the product temperature, while Pc is the 
chamber pressure. Rp is the dry product layer resistance to vapor transfer, and 
Rs is the resistance of the stopper. Rp is much larger than Rs, especially for 
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samples of high concentration and high fill depth [81]. According to this 
equation, the sublimation rate is directly correlated to the dry layer resistance of 
the product, which is determined by the freezing step related pore size of the 
product. The smaller the pores in the solute matrix previously occupied by ice 
crystals, the greater the resistance to water vapor flow from the product and the 
slower the sublimation rate [6].  
In secondary drying, the remaining unfrozen water, which can be about 20% for 
amorphous samples, requires diffusion through the solid matrix and a 
desorption step from the surface of the matrix [6]. Therefore, the sublimation 
rate in secondary drying strongly correlates with thickness and surface area of 
the interstitial matrix [57].  
Low supercooling close to the equilibrium freezing point results in the formation 
of large ice crystals and low surface area, and thus accelerated primary drying 
but slower secondary drying [57]. In contrast, a high degree of supercooling 
during freezing results in many small crystals and larger surface area and thus 
slower sublimation but faster desorption [57]. Primary drying dominates for most 
formulations with a low solid content [6]. Searles et al. [14] showed that a 1% 
increase in ice nucleation temperature resulted in a 3% increase in drying times. 
Freezing processes that result in pronounced supercooling, like shelf-ramped 
freezing or two-step freezing, require a substantially extended primary drying 
time compared to the other available methods [5,41].  
The pre-cooled shelf method can be used to reduce the drying time in cases 
when freezing has to be performed on the shelf of the freeze-drier without the 
possibility for controlled ice nucleation. Searles et al. [14] found that this method 
leads to an increase in drying rate by about 14% compared to shelf-ramped 
freezing. Similar results were obtained by Passot et al. [57], who described an 
approximately 18% shorter sublimation time.  
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However, annealing appears to be the most effective possibility to decrease 
drying rates in this case. Searles et al. [41] reported that annealing for only 
30 min increased the primary drying rate by a factor of 3.5 because larger ice 
crystals were formed due to Ostwald ripening. It was also found that the 
formation of large holes on the cake surface of the annealed surface could 
additionally have facilitated sublimation. In general, higher annealing 
temperatures and longer annealing times correlate with a faster drying rate [12].  
All drying rates are limited to maximum values that were reached when the 
sublimation rate is no longer controlled by mass transfer but by energy 
transfer [12]. However, annealing was not always found to increase the drying 
rate, as the physical state of the sample can also have an impact. For example, 
it was observed that in systems that contain a crystalline phase, such as 
mannitol/ trehalose/ sodium chloride, primary drying time was increased due to 
changes in the pore structure via changes in crystallinity [42].  
Meanwhile, freezing by immersion in liquid nitrogen has been shown to result in 
very small ice crystals and large surface area, and thus decreased primary 
drying rates compared to shelf-ramped freezing were observed [14]. The non-
vertical ice formation obtained by ice growth starting from the wall of the vial 
additionally contributes to the restricted ice sublimation for samples frozen by 
liquid nitrogen immersion [9].  
The controlled nucleation via depressurization of a 5% sucrose solution resulted 
in a increased pore size and led to a shortened drying time by 27% according to 
Bursac et al. [67]. In comparison, Kramer et al. [59] showed that the vacuum-
induced surface freezing method led to the formation of large, chimney-like 
pores, resulting in decreased primary drying times of 25% for a 2% mannitol 
formulation and of 15% for a 2% sucrose formulation. Conversely, 
Nakagawa et al. [54] reported that the controlled ice nucleation by ultrasound 
close to the equilibrium freezing temperature (-2 °C) increased the primary 
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drying rate by 60% when compared to samples that nucleated at lower 
temperatures (-8 °C). Passot et al. [57] observed only an 18% decrease in 
sublimation time for samples nucleated using ultrasound. When the biogenic ice 
nucleation agent P. syringae was added to the samples, a 30% [57] and 
60% [14] increase in drying rate was experienced. In this case, the faster drying 
rate was not only a result of the lowered degree of supercooling but also 
attributed to an increase in lamellar ice crystal content [14]. 
The addition of TBA was also found to increase the ice sublimation rate [82]. 
Kasraian et al. [77] found that the addition of 5% TBA to a 5% sucrose solution 
resulted in an approximate 10-fold decrease in product resistance and drying 
time. A reason for this is that TBA has the ability to modify the crystal habit of 
ice so that large needle-shaped ice crystals are formed and resulted in a 
decreased mass transfer resistance [76]. The fact that TBA itself has a high 
vapor pressure also plays a role in the increase of sublimation rates [74,82,83]. 
Daoussi et al. [83] reported a 10-30 times higher sublimation rate of a 90% TBA 
sample when compared to traditional aqueous formulations.  
The drying performance can be influenced by the direction of ice crystal 
formation and by the direct correlation between drying rate and pore size. The 
connection between pores and the formation of a skin on the top of the cake 
may also have an influence on the drying performance. For example, it was 
found that in vertically oriented ice obtained by vertical freezing, the sublimation 
rate was 40% faster and drying time was 50% shorter compared to standard-
frozen solutions [9]. Moreover, ice-structures formed by top-down freezing could 
be an additional factor for the increased drying rates with the presence of 
TBA [5]. With high solid content in combination with small ice crystals, the ice 
crystals can be completely coated by an amorphous matrix. In this case, 
sublimation is extremely slowed while the water vapor has to diffuse across the 
amorphous layer, due to the lack of connections between pores [9,11]. 
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Moreover, during slow freezing, the solute can concentrate ahead of the 
advancing freezing front and in extreme cases produce an almost impermeable 
glassy product skin at the top of the vial [11]. Patapoff et al. [9] reported that the 
dry layer resistance is high as the sublimation front moves through the skin. The 
resistance then increased more slowly once the sublimation front passed the 
skin. 
To generally optimize the process time of lyophilization, the product 
temperature should be as high as possible, while still low enough to avoid 
product melting or collapse. A controlled product temperature needs to be in 
equilibrium with the heat transfer rate to the product and removal of heat by 
sublimation, which is directly correlated to the mass transfer rate of water 
vapor [6]. Searles et al. [41] found that the product temperature of an annealed 
sample was 5 °C cooler than the corresponding non-annealed sample due to an 
increased heat removal by the sublimation.  
The mass transfer is directly correlated to product resistance. At low product 
resistance, the process is no longer controlled by mass transfer. It is instead 
controlled by heat transfer. In this case, the product temperature moves toward 
a temperature at which the vapor pressure of ice equals the chamber pressure. 
It is then insensitive to additional energy input [12]. This allows further 
optimizing of the drying time by increasing the shelf temperature well above 
Tg` [11]. The same effect was observed when using TBA as non-aqueous co-
solvent [77]. In contrast to pure sucrose samples, sucrose samples with TBA 
addition showed a fast sublimation rate and did not show collapse. This can be 
explained by the maintenance of a low product temperature due to the rapid 
sublimation and by the faster decrease in water content and increase in 
viscosity that prevented viscous flow of the sample. 
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4.4 Physical state of the sample 
The physical state of excipients is of significant importance for lyophilized 
biopharmaceuticals. It can influence reconstitution time, storage stability, and 
protein stability and governs the risk of vial breakage. Various studies 
demonstrate that the freezing rate can affect the physical state of the solutes. 
This was comprehensively studied for mannitol samples [84–90]. For example, 
after fast freezing (-20 °C/min), mannitol was found to be amorphous This 
amorphous form transformed to a meta-stable crystalline state in the frozen 
matrix [84]. In contrast, when the sample was cooled at -2 °C/min, mannitol was 
crystalline [85].  
The freezing process impacts also the preferred formation of different 
polymorphs. Izutsu et al. [86] detected a mixture of α- and β-polymorphs after 
slow freezing of 10% mannitol samples, and the formation of mainly the 
δ-polymorph after fast freezing. Cannon and Trappler [87] observed for a 
70 mM mannitol sample that shelf-ramped freezing resulted mostly in the 
δ-polymorph with a minor presence of the α-polymorph. Freezing on a pre-
cooled shelf produced mostly the α-polymorph with a minor β-content. A hold 
step at -20 °C during shelf-ramped freezing led to δ-polymorph formation, and 
after annealing at -20 °C for 1 h only the β-polymorph was detected. 
Kim et al. [88] reported that the physical state is affected by the freezing rate 
and the mannitol concentration. Fast freezing of a 10% mannitol sample 
produced the δ-polymorph, whereas fast freezing of 5% mannitol resulted 
primarily in the β-form. In addition, Nakagawa et al. [89] found that the freezing 
step influences the vertical distribution of mannitol polymorphs in the sample 
along the direction of heat flux during freezing. The polymorphic form was also 
influenced by the absence or presence of protein [90]. The formation of 
mannitol hemi-hydrate was completely inhibited with the presence of 
protein [90].  
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In order not to form a meta-stable state and not to decrease the Tg` of the 
formulation, annealing is essential for the crystallization of bulking agents such 
as glycine or mannitol [18,19]. For example, Hawe et al. [91] found that the 
application of an annealing step during lyophilization could increase the 
mannitol crystallinity in mannitol–sucrose–NaCl formulations. However, the 
annealing step favored the formation of mannitol hydrate, which is known to 
convert into the anhydrous polymorph upon storage. 
4.5 Residual moisture content 
All freezing methods that increase crystal size, thus decreasing the SSA, result 
in a limited desorption rate during secondary drying. Consequently, there is an 
increased residual moisture content in the final biopharmaceutical product if 
secondary drying time is not adequately adjusted [5]. When compared to shelf-
ramped frozen samples, Liu et al. [82] observed a slight increase in the residual 
moisture content for 15% sulfobutylether-7-beta-cyclodextrin (SBECD) samples 
after annealing, two-step freezing and vacuum-induced freezing.  
A twofold increase in residual moisture content of samples frozen with the ice 
nucleating agent AgI is correlated with a large increase in ice crystal size. 
Interestingly, the addition of TBA did influence the ice crystal morphology but 
the residual moisture content was not changed. In contrast to the pronounced 
increase in residual moisture content for samples containing AgI, Passot et 
al. [57] did not detect an increase in residual moisture content for samples with 
added P. syringae. The application of ultrasound did, however, induce 
nucleation, resulting in a 50% increase in the residual moisture content of 5% 
sucrose samples [57]. The increase in the freezing rate during shelf-ramped 
freezing from 0.2 to 1.0 °C/min also slightly increased the residual moisture 
content, which is comparable to the moisture content after freezing on pre-
cooled shelves [57,59].  
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In accordance with Liu et al. [5], Webb et al. [79] found a slightly increased 
residual moisture content in annealed versus non-annealed 
sucrose/HES/interferon-γ samples. Kramer et al. [59] reported that for mannitol 
samples the residual moisture content was higher after vacuum-induced 
freezing in comparison with shelf-ramped freezing. However, this was not the 
case for sucrose and glycine samples.  
4.6 Reconstitution time 
There are several factors that can influence the reconstitution properties of a 
lyophilized sample. These include the morphology of the cake, the surface area 
of the cake, the presence of cake collapse or meltback, the presence of 
hydrophobic coatings, the homogeneity of the dry matrix, and the formation of 
channels between pores and the physical solid state [74]. Therefore, it is difficult 
to propose a general relation between freezing process and reconstitution time.  
It is proposed that the changes that allow more efficient water vapor transport 
during drying may also improve wettability of the porous cake [12]. However, 
limited literature is available with regard to the correlation between freezing step 
and reconstitution time.  
Annealing can affect reconstitution time, but the absolute influence is 
controversially discussed [12]. For example, Searles et al. [41] found that 
annealed HES samples were completely dissolved slightly faster than 
unanimated samples. In contrast, Webb et al. [79] reported slower dissolution 
for annealed HES and sucrose/ HES formulations. The shorter reconstitution 
time observed by Searles et al. [41] upon annealing was explained by the 
formation of holes in the dried layers of the cake, facilitating liquid penetration. It 
is generally assumed that increased pore size produced by annealing increases 
the thickness of the matrix layers and reduces the surface area. Therefore, this 
process will prolong reconstitution times [41]. Based on this observation, it can 
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be assumed that freezing methods resulting in a low surface will slow down 
reconstitution. However, further studies are needed to proof this assumptions.  
In addition to sample morphology, the physical state of the samples could also 
influence reconstitution time. The amorphous form has a higher solubility 
compared to the crystalline form. Different polymorphic forms also have 
different dissolution rates [92]. Kim et al. [88] demonstrated that slow freezing of 
10% mannitol resulted in a mixture of α- and β-polymorphs with a reconstitution 
time of 78 s while nitrogen immersion produced the δ-polymorph with a 
reconstitution time of 36 s. This cannot be solely attributed to different 
dissolution rates of mannitol polymorphs, as the SSA was additionally affected 
by the freezing method. Modifying the reconstitution time by altering freezing 
process is also of high interest with regard to the high reconstitution times 
observed for lyophilized high-concentration protein samples [93]. 
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5 Consequences of the freezing step on protein stability 
In addition to the consequences of the freezing step on general quality 
attributes of biopharmaceuticals and drying performance, the freezing step will 
also affect protein stability. There are several factors that contribute to the 
detrimental effects on proteins during freezing. Most of the effects can be 
directly correlated to the freezing protocol used. 
5.1 General stress factors during freezing 
The three main stress factors that occur during freezing that could impact 
protein stability are cold denaturation, ice formation, and freeze-
concentration [16].  
The protein’s free energy of unfolding typically shows a parabolic function of 
temperature and becomes negative not only at high but also at low 
temperatures. This is referred to as cold denaturation [94–96]. Cold 
denaturation is related only to decreased temperatures and occurs in the 
absence of freezing. Therefore, it must be completely differentiated from 
freezing denaturation [97]. Cold denaturation is reported for a high number of 
proteins [16]. However, the impact of cold denaturation on protein stability in 
lyophilization is regarded as marginal. This is because the estimated cold 
denaturation temperatures are often well below lyophilization temperatures and 
are even further reduced in the presence of saccharides and polyols. 
Additionally, the rate of unfolding can be sufficiently slow on the time scale of 
the lyophilization process. Drying can be finished before significant unfolding 
occurs [1,12,16,98].  
The more significant changes in protein stability occur when ice crystallizes in 
the solution, promoting freeze-concentration and leading to a large ice–water 
interface. The solutes concentrate upon freeze-concentration and buffer 
components can crystallize, leading to a drastic pH shift. And depending on the 
formulation composition, liquid–liquid phase separation can occur.  
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Freeze-concentration of the solutes during freezing can also raise the solute 
concentration to a destabilizing level [32]. The rate of bimolecular degradation 
reactions is increased at high concentrations. However, the decrease in 
temperature and the increase in viscosity exhibit a counteracting effect and limit 
the extent of the rise in reaction rates [16]. When electrolytes are present in the 
protein formulation, the increase in concentration also increases the ionic 
strength. This will potentially destabilize proteins [16]. Here, the thermodynamic 
stability of the native conformation is reduced via charge-shielding effects or 
preferential binding of ions to the protein surface [95]. The role of freeze-
concentration on protein stability has been mostly speculated based on 
experience with enzymes, which might noticeably differ when stabilizers are 
present [16]. For instance, Bhatnagar et al. [97] found no lactate 
dehydrogenase (LDH) degradation in ice-free sucrose solutions, whereas 
significant degradation was observed in the freeze-concentrate of the same 
composition.  
All pKa and pKb values are directly affected by temperature, depending on the 
buffer-type, and causes the pH to change during cooling [11]. However, the 
selective crystallization of buffer salts during freeze-concentration results in 
more drastic pH shifts during freezing and is thus more detrimental with regard 
to protein stability. For instance, the decrease in pH can be 3 pH units or more 
for sodium phosphate buffers. The basic disodium salt is less soluble and has a 
higher eutectic point than the monosodium salt, leading to its precipitation [16]. 
Gomez et al. [99] observed that the extent of salt precipitation and pH decrease 
during non-equilibrium freezing, observed in lyophilization, are smaller than 
those predicted by the equilibrium freezing behavior. At extreme pH values, 
increased electrostatic repulsion between equal charges in proteins will induce 
protein unfolding or denaturation [94]. Freezing of a LDH solution in sodium 
phosphate buffer resulted in a pH drop from 7.5 to 4.5 and caused protein 
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denaturation [100]. Generally, the pH shift during freezing can be minimized by 
the optimal choice of buffer salts, keeping the buffer concentration at a 
minimum, maintaining all buffer species in the amorphous state via the addition 
further solutes, or by adjusting the freezing method [1,16,19].  
In addition to the crystallization of buffer salts during freeze-concentration, 
crystallization of additional solutes such as mannitol or glycine revokes their 
stabilizing effect on proteins [16,101]. In general, the crystallization of the 
solutes strongly depends on cooling rate and annealing conditions. It also 
depends on the presence of other co-solutes [32]. For example, inhibition of 
mannitol or glycine crystallization by adding sufficient co-solutes resulted in an 
increased LDH stabilization [85].  
Liquid–liquid phase separation of amorphous solutes can also be observed as a 
result of freeze-concentration. Phase separation is most common when 
polymers like PEG, PVP, dextran, or ficoll are used as cryoprotectants [32]. 
Phase separation will lead to the loss of the stabilizing effect of the excipient 
and thus negatively influence protein stability. Izutsu and Kojima [72] reported 
that freeze-concentration separated combinations of proteins (lysozyme, 
ovalbumin, BSA) and non-ionic polymers (ficoll, PVP) into different amorphous 
phases. Heller et al. [33] showed that the effects of liquid–liquid phase 
separation in PEG/dextran systems can be detrimental on the stability of 
recombinant human hemoglobin during freezing and drying. The phase 
separation promoted the protein partitioning into a PEG-rich and a dextran-rich 
phase and that the two phases differed in their lyoprotective properties [34]. 
 The formation of large ice-water interfaces due to ice crystallization occurs 
during freezing. This can promote surface-induced denaturation of surface-
sensitive proteins. The mechanism of protein denaturation at the ice surface is 
still being discussed. One hypothesis states the generation of an interfacial 
electrical field, via the preferential partitioning of one ionic species into the ice 
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lattice, influences protein stability [102]. Another hypothesis states that ice 
formation leads to an ordering of the water molecules in the direct vicinity of the 
protein. When the protein adsorbs on the ice, the ordered water is unblocked 
and entropy increases. This provides a thermodynamic driving force for protein 
unfolding [16,103].  
Protein denaturation at the ice surface can be reduced or prevented by addition 
of nonionic surfactants, which compete with proteins for adsorption at the ice–
water interface [16]. Chang et al. [104] observed a strong correlation between 
the tendency of a protein for freeze denaturation and its tendency for surface 
denaturation. As the ice crystal surface area during freezing is predetermined 
by the freezing protocol, the stability of a surface sensitive protein is additionally 
strongly influenced by the sole freezing step.  
It must be kept in mind that in addition to the freezing process, the formulation 
strongly affects freezing-induced protein stabilization. Cryoprotectants stabilize 
proteins during freezing by ‘‘preferential exclusion’’ [105]. These solutes tend to 
be excluded from the surface of the protein and therefore lead to a ‘‘preferential 
hydration’’ of the protein and increases the thermoydynamic stability of the 
native state [105]. Other factors can also control the stabilizing effects of 
cryoprotectants. These factors include the role of the stabilizer in minimizing 
protein adsorption on the ice surface, stress occurring late in freezing and the 
increased viscosity of the freeze-concentrate [12]. Stabilizers may also operate, 
at least in part, through their ability to prevent crystallization of buffer 
components, thereby reducing a potential pH shift [12]. Moreover, the 
vitrification hypothesis is discussed, according to which protein mobility and 
kinetics of unfolding are reduced in the glassy state [106]. 
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5.2 Influence of the freezing step on protein stability 
The freezing procedure in lyophilization can influence the crystallization of 
buffer components and other solutes, liquid–liquid phase separation and also 
the extent of the ice–water surface.  
With respect to protein denaturation at the ice–water interface, there exists a 
strong correlation between freezing rate and protein stability. At high freezing 
rates, smaller ice crystals and larger ice–water interfaces are formed, leading to 
a greater extent of surface- induced denaturation of surface-sensitive 
proteins [94]. It is therefore recommended to use freezing conditions that 
reduce ice crystal interfaces in order to minimize surface-induced protein 
destabilization. Strambini and Gabellieri [107] showed that the increase in ice 
crystal surface area induced changes in protein structure and protein 
aggregation. There are several studies demonstrating that faster freezing 
resulting in larger ice-water interfaces, when compared to slow freezing, caused 
increased protein instabilities. Sarciaux et al. [108] found a lower level of 
insoluble aggregates of bovine IgG in phosphate buffer with shelf-ramped 
freezing in comparison with liquid nitrogen immersion after lyophilization. 
Eckhardt et al. [109] observed the same trend for human growth hormone 
during freeze-thawing. Chang et al. [104] showed that slow freezing resulted in 
less turbidity of various proteins upon freeze-thawing as opposed to freezing in 
liquid nitrogen. Jiang and Nail [40] investigated the effect of different freezing 
methods on catalase, β-galactosidase, and LDH activity in phosphate buffers. 
The highest level of protein activity was observed when pre-cooled shelf 
(-40 °C) freezing was applied. Intermediate recovery was obtained by shelf-
ramped freezing (-0.5 °C/min) and lowest recovery by liquid nitrogen immersion. 
In this case, no direct correlation between cooling rate and protein stability 
could be proposed.  
98                                                                                                       Chapter 2 
 
This emphasizes again the importance of distinguishing between cooling rate 
and actual freezing rate. Although the cooling rate is slower for shelf-ramped 
freezing than for to the pre-cooled shelf method, the freezing rate is higher due 
to the higher degree of supercooling and improved thermal equilibrium 
throughout the sample volume. The cooling rate and the freezing rate are fast in 
the case of freezing by liquid nitrogen immersion, as the freezing behavior is 
shifted to directional solidification. Cochran et al. [38] used various methods to 
influence nucleation temperature during freezing and found an inverse 
relationship between the extent of supercooling and recovery of LDH activity 
after lyophilization and reconstitution. 
Annealing is directly correlated with a decrease in the specific surface area and 
is thus known to impact protein stability. Sarciaux et al. [108] found that 
annealing reduced the percentage of bovine IgG aggregates from 33% to 12%, 
attributing to the reduction in aggregation due to the lower surface area of the 
annealed samples. Ironically, during annealing, the protein has at first to endure 
the surface denaturation stresses during ‘‘normal’’ freezing. The ice surface is 
reduced only after annealing. It seems that the unfolding due to surface 
denaturation is reversible in the liquid state and is only fixed after drying. This is 
also consistent with the finding of Sarciaux et al. [108] that there was no 
damage of IgG after freeze-thawing but after lyophilization when freezing 
occurred rapidly. Webb et al. [68] hypothesized that aggregation of recombinant 
human interferon during freeze-drying and spray-freeze-drying is a result of a 
retained internal stress in the glass that forms on freezing and not as a result of 
adsorption at the ice surface. However, there are some contradictions found in 
literature to the aforementioned relation between freezing rate, ice surface area, 
and protein stability. For example, Nema and Avis [110] found that fast freezing 
results in a reduced loss of LDH activity compared to slow freezing. They 
explained their finding by the fact that fast freezing minimizes the time that a
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protein spends in the freeze-concentrated environment where degradation 
reactions can take place. Additionally, Heller et al. [39] observed that damage to 
hemoglobin in PEG/dextran formulations can be avoided by rapidly freezing the 
samples in liquid nitrogen. In this case, however, protein damage was a result 
of phase separation, which is more pronounced during slow freezing.  
On the other hand, annealing not only decreases the ice surface area but also 
promotes crystallization of some solutes which can be associated with a 
pronounced loss in protein activity. For example, Izutsu et al. [111] showed that 
the activity of beta-galactosidase in the presence of mannitol or inositol 
decreased after annealing. The same trend was observed for LDH and 
L-asparaginase when mannitol crystallization was promoted due to the 
annealing step [86]. It was also found that inhibition of crystallization of mannitol 
with the presence of additional solutes can improve protein stability [85]. 
However, even under fairly aggressive annealing conditions the protein itself 
can inhibit mannitol crystallization [112].  
The freezing rate will also influence the selective precipitation of buffer salts, 
thus influencing the extent of changes in the pH during freezing. Each buffer 
salt has its own critical cooling rate, above which crystallization is inhibited and 
will not result in a pH shift [113]. Annealing will further accentuate pH shifts and 
the protein will be exposed to unfavorable pH values for a increased period of 
time [41].  
There is only limited information available on the influence of protein stability 
with freezing procedures other than shelf-ramped freezing and liquid nitrogen 
immersion. Passot et al. [57] found that the freezing method only influenced the 
recovery of catalase when the poor stabilizer maltodextrin was used. Under 
these conditions, a higher activity was observed after lyophilization and storage 
when the ultrasound technology or the pre-cooled shelf method was used. 
Bursac et al. [67] found for samples of 1 mg/ml LDH in 5% mannitol, a 22% 
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decrease in protein activity frozen with the depressurization technique. Whereas 
stochastic shelf-ramped freeze-thawing results in a 39% loss of activity.  
Even the storage stability of a protein can be impacted by the freezing 
procedure. Hsu et al. [114] observed that fast freezing during lyophilization of a 
recombinant tissue plasminogen activator resulted in weaker storage stability of 
the protein. The authors proposed that the protein diffuses during freezing into 
the large ice– water interface and is then less protected by the excipient during 
storage. This is in accordance with the finding of Patapoff et al. [9] that the 
aggregation rate of a therapeutic protein is decreased upon storage when an 
annealing step was performed during lyophilization. The pH drop during 
freezing can also potentially affect the storage stability of lyophilized proteins as 
lyophilized proteins exhibit a ‘‘pH memory’’ [115–117]. For example, lyophilized 
interleukin aggregated more rapidly when formulated in a phosphate buffer at 
pH 6.5 in comparison with a citrate buffer at the same pH during storage [115]. 
Furthermore, the crystallization of meta-stable amorphous excipients or 
conversion hydrates to the anhydrous polymorphs can affect storage stability of 
proteins. For example, mannitol crystallization might be inhibited during fast 
freezing, but in situ crystallization of the meta-stable mannitol could be 
facilitated under storage conditions. The protein-stabilizing effect will be lost as 
a result. In addition, meta-stable mannitol hydrate transfers with liberation of 
water under storage conditions that can be critical with regard to protein 
stability [91].  
In summary, the stability of proteins during freezing is affected differently by 
varying freezing rates and depending on the present protein denaturation 
mechanism. These mechanisms include surface-induced denaturation, pH-
induced denaturation, denaturation due to the crystallization of the stabilizing 
excipient or phase-separation-induced denaturation. 
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6 Conclusion and practical considerations 
During freezing, the samples first experience supercooling until heterogeneous 
ice nucleation occurs. The ice nuclei then grow, leading to cryoconcentration of 
the sample. Eutectic crystallization or vitrification of the solutes is observed 
when a critical concentration is exceeded. In regard to global supercooling 
versus directional 
solidification, the ice crystal number and size is directly controlled by the degree 
of supercooling or by the freezing rate.  
The random nature of ice nucleation is a big challenge for process control and 
results in vial-to-vial and batch-to-batch heterogeneity. Especially, the difference 
in the degree of supercooling when operating in a typical sterile manufacturing 
environment, containing much less foreign particles that can act as 
heterogeneous  ice nucleation sites, is one of the biggest challenges in up-
scaling [20]. In this case, samples show a more pronounced degree of 
supercooling and result in smaller ice crystals and increased product layer 
resistance. Longer drying rates are also required, and there is an increased risk 
for product lost [1]. Freezing methods that directly control ice nucleation are 
therefore essential in order to counter this challenge.  
Various freezing methods have been developed in order to manipulate the 
freezing behavior. However, only a few are capable to directly control ice 
nucleation and have the potential to be applied in manufacturing scale.  
The freezing step is of significant importance during lyophilization because it is 
the main desiccation step. Moreover, the freezing procedure directly impacts ice 
crystal formation and thus product morphology. Freezing methods that result in 
a high degree of supercooling freeze by global supercooling and result in the 
formation of small, spherulitic ice crystals. The size of these crystals is directly 
correlated to the degree of supercooling. Procedures that induce ice nucleation 
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at a low degree of supercooling freeze by global solidification. In this case, the 
interface velocity determines the size of the ice crystals.  
Primary drying rates correlate with dried product resistance. Resistance is 
determined by pore size and the orientation of the pores. The formation of a 
skin at the top of the product can also determine resistance. Thus, freezing 
methods that result in the formation of large, vertically oriented ice crystals can 
drastically decrease primary drying time and show a decrease in product 
temperatures. This is due to the shift from mass transfer to heat transfer 
controlled product resistance, which results in more space for process 
optimization. However, reduction in primary drying time frequently involves the 
extension of the secondary drying step. Although primary drying times 
dominate, a compromise between primary and secondary drying rate must be 
found in order to minimize the total cycle length and reach the desired final 
moisture content.  
The freezing step also affects the physical state of the excipients. Depending on 
the freezing rate, various polymorphs can be formed and the formation of meta-
stable amorphous states or hydrate formation can be promoted. This can 
severely influence storage stability or lead to vial cracking during drying.  
The freezing step also impacts the selective crystallization of excipients, 
especially in buffer components. This potentially leads to significant pH shifts, 
induces liquid–liquid phase separation and determines the extent of ice-water 
interfaces. Protein stability is therefore directly dependent on the freezing 
procedure. In the case of a surface-sensitive protein, slow freezing rates and 
the application of an annealing step could improve protein stability. For these 
slow freezing conditions, however, buffer crystallization and phase separation 
can be more pronounced. This can negatively impact protein stability. Fast 
freezing rates should be used and annealing should be avoided if a shift in pH, 
crystallization or phase separation of the stabilizing excipients is observed. 
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Thus, process optimization and formulation development should be 
accomplished hand in hand. Freezing methods that allow controlled ice 
nucleation at temperatures close to the equilibrium freezing point are 
suggested. These methods result in the formation of large oriented ice crystal, 
increase the drying rates, improve batch uniformity, reduce meta-stable glass 
formation, facilitate process scale-up and minimize protein damage at the 
reduced ice-water interfaces. Annealing provides a promising alternative if no 
controlled ice nucleation method is available. The presence of additives like ice 
nucleating agents or TBA could also have a positive effect. However, ice 
nucleating agents have to face regulatory concerns.  
The awareness of the complexity of the freezing process and its consequences 
on product quality and process performance is essential for successful 
lyophilization. The knowledge of how to control, or at least manipulate, the 
freezing step will help to develop more efficient lyophilization cycles and 
biopharmaceutical products with an improved stability. 
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Chapter 3 
Objectives of the thesis 
 
The objective of the thesis was the lyophilization of cationic polymer-based 
pDNA or siRNA nanoparticles (i.e. pDNA or siRNA polyplexes) with a special 
focus on the development of long-term stable formulations, the investigation of 
stabilization mechanisms especially during freezing, and the advanced 
monitoring of the lyophilization process. 
 
One essential prerequisite for the successful development of lyophilized nucleic 
acid complex formulations is the availability of the initial nanoparticles at a 
constant and defined quality. Thus, the first aim of this thesis was to establish 
and up-scale a micro-mixer method for the standardized and reproducible 
preparation of plasmid/LPEI polyplexes in order to overcome the drawbacks 
that are related to the classical preparation by mixing via pipetting (Chapter 4). 
In a second step, this approach had to be transferred to up-scale the 
preparation of siRNA/oligoaminoamide polyplexes (Chapter 7). 
 
In order to avoid the risks associated with the need for always fresh preparation 
of the polyplexes by the mixing nucleic acid component with the carrier solution 
in clinical application, the production of large standardized batches of well-
defined, transfection efficient polyplexes with long-term stability by lyophilization 
is a desirable goal. Thus, one primary objective of this thesis was the 
development of lyophilized, long-term stable formulations for plasmid/LPEI 
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polyplexes (Chapter 5). In this context, a variety of excipients was tested and an 
extended set of analytical methods were to be employed to assure the 
pharmaceutical product quality. 
 
It was found that the undesirable aggregation of plasmid/LPEI polyplexes 
occurs predominantly during the freezing and not during the drying step of the 
lyophilization process. Hence, an additional focus of this thesis was on the 
effect of different freezing parameters, such as ice nucleation temperature or 
freezing rate, on the stability of plasmid/LPEI polyplexes, in order to better 
understand the underlying stabilization mechanisms (Chapter 6). The 
theoretical background on the freezing process, physico-chemical fundamentals 
of freezing, available freezing methods, and consequences of freezing on 
product quality was reviewed beforehand (Chapter 2). 
 
On the basis of the successful development of lyophilized plasmid/LPEI 
polyplexes, a further objective of this thesis was the formulation development of 
lyophilized, long-term stable siRNA/oligoaminoamide polyplexes (Chapter 7). In 
this context, the correlation between the chemical structure of the used 
oligomers and the freeze-thaw stability of the corresponding siRNA polyplexes 
had to be studied and the possibility to achieve high concentration siRNA 
polyplex formulations by reconstitution to reduced volumes needed to be 
evaluated. 
 
Finally, an optical fiber system, that is based on fiber Bragg gratings, was to be 
established as a novel process monitoring tool during lyophilization (Chapter 8). 
Here, the potential of the optical fiber sensors for non-invasive or three-
dimensional temperature monitoring and the sensitivity of the sensors to detect 
physico-chemical events during freezing was of high interest. 
  
 
 
Chapter 4 
Establishment of an up-scaled micro-mixer method 
 
The following chapter has been published in the European Journal of 
Pharmaceutics and Biopharmaceutics and appears in this thesis with the 
journal`s permission: 
 
Julia Christina Kasper, David Schaffert*, Manfred Ogris, Ernst Wagner, 
Wolfgang Friess 
The establishment of an up-scaled micro-mixer method allows the standardized 
and reproducible preparation of well-defined plasmid/LPEI polyplexes 
Eur. J. Pharm. Biopharm. 77 (2011) 182-185  
 
*LPEI synthesis and cell culture experiments were performed by D. Schaffert. 
 
Graphical Abstract 
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Abstract 
Polyplexes based on linear polyethylenimine (LPEI) and plasmid DNA are 
known as efficient non-viral gene delivery systems. However, the requirement 
for freshly prepared complexes prior to administration due to their instability in 
aqueous suspension poses the risk of batch-to-batch variations. Therefore, the 
aim of the study was the establishment of a reproducible and up-scalable 
method for the preparation of well-defined polyplexes. 
Polyplexes consisting of pCMVLuc plasmid and 22 kDa linear polyethylenimine 
(LPEI) were prepared by classical pipetting or with a micro-mixer method using 
different mixing speeds and plasmid DNA concentrations (20–400 µg/mL). The 
z-average diameter of the polyplexes was measured by dynamic light 
scattering. Metabolic activity and transfection efficiency was evaluated on 
murine neuroblastoma cells after transfection with polyplexes. 
When varying mixing speeds of the micro-mixer, polyplex size (59–197 nm) and 
polydispersity index (0.05–0.19) could be directly controlled. The z-average 
diameter (65–170 nm) and polydispersity index (0.05–0.22) of the polyplexes 
increased with increasing plasmid DNA concentration (20–400 µg/mL). 
The established up-scaled micro-mixer method allows the standardized and 
reproducible preparation of well-defined, transfection-competent plasmid/LPEI 
polyplexes with high reproducibility. 
 
Keywords 
Non-viral gene delivery, well-defined polyplexes, up-scaled preparation, 
influence of mixing speed, influence of concentration 
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1 Introduction 
Non-viral, plasmid-based therapeutics represent a new class of 
pharmaceuticals that offer the potential to cure several diseases currently 
considered untreatable [1]. Non-viral vectors, based on DNA complexes with 
cationic lipids (lipoplexes) or polycationic polymers (polyplexes), are attractive 
because of their low cost and high flexibility and have been proven safe and 
non-immunogenic in clinical trials [1,2]. On the other hand, depending on the 
polymer used, polyplexes suffer from drawbacks such as toxicity and non-
specific interactions with the cells [3]. Another limiting factor for their clinical 
practicability is the requirement for freshly prepared formulations prior to 
administration because of the tendency towards particle aggregation in liquid 
formulations [2,4]. However, the day-to-day preparation poses the risk of 
batch-to-batch variability, including significant variations in product quality, 
safety and transfection rates, and the inability to perform extensive quality 
control prior to the actual administration due to time constraints [2,4]. Currently, 
the classical preparation of non-viral vectors, mixing a solution of DNA with a 
solution of cationic agents (i.e. lipid or polymer) via pipetting, is restricted to 
relatively small volumes [1]. This poorly defined and difficult to control 
preparation method can result in the formation of highly heterogeneous 
complexes with a broad range of sizes and charge ratios [5]. Thus, the 
controlled reproducible production of standardized batches of well-defined non-
viral complexes is a major challenge [4,5]. Zelphati et al. [5] developed an 
automated and controllable production process for the preparation of lipoplexes 
utilizing a specially designed continuous flow pumping system, in which the 
DNA and liposome solution are mixed at 90° angles at the junction of a T-
connector. In accordance to that first effort, Clement et al. [4] introduced a 
continuous mixing technique for the large-scale preparation of lipoplexes. 
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However, such automated up-scaled mixing has not yet been established for 
the preparation of polyplexes.   
Hence, we aimed at establishing an up-scaled method for the reproducible 
preparation of well-defined polyplexes based on plasmid DNA and 22 kDa LPEI. 
The influence of the preparation procedure (classical pipetting versus up-scaled 
preparation), the mixing speed and the plasmid/LPEI concentration on particle 
size, polydispersity and in vitro performance (transfection efficiency and toxicity) 
of the polyplexes was investigated.  
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2 Materials and methods 
2.1 Materials 
The plasmid (pCMVLuc) was produced by PlasmidFactory (Bielefeld, 
Germany). As described, 22 kDa LPEI was synthesized by acid-catalyzed 
hydrolyses from commercial poly(2-ethyl-2-oxazoline) (Sigma Aldrich, 
Steinheim, Germany) [6]. Plasmid and LPEI stock solutions were diluted in 
10 mM L-histidine (Merck, Darmstadt, Germany) buffer pH 6.0, so that mixing 
equal volumes of the two dilutions always resulted in a N/P ratio (molar ratio of 
LPEI nitrogen (N) to DNA phosphate (P)) of 6/1. Indicated polyplex 
concentrations always refer to the plasmid DNA concentration of the samples. 
2.2 Preparation of plasmid/LPEI polyplexes by pipetting 
For the traditional preparation of the polyplexes (n=3), 250 µL of plasmid 
solution were pipetted into the same volume of LPEI solution in a 1.5-mL 
reaction tube, mixed by rapid pipetting and incubated for 30 min at room 
temperature. For direct comparison with the up-scaled method, polyplexes were 
also prepared (n=3) at increased volumes, mixing 2.5 mL of plasmid solution 
with 2.5 mL of LPEI solution with a 5-mL pipette in a 15-mL reaction tube.  
2.3 Up-scaled preparation of plasmid/LPEI polyplexes 
Equal volumes (2.5 mL) of plasmid solution and LPEI solution were loaded into 
two separate syringes with luer lock tip (Terumo, Leuven, Belgium), connected 
via polyetheretherketone tubings (0.5 mm inner diameter, 5.0 cm length) to a 
T-connector (Micro Tee P-890) (Upchurch Scientific, Oak Harbor, USA) and 
fixed into two common syringe drivers. The mixing occurred when the carriages 
on the syringe driver pushed the plunger of the syringes simultaneously at the 
same speed. The flow rate could be controlled either by using different-sized 
syringes (2.5, 5.0 or 10.0 mL) and/or by adjusting the plunger speed (0.1, 0.2, 
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0.5 or 1.0 cm/min) on the syringe driver. After mixing (n=3), the polyplexes were 
incubated for 30 min at room temperature. 
2.4 Particle size determination 
The z-average particle diameter was measured by dynamic light scattering 
(DLS) using the DLS plate reader DynaPro Titan (Wyatt Technology, Dernbach, 
Germany) at a laser wavelength of 830 nm and a scattering angle of 150°. One 
hundred microliters per sample (n=3) was pipetted into 96 UV-well plates 
(Costar™, Corning, USA) and analyzed at room temperature using five 
acquisitions, with 5 s each. Polyplexes were assumed as linear polymers with a 
refractive index increment value dn/dc of 0.185, and for the dispersant, the 
refractive index of water (1.33) was used. The functionality of the DLS plate 
reader was checked by polystyrene nanosphere-sized standards (Thermo 
Fisher Scientific, Fremont CA, USA). DLS autocorrelation data were analyzed 
with the Dynamics V6 software based on cumulant analysis with respect to 
particle size and polydispersity. 
2.5 Cell culture 
In vitro transfection experiments were performed using murine neuroblastoma 
(Neuro-2A) cells. Two parallel transfection series were carried out in separate 
96-well plates. Cells were seeded 24 h prior to transfection with a density of 104 
cells in 200 µL/well of culture medium containing 10% serum, 100 U/mL 
penicillin and 100 µg/mL streptomycin. Immediately before transfection, medium 
was removed and 100 µL of polyplexes diluted in culture medium (200 ng DNA) 
was added to the cells for 24 h until cytotoxicity and luciferase activity were 
analyzed. Cytotoxicity was evaluated 24 h after treatment by 
methylthiazoletetrazolium (MTT)/thiazolyl blue assay [7]. Metabolic activity (%) 
was expressed relative to the metabolic activity of untreated control cells (HBG 
buffer pH 7.4 only (5% glucose, 20 mM 4-(2-hydroxyethyl)-1-piperazineethane-
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sulfonic acid) (both, Merck, Darmstadt, Germany)), defined as 100%. To 
determine the luciferase reporter gene expression, the medium was removed 
and cells were lysed in 50 µl 0.5X Promega cell lysis solution 24 h after initial 
transfection. Luciferase light units were recorded with a Lumat LB9507 
instrument (Berthold, Bad Wildbad, Germany) from a 22 µL aliquot of the cell 
lysate with 10-s integration time after automatic injection of freshly prepared 
luciferase assay reagent using the Luciferase assay system (Promega, 
Mannheim, Germany). Luciferase activity (%) of the samples was expressed 
relative to the luciferase activity of plasmid/LPEI control polyplexes (formulated 
in HBG buffer via pipetting), defined as 100%. 
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3 Results and discussion 
3.1 Establishment of the up-scaled micro-mixer method for the 
preparation of plasmid/LPEI polyplexes 
Particle size and aggregation behaviour of the complexes are strongly affected 
by the preparation conditions like the way of adding the polymer solution to the 
nucleic acid solution or vice versa, diluting the complexes after their preparation 
or the used complexation time [8]. Up to date, the classical preparation of 
plasmid/LPEI polyplexes is to mix plasmid and LPEI solutions via pipetting that 
is traditionally performed at small volumes and often results in more or less 
heterogeneous batches [1,5]. Therefore, we established an up-scaled method 
for the preparation of polyplexes in accordance to the method described by 
Zelphati et al. [5]. Using two common syringe drivers, the plasmid and LPEI 
solutions were mixed at the junction of a T-connector and the mixing speed was 
controlled by syringe size and/or plunger speed (Figure 4-1).  
 
Figure 4-1: Schematic representation of the up-scaled micro-mixer method for the preparation 
of plasmid/LPEI polyplexes: (1) syringe driver, (2) plunger speed control, (3a) syringe with luer 
lock tip loaded with poly-nucleic acid solution, (3b) syringe with luer lock tip loaded with 
polycation solution, (4) polyetheretherketone tubings, (5) T-connector site of mixing, (6) formed 
polyplex, (7) glass vial. 
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Plasmid/LPEI polyplexes prepared by the up-scaled micro-mixer method at 
varied mixing speeds were compared to those prepared by classical pipetting. 
In general, with increasing mixing speeds, achieved by using increased plunger 
speeds and/or bigger syringe sizes, the z-average diameter as well as the 
polydispersity index (PdI) of the plasmid/LPEI polyplexes decreased from 
approximately 200 to 50 nm and 0.2 to 0.05, respectively (Figure 4-2). Only 
when using a 10-mL syringe, the polydispersity index of about 0.15 remained 
constant with increasing flow rate as the handling of the small filling volume 
compared to the high volume of the syringe was hindered. In addition, 
polyplexes were prepared by pipetting at large volume (5 mL). This preparation 
method resulted in larger and more heterogeneous polyplexes compared to 
pipetting at low volumes (0.5 mL).  
 
Figure 4-2: z-average diameter (nm) and PdI of plasmid/LPEI polyplexes (20 µg/ml) prepared by 
classical pipetting (Pip.) at low volumes (0.5 mL) or at large volumes (5 mL) or by the up-scaled 
preparation method using different syringe sizes (2.5, 5 and 10 ml) and different plunger speeds 
(1.0, 0.5, 0.2 and 0.1 cm/min). Values represent the mean ± 1 SD (n=3). 
As traditionally pipetting and using the up-scaled micro-mixer method with a 
mixing speed of about 10.6 mL/min (1.0 cm/min in combination with a 5-mL 
syringe, 13 mm inner syringe diameter) led to comparable results (polyplex size 
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65 nm, PdI 0.05), polyplexes prepared with these two settings were tested in 
cell culture experiments (Figure 4-3). No differences in metabolic activity or 
reporter gene expression for up-scaled and classically prepared polyplexes 
were observed. Hence, we conclude that in vitro results were not significantly 
influenced by the preparation method. 
 
Figure 4-3: Influence of the preparation method, pipetting (0.5 mL) versus up-scaled 
preparation, of freshly prepared plasmid/LPEI polyplexes and corresponding placebo 
formulations (only buffer) on (A) the metabolic activity (%) relative to HBG-treated murine 
neuroblastoma (Neuro-2A) cells determined via MTT assay and (B) in vitro transfection activity 
in murine neuroblastoma (Neuro-2A) cells determined as luciferase activity, normalized to the 
activity of the LPEI/CMVLuc control. Experiments were performed in quintuplicates using N/P 6. 
Large batches of polyplexes should not be simply prepared by mixing increased 
volumes of plasmid and polymer solution via pipetting. This approach can lead 
to heterogeneous batches of larger polyplexes, as the mixing process at larger 
volume becomes less controllable. The establishment of a controllable and up-
scalable micro-mixer method for the highly reproducible preparation of 
homogenous, standardized and well-defined polyplexes can minimize handling 
inconsistencies among different operators. Concerns regarding the order of 
addition, adding the DNA solution to the polymer solution or vice versa, are 
avoided by mixing the two solution feeds at a constant N/P ratio during the 
entire procedure leading to homogenous and standardized batches. Moreover, 
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by using this method, the size and polydispersity of the plasmid/LPEI polyplexes 
can be directly controlled via the mixing speed. Up to now, an automated up-
scaled mixing method was only established for the preparation of 
lipoplexes [4,5]. Zelphati et al. [5] introduced an analogous method for the 
preparation of cationic lipoplexes with well-defined sizes and also demonstrated 
that the particle size is influenced by the mixing rate. Using this method, the 
preparation volume is limited by the syringe size but can be easily scaled up. 
For example, Clement et al. [4] showed that mixing the two solutions via 
pumping is a viable alternative to the use of syringes, allowing the preparation 
of almost unlimited batch volumes. 
3.2 Influence of the plasmid concentration on particle size and 
polydispersity of plasmid/LPEI polyplexes 
In a next step, the influence of the preparation concentration on particle size 
and polydispersity of plasmid/LPEI polyplexes was evaluated. Plasmid/LPEI 
polyplexes were prepared at various plasmid DNA concentrations by the up-
scaled micro-mixer method and compared to polyplexes prepared by classical 
pipetting (Figure 4-4).  
The z-average diameter and the PdI decreased with decreasing plasmid DNA 
concentration and ranged from 170 nm respectively PdI 0.22 at a plasmid DNA 
concentration of 400 µg/mL to 65 nm respectively PdI 0.05 at 20 µg/mL. At low 
concentrations, the z-average diameter and the PdI for polyplexes prepared by 
the up-scaled micro-mixer method were identical compared to those prepared 
by classical pipetting. However, with increasing concentration, the polydispersity 
of samples prepared by classical pipetting increased drastically compared to the 
micro-mixer method. The sample at 400 µg/mL prepared by classical pipetting 
had to be diluted for the dynamic light-scattering measurements due to high 
scattering by extremely large particles. 
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Figure 4-4: z-Average diameter (nm) and PdI of plasmid/LPEI polyplexes prepared at different 
concentrations (20, 50, 100, 200 and 400 µg/ml) in L-histidine buffer pH 6.0 by classical 
pipetting (0.5 mL) and by the up-scaled preparation method using a 5-ml syringe and a mixing 
speed of 1.0 cm/min (n = 3). *Sample had to be diluted (1:10) prior to DLS measurement). 
The results indicate that at higher concentrations, polyplexes become more 
unstable, leading to a stronger aggregation. This fact has been already 
observed and discussed in literature [9,10]. For example, Duguid et al. [10] 
showed that the hydrodynamic diameter of polyplexes composed of poly-(L-
lysine) and synthetic polypeptides varied from 30-60 nm at a DNA concentration 
of 20 µg/mL to 80-160 nm at 400 µg/mL along with a large increase in 
polydispersity. Commonly, polyplexes are prepared at 50 µg/mL for in vitro 
experiments, whereas higher concentrations of 1-5 mg/mL can be only 
achieved if polyplexes are chemically modified to inhibit aggregation [11]. 
Especially at high concentrations, a more distinct heterogeneity of the 
polyplexes was observed when prepared via the classical preparation method. 
An explanation for this might be that higher polymer and DNA masses are 
mixed in a less controlled fashion at one time. 
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4 Conclusion 
It is very difficult to achieve the same quality attributes of polyplexes when these 
carrier systems are prepared at large volumes by simple pipetting compared to 
the standard laboratory pipette mixing at low volume. The established micro-
mixer method allows the highly reproducible preparation of large, standardized 
batches of homogenous, well-defined and transfection-competent polyplexes, 
banishes the risk of batch-to-batch variations and prevents handling 
inconsistencies among different operators, resulting in an increased polyplex 
quality. Moreover, by using this preparation method, the size and polydispersity 
of plasmid/LPEI polyplexes can be directly controlled via the mixing speed. The 
z-average diameter and the PdI of the polyplexes increased with increasing 
plasmid DNA concentration. The benefit of the up-scaled micro-mixer method is 
accentuated especially at high concentration as far less heterogeneity was 
observed in the up-scaled micro-mixer method compared to the classically 
produced particle preparations. Using this method, the batch volume can be 
easily further increased, which might be of high importance with regard to the 
production of large standardized batches of stable polyplex formulations. Thus, 
the possibility to reproducibly manufacture large standardized batches of well-
defined, transfection-competent polyplexes is an important step closer from 
promising technology to clinical application. 
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Abstract 
Cationic polymer/DNA complexes are limited by their instability in aqueous 
suspensions and usually have to be freshly prepared prior to administration. 
Thus, the development of isotonic lyophilized polyplex formulations with long-
term stability is a desirable goal. 
Polyplexes based on 22 kDa linear polyethylenimine were prepared using a 
micro-mixer method. Freeze-thawing and lyophilization were performed on a 
pilot scale freeze-drier. Several excipients (trehalose, sucrose, lactosucrose, 
dextran, hydroxypropylbetadex or povidone and combinations thereof) at 
varying concentrations were evaluated for their stabilizing potential against 
freezing and dehydration induced stresses. For stability testing the lyophilized 
samples were stored for 6 weeks at 2–8 °C, 20 °C and 40 °C, respectively. 
Polyplex samples were characterized for particle size, zeta potential, their in 
vitro transfection efficiency and metabolic activity in Neuro-2A cells. In addition, 
liquid samples were investigated for turbidity and number of subvisible particles 
and solid samples were analyzed for residual moisture content, glass transition 
temperature and sample morphology. 
L-histidine buffer pH 6.0 was selected as effective buffer. In isotonic 
formulations with 14% lactosucrose, 10% hydroxypropylbetadex/ 6.5% sucrose 
or 10% povidone/ 6.3% sucrose, particle size was <170 nm for all formulations 
and did not change after storage for 6 weeks at 40 °C. Polyplexes formulated 
with lactosucrose or hydroxypropylbetadex/sucrose showed high transfection 
efficiencies and cellular metabolic activities. Absence of large aggregates was 
indicated by turbidity and subvisible particle number measurements. The 
current standard limits for particulate contamination for small volume 
parenterals were met for all formulations. All samples were amorphous with low 
residual moisture levels (<1.3%) and high glass transition temperatures 
(>90 °C). 
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1 Introduction 
Non-viral gene delivery systems offer a significant promise to cure, treat or 
prevent various, up to now, incurable diseases [1]. Most nonviral gene delivery 
vectors are based on cationic lipids (lipoplexes) or cationic polymers 
(polyplexes) which interact electrostatically with the negatively charged nucleic 
acids and form condensed complexes [1]. Among the cationic polymers, linear 
polyethylenimine (LPEI) is the most potent polycationic transfection agents, 
known as a “golden standard” for polymeric gene delivery [1]. 
The major drawbacks of these non-viral vectors are the limited efficacy in 
delivering DNA compared to viral vectors particularly after in vivo application, 
and the high instability in aqueous suspensions [2]. To date, the predominant 
focus in non-viral gene therapy has been on the development of more efficient 
vectors but other crucial pharmaceutical aspects including quality control, long-
term stability and practicability in clinical trials have been rather ignored [3,4]. A 
limiting factor for the clinical practicability is the requirement for freshly prepared 
formulations prior to administration because of the tendency towards particle 
aggregation in liquid formulations, which is known to correlate with a loss of 
transfection efficiency [5-7]. However, the day-to-day preparation poses the risk 
of batch to batch variations, including significant variations in product quality, 
safety and transfection rates, and the inability to perform extensive quality 
control prior to the actual administration, due to time constraints [5,7]. Thus, to 
achieve stable, transfection competent non-viral complexes is a desirable 
goal [5] and an important step from a promising technology to application [7]. 
Lyophilization is a very gentle and therefore highly attractive way to achieve 
dried pharmaceuticals in general [8,9] and DNA-based formulations in 
particular [6,7,10]. Freeze-dried formulations possess the advantage of long-
term storage stability. However, the lyophilization process involves two 
stresses, freezing and drying, that are known to be damaging to
Lyophilization of plasmid/LPEI polyplexes                                                       133 
 
 macromolecules and nanoparticulate structures, unless appropriate stabilizers 
are used [2,11]. During freezing, particle stability can be influenced by 
cryoconcentration of the complexes or other solutes leading to a complex-rich 
phase or increased ionic strength [8,9,11], by exposure to ice-liquid 
interfaces [12], by pH shifts due to selective crystallization of buffer species [13], 
and by mechanical damage due to growing crystals of ice or excipient [9,12]. 
During drying the removal of the ice and unfrozen water, which act as stabilizing 
hydration shell, can affect the stability of the complexes [11] and additional 
damage after lyophilization may result from the effects of dehydration–
rehydration on complexes [6].  
Freeze-thawing and lyophilization in the absence of excipients cause 
complexes to aggregate and reduced transfection rates [14,15]. However, 
several studies have shown that the addition of excipients can protect the 
product from freezing and drying stresses and can increase storage stability of 
proteins or liposomes [16,17] and nonviral vectors [6]. Different excipients have 
been used as stabilizers: monosaccharides (glucose), disaccharides (trehalose 
and sucrose), oligosaccharides (inulin and isomaltotriose) or polysaccharides/ 
polymers (hydroxyethyl starch, high molecular weight dextrans, and 
polyvinylpyrrolidone) [11,18-20]. The choice of stabilizer is critical but also the 
mass ratio stabilizer/nanoparticle is important [11,15]. 
Moreover, the reconstituted preparations should not greatly exceed 
isotonicity [2]. Among non-viral delivery systems most literature is available on 
freeze-thawing and freeze-drying studies of lipid–DNA complexes [15,21-26] or 
complexes based on polymers like poly (2-dimethylamino)ethyl methacrylate 
(PDMAEMA) [14,27,28]. However, only little is known on freeze-thawing [29–31] 
and freeze-drying [7,10,29] of PEI-based polyplexes. Here, the main focus was 
generally to preserve transfection efficiency. Brus et al. [10] also investigated 
particle size, in addition to transfection efficiency. They observed only marginal 
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changes in size and transfection efficiency for complexes of short 
oligodeoxynucleotides and PEI after lyophilization. In contrast, plasmid/PEI 
complexes were found to aggregate and biological activity decreased. 
The aim of the study was to develop a lyophilized formulation for plasmid/LPEI 
polyplexes with long-term stability. Therefore, freeze-thawing studies were 
performed prior to lyophilization to select the best cryoprotectant for effective 
particle stabilization at isotonic concentrations. Here, a variety of excipients 
were tested: trehalose, sucrose, lactosucrose, hydroxypropylbetadex 
(HP-β-CD), and dextran or povidone (PVP). A selection of formulations was 
lyophilized and long-term storage stability over 6 weeks was investigated. 
Plasmid/LPEI polyplexes were characterized with respect to their hydrodynamic 
radius and polydispersity using dynamic light scattering as well as their 
transfection efficiency and their influence on the metabolic activity of murine 
neuroblastoma cells. In addition, freshly prepared or reconstituted, liquid 
formulations were analyzed for their osmotic pressure, turbidity and amount of 
subvisible particles. Dried formulations were examined by Karl Fischer titration, 
differential scanning calorimetry (DSC) and X-ray powder diffraction (XRD). The 
ability to prepare lyophilized polyplexes with high transfection efficiency and 
long-term stability would be an important step towards clinic-friendly drugs. 
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2 Materials and methods 
2.1 Materials 
The plasmid (pCMVLuc) was produced by PlasmidFactory (Bielefeld, D). 
22 kDa LPEI was synthesized as described in [32]. Dilutions of plasmid and 
LPEI were prepared in HBG buffer pH 7.4 (5% glucose, 20mM HEPES) or a 
10mM L-histidine buffer pH 6.0 (all, Merck, Darmstadt, D), so that mixing equal 
volumes of the two dilutions resulted in a N/P ratio of 6/1. The stabilizer sucrose 
(Südzucker, Mannheim, D), trehalose 100 and lactosucrose (purity 92.8%) 
(Nyuka-OligaTM LS-90P) (Hayashibara, Okayama, Jp), hydroxypropylbetadex 
(HP-β-CD) (CavasolTM W7 HP) (Wacker, Munich, D), povidone (PVP) 
(KollidonTM 17 PF, BASF, Ludwigshafen,D), dextran 8 (Serva,Heidelberg, D) 
and polysorbate 20 (Tween 20TM, Merck, Darmstadt, D) were used without 
further purification. Stabilizer solutions [% w/v] were prepared in 10mM 
L-histidine buffer pH 6.0 and mixed 1:1 with the formed polyplexes. 2R glass 
vials (FiolaxTM clear, Schott, Müllheim, D) with rubber stoppers (West, 
Eschweiler, D) were used. 
2.2 Preparation of plasmid/LPEI polyplexes 
Plasmid/LPEI polyplexes were prepared by an established micromixer method 
[33] (see Chapter 4). 
2.3 Freeze-thawing studies 
For the freeze-thawing studies, 100 µg/mL plasmid/LPEI polyplexes were 
prepared (5.0 mL syringe, mixing speed of 1.0 cm/min) in the 10 mM L-histidine 
buffer pH 6.0. 125 µL polyplex solution was mixed with 125 µL stabilizer solution 
in 2R vials resulting in a plasmid concentration of 50 µg/mL. Freeze-thawing 
was performed once or five times on a pilot scale freeze-drier (Lyostar II, SP 
Scientific, Stone Ridge USA). Samples were frozen at -1 °C/min to -50 °C. After 
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30 min at -50 °C, the samples were thawed at 1 °C/min to 10 °C with a 30 min 
hold. 
2.4 Lyophilization of plasmid/LPEI polyplexes 
Three isotonic formulations (14% lactosucrose, 10% HP-β-CD with 
6.5% sucrose or 10% PVP with 6.3% sucrose) at 50 µg/mL plasmid were 
lyophilized on the pilot scale freeze-drier. For cell culture experiments, the 
samples were prepared under aseptic conditions. 500 µL sample per 2R vial 
was frozen at -1 °C/min to -50 °C and held for 120 min. Primary drying was 
performed at 34 mTorr and -20 °C. During the first two-thirds of the primary 
drying step, the product temperature, monitored with thermocouples, was kept 
below the glass transition temperature of the maximally frozen concentrate (Tg′) 
which was determined by DSC and the endpoint of primary drying was defined 
by manometric endpoint determination. Secondary drying was performed at 
20 °C and 8 mTorr. Samples were stoppered at 600 Torr nitrogen. Lyophilized 
samples were reconstituted with 500 µL purified water. 
2.5 Long-term stability 
For stability testing the sealed, lyophilized samples were stored at 2-8 °C, 20 °C 
and 40 °C for 6 weeks. 
2.6 Plasmid/LPEI polyplex characterization 
Using the dynamic light scattering (DLS) platereader DynaPro Titan (Wyatt 
Technology, Dernbach, D) the particle size of the polyplexes was measured. 
100 µL sample (n=3) per well of a 96 UV-well plate (CostarTM, Corning, USA) 
was analyzed at RT using 5 acquisitions, with 5 s each. For all samples the 
corresponding preset refractive index parameters were used. For the polyplexes 
the refractive index increment value dn/dc for linear polymers of 0.185 was 
assumed. The viscosity of the samples was determined using a 
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microviscosimeter (AMVn, Anton Paar, Ostfildern, D). DLS autocorrelation data 
was analyzed with the Dynamics V6 software.  
The zeta-potential was determined using the Zetasizer Nano ZS (Malvern 
Instruments, Herrenberg, D) in a DTS 1060c cell with 10 up to 100 subruns of 
10 s at 20 °C (n=3) and was calculated by the Smoluchowski equation. 
2.7 Osmometry 
The osmotic pressure of 150 µL of each lyophilized polyplex formulation (n=3) 
was determined after reconstitution with an automatic semi-micro osmometer 
(Knauer, Berlin, D). 
2.8 Turbidimetry 
Turbidity of 1.5 mL of freshly prepared or reconstituted samples in formazine 
nephelometric units (FNU) was determined (n=3) by using a NEPHLA 
turbidimeter (Dr. Lange, Düsseldorf, D). 
2.9 Light obscuration 
Subvisible particle analysis was carried out according to Ph.Eur. 2.9.19 [34] 
using a particle counter SVSS-C (PAMAS, Rutesheim, D). Three 
measurements of 0.3 mL of a 1.5 mL sample were performed with a pre-run 
volume of 0.3 mL at a fixed fill rate, emptying rate and rinse rate of 5 mL/min 
(n=3). 
2.10 Cell culture: cytotoxicity and luciferase reporter gene 
expression 
In vitro transfection experiments were performed on murine neuroblastoma 
(Neuro-2A) cells. Cells were seeded 24 h prior to transfection with a density of 
104 cells in a 200 µL culture medium, containing 10% serum, 100 U/mL 
penicillin and 100 µg/mL streptomycin, per well. Immediately before 
transfection, the medium was removed and 100 µL of a dilution of polyplexes 
(200 ng DNA) in culture medium was added to the cells. Cytotoxic potency was 
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evaluated 24 h after treatment by methylthiazoletetrazolium (MTT)/thiazolyl blue 
assay [35]. Metabolic activity was calculated relative to untreated control cells 
(HBG buffer only). To determine gene expression, the medium was removed 
and cells were lysed in a 50 µL 0.5X Promega cell lysis solution 24 h after 
transfection. Luciferase light units were recorded with a Lumat LB9507 
(Berthold, Bad Wildbad, D) from a 20 µL aliquot with 10 s integration time after 
injection of Luciferase assay reagent (Promega,Mannheim, D). Luciferase 
activity [%] was expressed relative to the Luciferase activity of plasmid/LPEI 
reference polyplexes (formulated in HBG buffer via pipetting). 
2.11 Karl Fischer titration 
Lyophilized samples (n=3) were dissolved in dried Methanol (HydranalTM 
Methanol, Fluka, Sigma-Aldrich, D), and the methanol samples were injected 
into the titration solution (HydranalTM Coulomat AG, Riedel-de Haen, Seelze, D) 
and titrated using a Metrohm 756 KF Coulometer (Metrohm, Herisau, CH). 
Empty vials were treated identically as blanks. 
2.12 Differential scanning calorimetry (DSC) 
DSC measurements were carried out in 40 µL aluminium crucibles using a 
Mettler Toledo DSC821 (Mettler Toledo GmbH, Giessen, D). For determination 
of glass transition temperature of the maximally frozen concentrate (Tg′) 30 µL 
of the samples were analyzed (n=3). Samples were cooled from 20 °C to 
-50 °C with -1 °C/min, held at -50 °C for 10 min and reheated to 20 °C with 
5 °C/min. Approximately 10 mg of the lyophilized product (n=3) were weighed 
into 40 µL aluminium crucibles in a glove box, purged with dry air. Samples 
were cooled from 20 °C to 0 °C with -5 °C/min, held at 0 °C for 1 min and 
reheated to 150 °C with 10 °C/min. 
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2.13 X-ray powder diffraction (XRD) 
XRD was performed with a XRD 3000 TT (Seifert, Ahrenburg, D). Sample was 
filled in a copper sample holder with 1 mm fill depth and exposed to CuKa 
radiation (40 kV, 30 mA, wavelength 154.17 pm). Samples were analyzed with 
steps of 0.05° 2-Θ and a duration of 2 s per step from 5 to 45° 2-Θ. 
2.14 Statistical analysis 
Statistically significant differences were determined using a two-tailed student t 
test with a GraphPad Software, QuickCalcs (La Jolla, CA, USA). Mean values 
having p values >0.05 were judged to be not significantly different. 
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3 Results  
3.1 Influence of the buffer composition 
Typically, low molality buffers such as 10 or 20 mM HEPES at a pH of 7.4 are 
used for the preparation of polyplexes and tonicity is adjusted using sugars like 
glucose [28]. As HEPES is not listed as an approved inactive ingredient by the 
US Food and Drug Administration [36] the initial buffer composition (HBG buffer 
pH 7.4 which contained 5% glucose and 20 mM HEPES) was changed to 
L-histidine buffer pH 6.0 to move a step closer towards application. To evaluate 
the influence of the buffer composition on the z-average diameter, 
polydispersity index, zeta-potential and transfection efficiency of plasmid/LPEI 
polyplexes, complexes were prepared in HBG buffer pH 7.4 or L-histidine buffer 
pH 6.0.  
 
Figure 5-1: Influence of the formulation buffer on (A) the metabolic activity of Neuro-2A cells 
and (B) transfection activity in Neuro-2A cells (n=5); (*p>0.05: mean values are not significantly 
different). 
Polyplexes formulated in HBG buffer pH 7.4 were found to have a z-average 
diameter of about 176 nm with a polydispersity index of 0.18 and a zeta-
potential of 29.6 mV. When using 10 mM L-histidine buffer pH 6.0 the size and 
the polydispersity index decreased to 118 nm and 0.13 respectively and the 
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zeta-potential was raised to 36.3 mV. In vitro performance (metabolic 
activity/gene expression) was not significantly influenced by the buffer system 
(Figure 5-1). 
3.2 Freeze-thawing studies 
In order to select the most effective cryoprotectant and its stabilizing 
concentration freeze-thawing studies were performed, prior to freeze-drying. 
Therefore, plasmid/LPEI polyplexes were prepared in 10 mM L-histidine buffer 
pH 6.0 at a plasmid DNA concentration of 50 µg/mL using a micro-mixer 
method [33]. These polyplexes exhibited a z-average diameter of 104 nm and a 
zetapotential of 39.9 mV. The polyplexes were freeze-thawed once or five times 
without stabilizers or in the presence of trehalose, sucrose, lactosucrose or 
HP-β-CD at various concentrations (8, 12, 16 and 20%). The high molecular 
weight excipients dextran and povidone were only tested at a concentration 
level of 20% to stay closer to isotonicity. Subsequently samples were analyzed 
for their z-average diameter by DLS (Figure 5-2), as particle size is an important 
quality criterion. 
Without the addition of stabilizers the z-average diameter drastically increased 
already after one freeze-thawing cycle. The formation of these large polyplex 
aggregates might explain the observed tenfold decrease of reporter gene 
expression in cell culture (Fig. 5B). With increasing concentrations of the 
commonly used disaccharides trehalose or sucrose the z-average diameter of 
the polyplexes was increasingly preserved upon freeze-thawing. To inhibit an 
increase in particle size after one freeze-thawing cycle in the case of sucrose or 
trehalose as stabilizer a concentration of 20% was required, greatly exceeding 
isotonicity and indicating the prerequisite of a certain stabilizer/polyplex mass 
ratio. Lactosucrose, a trisaccharide, HP-β-CD, a cyclic heptasaccharide, 
dextran, a polysaccharide, and povidone, a vinyl polymer, represent alternative 
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cryoprotectants as these excipients showed lowered osmotic pressure at equal 
stabilizer/polyplex mass ratios. 
 
Figure 5-2: Z-average diameter [nm] of freshly prepared, non-stressed (NS) or once (1×FT) or 
five times (5×FT) freeze-thaw stressed plasmid/LPEI polyplexes (50 µg/mL) formulated in L-
histidine buffer pH 6.0 without (0%) or with the addition of stabilizers (trehalose, sucrose, 
lactosucrose, HP-β-CD, dextran (Dex) or PVP) at varying concentrations (8, 12, 16 or 20%) 
(n=3); (*p>0.05: samples are not significantly different compared to the non-stressed sample). 
At corresponding concentrations the stabilizing effects of lactosucrose and 
HP-β-CD were comparable to trehalose or sucrose. Dextran at high 
concentrations was a poor cryoprotectant for reproducible polyplex stabilization. 
Povidone showed promising stabilization effects after five freeze-thaw cycles. 
Based on these results, isotonic polyplex formulations were prepared and 
particle size was analyzed after freeze-thawing (Figure 5-3).  
After one freeze-thawing cycle using trehalose or sucrose at isotonic 
concentrations the increase in z-average diameter and polydispersity was more 
pronounced compared to the other selected recipients. Addition of 0.02% of the 
surfactant polysorbate 20 did not significantly improve the preservation of 
particle size. Using lactosucrose, HP-β-CD/sucrose or PVP/sucrose, 
satisfactory polyplex stabilization with an increase in size of less than 40% was 
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observed. HP-β-CD and povidone were combined with sucrose as sucrose is a 
commonly used stabilizer in lyophilization. However, the observed 
polydispersity index of 1 for PVP/sucrose samples indicates a multimodal size 
distribution due to the fact that not only the polyplexes but also the polymer 
povidone contributes to the intensity versus size distribution determined by 
DLS, as seen from the analysis of placebo samples (data not shown), and leads 
to a decreased z-average diameter. 
 
 
Figure 5-3: Z-average diameter [nm] and polydispersity index of freshly prepared, nonstressed 
(NS) or once (1×FT) or five times (5×FT) freeze-thaw stressed plasmid/LPEI polyplexes 
(50 µg/mL) formulated in L-histidine buffer pH 6.0 without (0%) or with the addition of stabilizers 
at isotonic concentrations of 9% trehalose (Tre), 9% sucrose (Suc), 9% sucrose with 0.02% PS 
20 (Suc+PS), 14% lactosucrose (LSuc), 10% HP-β-CD/6.5% sucrose (CD+Suc) or 10% 
PVP/6.3% sucrose (PVP+Suc) (n=3); (*p>0.05: samples are not significantly different compared 
to the non-stressed sample). 
As the latter three isotonic formulations, showed the best protection against 
freeze-thawing induced aggregation of polyplexes, these formulations were 
selected for freeze-drying and long-term stability studies. 
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3.3 Physico-chemical and biological properties of lyophilized 
plasmid/LPEI polyplexes 
The isotonic polyplex formulations with lactosucrose, HP-β-CD/sucrose and 
PVP/sucrose as stabilizers were lyophilized using a conservative freeze-drying 
cycle. To insure the complete solidification and glass formation, the samples 
were frozen to -50 °C well below the Tg′ of the samples (Table 5-1). Moreover, 
by monitoring the product temperature during lyophilization we insured that the 
temperature was maintained below Tg′ at least in the first two-thirds of the 
primary drying step. All lyophilized samples, except the sample without 
stabilizers, showed good cake appearance and instantly (<5 s) dissolved in 
water. 
Tabelle 5-1: Tg′ prior to freeze drying (prior to FD) and Tg and residual moisture (RM) of solid 
freeze dried formulations directly after freeze-drying (after FD) and after 6 weeks of storage at 
2-8 °C, 20 °C and 40 °C (n=3). 
  prior to FD after FD 2-8 °C 20 °C 40 °C 
Tg`/Tg [°C] -25.11±0.06 113.6±0.3 112.4±0.3 111.4±0.4 108.9±0.75 14% lacto-
sucrose RM [%w/w]  0.36±0.04 0.41±0.11 0.51 ± 0.07 0.85 ± 0.18 
Tg`/Tg [°C] -22.77±0.08 115.7±2.2 109.2±2.9 104.7±0.6 91.8±0.4 10% HPβCD+ 
6.5% sucrose RM [%w/w]  0.10±0.01 0.10±0.02 0.27±0.06 0.71±0.04 
Tg`/Tg [°C] -26.08±0.06 108.7±0.6 106.6±2.2 104.4±1.0 102.5±0.1 10% PVP+       
6.3% sucrose RM [%w/w]  0.17±0.01 0.18 ± 0.01 0.40 ± 0.02 1.26 ± 0.04 
 
After reconstitution few large, visible undissolved particles were observed for 
the lyophilized samples without stabilizers, and for all other lyophilized samples 
no particles or turbidity was visible by the naked eye. The z-diameter and 
polydispersity index increased drastically after lyophilization for the samples 
without stabilizers (Figure 5-4). This increase appears to be less pronounced 
compared to the samples without stabilizers after one freeze-thaw cycle. 
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However, for the samples lyophilized without stabilizers extremely large, visible 
particles were observed and only the soluble fraction of the polyplexes was 
analyzed. 
 
 
Figure 5-4: Z-average diameter (nm) and polydispersity index of plasmid/LPEI polyplexes 
(50 µg/mL) formulated in histidine buffer without (buffer) or with the addition of stabilizers (14% 
lactosucrose, 10% HP-β-CD/6.5% sucrose or 10% PVP/6.3% sucrose). Samples were freshly 
prepared and non-stressed (NS), freeze-thawed (FT), freeze-dried (FD) or freeze-dried and 
stored at 2-8 °C, 20 °C or 40 °C for 6 weeks (n=3). Polyplexes precipitated; (*p>0.05: samples 
are not significantly different compared to the corresponding non-stressed sample). 
Metabolic activity was not reduced for the lyophilized polyplex sample without 
stabilizers (Figure 5-5A). However, freeze-drying of polyplexes in the absence 
of stabilizers had a detrimental effect on reporter gene expression resulting in a 
hundredfold reduced luciferase activity while freeze-thaw stressing of the 
formulation only resulted in a tenfold decrease of activity (Figure 5-5B). All 
stabilizer containing samples showed a marginal (<45%) but, due to the small 
standard deviations among the triplicates, partially significant rise in the z-
average diameters (Figure 5-4). However, for the HP-β-CD/sucrose formulation 
an increased PdI of 1.0 was measured. Taking the DLS size distribution by 
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intensity into account, an additional peak in the low nanometer range was 
observed (data not shown). This peak was also detected for lyophilized placebo 
HP-β-CD/sucrose formulations in the absence of polyplexes, indicating that 
small particles are formed by the excipient itself during freeze-drying.  
 
Figure 5-5: Influence of the formulation of plasmid/LPEI polyplexes and corresponding placebo 
samples on (A) the metabolic activity of Neuro-2A cells and (B) relative in vitro transfection 
activity in Neuro-2A cells (n=5). Samples were formulated in histidine buffer pH 6.0 without 
(buffer) or with the addition of stabilizers (14% lactosucrose, 10% HP-β-CD/6.5% sucrose or 
10% PVP/6.3% sucrose). Samples were freshly prepared and non-stressed (NS), freeze-
thawed (FT) or freeze-dried (FD) and stored at 2-8 °C, 20 °C or 40 °C for 6 weeks. Polyplexes 
precipitated; (*p>0.05: samples are not significantly different compared to the corresponding 
freshly prepared and non-stressed sample). 
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After freeze-drying, turbidity (Figure 5-6) raised only marginally but significantly 
for HP-β-CD/sucrose and povidone/sucrose formulations. For the lactosucrose 
formulation a more pronounced increase in turbidity was observed. However, 
here, the placebo lactosucrose formulation containing no polyplexes showed a 
higher turbidity compared to the corresponding polyplex formulation. 
In a next step, the number and size of individual sub-visible particles in a size 
range between 1 µm and 200 µm were determined (Figure 5-7). 
 
Figure 5-6: Turbidity in formazine nephelometric units (FNU) of plasmid/LPEI polyplex 
(50 µg/mL) and corresponding placebo samples formulated in histidine buffer pH 6.0 without 
(buffer) or with the addition of stabilizers at isotonic concentrations (14% lactosucrose, 10% 
HP-β-CD/6.5% sucrose or 10% povidone/6.3% sucrose). Samples were freshly prepared and 
non-stressed (NS), freeze-thawed (FT), freeze-dried (FD) or freeze-dried and stored at 2-8 °C, 
20 °C or 40 °C for 6 weeks (n=3). Polyplexes precipitated. All lyophilized and stored samples 
were significantly different (p≤ 0.05) compared to the corresponding freshly prepared and non-
stressed polyplex sample. 
In contrast to the one time freeze-thawed sample without stabilizers, which 
showed drastically increased particle numbers in all size ranges, the freeze-
dried sample without stabilizers exhibited only slightly raised particle numbers, 
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because most of the polyplexes had precipitated and could not be analyzed, as 
aforementioned.  
 
Figure 5-7: Number of sub-visible particles/mL with a particle diameter bigger than 1 µm (A), 
bigger than 10 µm (B) or bigger than 25 µm (C) of plasmid/LPEI polyplex (50 µg/ mL) samples 
and corresponding placebo samples formulated in histidine buffer pH 6.0 without (buffer) or with 
the addition of stabilizers (14% lactosucrose, 10% HP-β-CD/ 6.5% sucrose or 10% PVP/6.3% 
sucrose). Samples were freshly prepared and nonstressed (NS), freeze-thawed (FT), freeze-
dried (FD) or freeze-dried and stored at 2-8 °C, 20 °C or 40 °C for 6 weeks (n=3). Polyplexes 
precipitated; (*p>0.05: samples are not significantly different compared to the corresponding 
freshly prepared and non-stressed polyplex sample). 
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All freeze-dried formulations showed drastically increased numbers of 
subvisible particles in the size range ≥ 1 µm. However, the increase in particle 
numbers ≥ 1 µm for the freeze-dried formulations was less distinct compared to 
the freeze-thawed sample without stabilizers. Moreover, the corresponding 
placebo formulations, containing no polyplexes, showed almost the same or 
even slightly higher numbers of subvisible particles ≥ 1 µm. In the size ranges 
≥ 10 µm and ≥ 25 µm the amount of subvisible particles was only slightly 
increased in the formulations after freeze-drying compared to the freeze-thawed 
sample without stabilizers. These results confirm the ability of the selected 
stabilizers to inhibit the formation of large polyplex aggregates. The osmolality 
of the lyophilized and reconstituted samples was determined to be close to 
isotonicity for all samples and varied between 276 and 290 mOsm/kg. 
 
Additionally, the influence of the lyophilized formulations on metabolic activity 
(Figure 5-5A) and the in vitro transfection efficiency of the lyophilized polyplexes 
(Figure 5-5B) were tested and compared to freshly prepared samples. Freshly 
prepared and lyophilized lactosucrose or HP-β-CD /sucrose samples had no 
significant effect on in vitro performance. Freshly prepared polyplex solutions 
containing PVP/sucrose as well as the corresponding placebo formulation 
severely interfered with the metabolic activity of the Neuro-2A cells resulting in a 
drop of metabolic activity to 20% and a hundredfold decrease in reporter gene 
expression after polyplex application. Freeze-drying diminished this effect 
leading to a significantly increased metabolic activity, however not completely.  
For all freeze-dried samples the residual moisture levels were low (<0.4%) 
(Table 5-1). The glass transition temperature determined by DSC ranged from 
108.7 to 115.8 °C (Table 1). All samples were totally amorphous as no peaks of 
crystallinity were observed in the XRD spectra (data not shown). 
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3.4 Physico-chemical and biological properties of lyophilized 
plasmid/LPEI polyplexes after storage 
In order to evaluate long-term stability the sealed lyophilized formulations were 
stored at 2-8 °C, 20 °C and 40 °C for 6 weeks. After reconstitution, samples 
were analyzed for polyplex particle size, turbidity, amount of subvisible particles, 
transfection efficiency and influence on metabolic activity in murine 
neuroblastoma cells. Solid samples were characterized by Karl–Fischer titration, 
DSC and XRD. 
After storage the z-average diameter of the polyplexes was less than 170 nm 
for all formulations, stress conditions and time points (Figure 5-4). Storage 
temperature did not influence particle size when polyplexes were formulated 
with lactosucrose or HP-β-CD/sucrose. For the PVP/sucrose formulations 
polyplex size was found to slightly increase with elevated storage temperature. 
A polydispersity index of 1.0 was determined for the HP-β-CD/sucrose and 
PVP/sucrose formulations due to the additional peaks in the low nanometer 
range observed in the intensity versus size distribution determined by DLS for 
the polyplex but also for the placebo formulations (data not shown). However, 
no additional peaks in the intensity versus size distribution at bigger particle 
diameters were detected. Turbidity of the samples after storage was 
comparable to the turbidity determined directly after lyophilization (Figure 5-6). 
Only the lactosucrose placebo formulations showed an increase in turbidity with 
elevated storage temperature. Furthermore, the number of subvisible particles 
≥ 1 µm did not significantly change during storage for the lactosucrose and 
HP-β-CD/sucrose formulations and increased about 25% for the PVP/sucrose 
formulations independent of storage temperature (Figure 5-7). The lactosucrose 
formulations showed a substantial decrease in the number of subvisible 
particles ≥ 10 µm after storage at all temperatures. The number of subvisible 
particles ≥ 10 µm increased for the HP-β-CD/sucrose formulation when stored 
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at 20 °C or 40 °C and for the PVP/ sucrose formulation when stored at 2-8 °C or 
20 °C. No formation of particles ≥ 25 µm was observed. 
In cell culture (Figure 5-5), metabolic activity was not significantly changed by 
lactosucrose and HP-β-CD/sucrose formulations independent of storage 
temperature and only a marginal decrease in reporter gene expression was 
observed when cells were treated with polyplex formulations which had been 
stored at elevated temperatures. For the PVP/sucrose formulations metabolic 
activity was not changed when stored at 2-8 °C and 20 °C respectively. Storage 
at elevated temperature further affected transfection efficiency with a slight 
decrease when stored at 20 °C and a complete collapse of delivery efficiency 
although metabolic activity was still high when stored at 40 °C.  
For all formulations residual moisture content was only slightly increased when 
stored at 2-8 °C for 6 weeks. However, when samples were stored at 20 °C and 
40 °C residual moisture increased with increasing storage temperature but was 
still less than 1.4% for all samples. An opposed trend was observed for the 
glass transition temperature. Here, Tg decreased with increasing storage 
temperature. All samples remained in the amorphous state as no peak of 
crystallinity was detected with XRD after storage (data not shown). 
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4 Discussion 
In general, the size and charge of polyplexes are influenced by the ionic 
strength of the buffer and the degree of protonation of the polycation depending 
on the surrounding pH [37]. As an increased salt concentration reduces the 
hydrate layer around the particles and promotes their aggregation ionic strength 
of the buffer should be low [37]. To keep ionic strength low, but to provide 
sufficient buffer capacity L-histidine buffer pH 6.0 was selected because it 
provides high buffer capacity at low concentrations (10 mM) as its pKa of 6.1 is 
close to the buffers' pH. As PEI has a very high density of amines, the degree of 
protonation changes with pH. At physiological pH only 10-15% of the amines 
are protonated whereas at a pH of 6.0 30-35% of the amines are 
protonated [38]. Thus, the more acidic pH of the L-histidine buffer leads to a 
higher degree of protonation resulting in the formation of smaller polyplexes in 
combination with an increased zeta-potential. This increased positive surface 
charge can prevent polyplex aggregation by repulsion of positive charges [37]. 
Therefore, a higher stability of the plasmid/LPEI polyplexes prepared in 
L-histidine buffer is expected compared to those prepared in HBG buffer.  
As aforementioned, the stability of polyplexes can be drastically affected during 
freezing. Several studies reported that complex size increased drastically 
without the presence of stabilizers after freeze-thawing [14,18,26,28]. As 
alterations in particle size are known to influence toxicity and biodistribution in 
vivo, particle size is a critical issue in product development and is therefore 
routinely monitored in quality control [29]. The dramatic increase in particle size 
of polyplexes in the absence of stabilizers indicates the necessity of using 
cryoprotectants to inhibit freezing-induced aggregation. We found dextran to be 
a poor cryoprotectant for the stabilization of polyplexes. Accordingly, it is 
reported that dextran also failed to protect frozen PEGylated lipoplexes [39]. 
Overall, the stabilizer/polyplex weight ratio seems to be the more critical 
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parameter as large particle aggregates were formed at low excipient/polyplex 
ratios. Recent studies have also shown that a certain concentration of 
stabilizers is required for the preservation of particle size depending on the 
particle concentration [23,26]. In our study, 20% sucrose was necessary to 
stabilize plasmid/LPEI polyplexes, corresponding to a sucrose/DNA weight ratio 
of 4000. In comparison, Talsma et al. [7] showed that a sucrose/DNA ratio of 
10000 was required to protect transferrin–PEI complexes. In another study, full 
conservation of the size of PEI-based polyplexes was observed  at a 
sucrose/DNA ratio of 7500 [21]. For the protection of DMAEMA polyplexes a 
sucrose/DNA ratio of 1250 was sufficient [28]. In contrast to these results for 
polyplexes, lipoplexes could be successfully protected in general at lower 
sucrose/DNA ratios [15,21–23]. These high amounts of excipients, necessary 
for polyplex stabilization during freezing, do not only result in a hypertonic 
formulation but also in prolonged lyophilization cycles. 
The mechanism how cryoprotectants stabilize non-viral vectors during freezing 
is still not fully understood [6].Here, preferential exclusion [6,16], vitrification [6] 
and particle isolation [23] are discussed. According to the preferential exclusion 
hypothesis, established for protein stabilization, the solutes are unable to 
access the surface of the protein and are therefore preferentially excluded from 
contact with the protein's surface resulting in the formation of a stabilizing 
solvent layer [6,16]. However, it is not clear whether the preferential exclusion 
hypothesis can be adapted to the stabilization of non-viral vectors. The 
relatively high amounts of cryoprotectants that are necessary to preserve 
particle size during freezing suggest that the stabilization is related to 
nonspecific bulk characteristics of the formulation [20]. Based on the vitrification 
hypothesis the non-viral vectors are entrapped in the amorphous glassy matrix, 
which forms when the sample is cooled below the glass transition temperature 
of the maximally freeze-concentrated system (Tg′) [6,20]. The high viscosity of 
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these glasses immobilizes the non-viral vectors [29], inhibits their diffusion on a 
relevant time scale [20] and prevents their bimolecular collision [6]. However, 
vitrification cannot be the only stabilization mechanism because some sugars 
are able to maintain particle size at temperatures well above Tg′ [23]. The 
particle isolation hypothesis is based on the fact that crowding of particles 
facilitates aggregation and that there is a critical excipient/complex ratio at 
which protection is observed, as particles are more distinctly diluted in the 
freeze-concentrate with increasing excipient concentration [23]. Moreover, 
during cooling, the viscosity of the solute freeze-concentrate increases with 
decreasing temperatures and leads to a retarded and limited vector diffusion. 
Therefore, viscosity of the freeze-concentrated matrix only needs to be high 
enough independent of the type of excipient used, and matrix vitrification may 
not be required, in order to prevent aggregation [6]. 
In absence of stabilizer polyplexes were also found to dramatically aggregate 
during lyophilization leading to the precipitation of large visible particles. As for 
the freeze-thawed sample without stabilizers only an increase in particle size 
and turbidity but no precipitation was observed, and it can be concluded that the 
dehydration of the samples during drying adds further stress in addition to the 
freezing step. For all formulations, containing lactosucrose, HP-β-CD /sucrose 
and PVP/ sucrose only a slightly increased particle size (<45%) was observed. 
This is the first time, to our knowledge, that only such a marginal increase in 
particle size for plasmid/PEI complexes is reported upon lyophilization. In 
comparison, Brus et al. [10] found plasmid/LPEI polyplexes to increase in size 
from 100 nm to about 500 nm after lyophilization, however at low sucrose/DNA 
ratios. Hinrichs et al. [18] showed that the size of PEI polyplexes increased to 
160% or 240% when using inulin or dextran as stabilizers at an 
oligosaccharide/DNA ratio of 1000. It is well-reported in literature that in addition 
to stresses during freezing, dehydration may influence complex function [22]. 
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During the drying step the separation of the particles inside the glass matrix, 
that was formed during freezing, can potentially be maintained [23]. In addition 
to the entrapment in the glassy matrix the “water replacement hypothesis” [40] 
is discussed as a stabilizing mechanism during drying, as product vitrification 
was found to be not obligatory to maintain particle size [6,21]. According to this 
concept, the excipients directly interact with the surface of the particles, replace 
the surrounding water and mimic the “hydrated” condition, thus preserving 
particle size and transfection efficiency of non-viral vectors in the dried 
state [6,22]. 
The z-average diameter of the polyplexes in the selected isotonic formulations 
only marginally changed after lyophilization compared to the samples stressed 
by one time freeze-thawing, indicating that in the presence of stabilizers the 
increase in particle size usually occurs during the freezing step rather than 
during the drying step of the lyophilization process. Comparable results were 
reported for lipid/ DNA complexes [21,23,26]. However, for PDMAEMA 
complexes dehydration seemed to be a more destructive stress [28]. 
Particle size is not only an important criterion for quality control but can also 
influence transfection efficiency in vitro. In general, particle size may influence 
endosomal uptake, the transport in the cytoplasma and the migration through 
the nucleopores into the nucleus and the size dependency may differ in different 
cell types and applications [41]. The observed increase in particle size for the 
freeze-thawed and lyophilized polyplexes in the absence of stabilizers 
correlated with a pronounced decrease in transfection efficiency. This confirms 
the necessity of cryo- and lyoprotectants for maintaining polyplex function 
during lyophilization. Accordingly, Talsma et al. [7] reported an at least 3 log 
units drop in gene expression of freeze-dried pCMVL/transferrin-PEI complexes 
in the absence of sucrose. It is reported that in the case of large particle 
formation the reduction of transfection rates is presumably due to structural 
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alterations within the complexes or perturbed interaction between plasmid DNA 
and cationic polymer [6]. Transfection efficiency and metabolic activity of 
lyophilized polyplexes formulated with lactosucrose and HP-β-CD /sucrose was 
comparable to the freshly prepared formulations. When formulated with 
lactosucrose transfection efficiency was only slightly decreased when stored for 
6 weeks at 40 °C. These findings are similar to the 25% decrease in 
transfection efficiency of freeze-dried PDMAEMA complexes when stored at 
40 °C for 10 months; storage at 4 °C or 20 °C resulted in retained transfection 
efficiency [27]. Freshly prepared PVP/sucrose formulations were found to be 
cytotoxic in contrast to the lyophilized formulations. Although we did not further 
investigate this effect, we suggest that peroxide impurities [42] in the povidone 
might influence metabolic activity of murine neuroblastoma cells and that the 
peroxide impurities are removed by the use of lyophilization. Kumar and 
Kalonia [43] demonstrated that vacuum drying can be used to remove 
peroxides in polyethylene glycols resulting in an increased stability of biotech 
and pharmaceutical formulations, supporting our findings. However, when the 
PVP/sucrose formulations were stored at 40 °C a drastic four log unit decrease 
in transfection efficiency was observed. As metabolic activity and particle size 
were only marginally changed we presume a chemical change in the 
formulation due to the increased storage temperature, but this presumption was 
not further investigated. Numerous studies have demonstrated that structural 
modifications due to chemical changes in the formulation other than alterations 
in particle size can also influence gene delivery efficiency [26]. 
In order to investigate supplementary physical characteristics turbidity and 
number of subvisible particles were analyzed as well. Turbidity only refers to the 
presence of large aggregated particles, when it is clearly increased, as it was 
observed for the freeze-thawed polyplex sample without stabilizers. The 
samples with stabilizers showed an increased turbidity after lyophilization and 
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reconstitution. But the increased turbidity also manifested in the placebo 
formulations. This can be explained by the fact that small particles are formed 
by the excipient itself after lyophilization and reconstitution. This observation 
was also described by Anchordoquy et al. [15]. In addition, the fact that for the 
lyophilized HP-β-CD/sucrose samples additional peaks were detected in the 
DLS size distribution by intensity, regardless of whether polyplexes were 
present or not, might be related to the particle formation of the excipient itself. It 
is reported in literature, that cyclodextrins form self assembled aggregates or 
nanoparticles at increased concentrations (>1%) [44]. The particularly high 
turbidity in combination with a large number of subvisible particles in the very 
low micrometer range for samples containing lactosucrose may be presumably 
related to impurities that favour particle formation upon lyophilization as the raw 
material has only a purity of ≥ 90%. Interestingly, only the lactosucrose placebo 
formulations showed raised turbidities with increasing storage temperature but 
the formation of excipient particles was inhibited by the presence of polyplexes 
via an unknown and not further investigated mechanism. In general, all placebo 
and verum samples showed large numbers of subvisible particles ≥ 1 µm. 
Thus, it can be stated that the excipients themselves and the manufacturing 
environment may lead to these high numbers of small particles. However, all 
samples meet the current standard limits for small volume parenterals specified 
in the Ph.Eur. [34] and USP [45]. Moreover, in accordance with literature [29], 
no correlations between turbidity or number of subvisible particles and 
transfection efficiency were observed, confirming our hypothesis that the 
variation in turbidity and number of subvisible particles is not evoked by the 
formation of polyplex aggregates. 
All formulations showed substantially higher Tg′ values compared for example 
to pure sucrose samples for which a Tg′ of about -31 °C is reported in 
literature [39]. According to the Fox-Flory theory [46], the Tg′ increases with 
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increasing molecular weight. This is the reason for the increased Tg′ found for 
the lactosucrose and HP-β-CD/sucrose or povidone/sucrose samples. For pure 
HP-β-CD and pure povidone Tg′ values of about -15.4 °C and -22.1 °C are 
reported in literature [47]. The mixtures with sucrose result in a Tg′ value which 
is in correspondence to the mixing ratio used. The Tg of the freeze-dried 
formulations showed the same trend of higher Tg values for the formulations 
containing excipients with higher molecular weights, when compared to the Tg 
value of pure sucrose of 72 °C mentioned in literature [48]. The Tg of 113.6 °C 
determined for the lactosucrose sample in our study is in accord with the Tg 
reported for spray-dried lactosucrose [49]. For pure PVP a Tg of 110 °C and for 
β-CD a Tg of 108 °C are reported [47,50]. However, when comparing Tg values 
residual moisture has to be considered, which was very low in our study. In 
general, residual moisture contents of less than 1% after lyophilization are 
considered to be optimal for storage stability [9]. The observed increase in 
residual moisture at elevated storage temperature could be explained by the 
fact that at higher temperatures the potential for water transfer out of the 
stopper to the dried cake is more pronounced [51]. In general, an increase in 
water content can be critical for storage stability as it is associated with a 
decrease in the glass transition temperature. As complexes have to be 
remained spatially separated in the dried cake to prevent aggregation, product 
vitrification may not be important for the particle stabilization during 
lyophilization but is essential for long-term stability [23]. After storage, all 
formulations exhibit still high glass transition temperatures compared e.g. to 
pure sucrose. Therefore, oligosaccharides and polymers are more auspicious 
lyoprotectants than disaccharides because they can be exposed to higher 
relative humidity during storage without passing the glass transition temperature 
and can therefore optimize storage stability [39].  
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In general all three selected formulations, 14% lactosucrose, 10% HP-β-CD with 
6.5% sucrose or 10% PVP with 6.3% sucrose, are suitable to preserve polyplex 
particle size upon lyophilization and storage at isotonic concentrations. 
However, the knock-out criterion of the PVP/ sucrose formulation is its 
pronounced cytotoxicity and reduced transfection efficiency. For lactosucrose 
the increased turbidity and number of subvisible particles in the low micrometer 
range is a less critical constraint, as the current standard limits of small volume 
parenterals are met. The HP-β-CD /sucrose formulations exhibited an additional 
peak in the intensity versus size distribution of the DLS measurements after 
lyophilization and storage, indicating the formation of nano-meter ranged 
HP-β-CD aggregates. But this represents only an analytical limitation. As the 
lactosucrose and HP-β-CD sucrose formulations preserved the particle size and 
showed comparable transfection efficiencies and metabolic activities, we 
suggest these two formulations as very promising selections to conserve 
polyplexes and other non-viral vectors. However, the stability of the complexes 
against freezing and drying stresses has to be considered, which might depend 
on the actual composition e.g. DNA versus siRNA or non-pegylated versus 
pegylated, the size and surface charge of the complexes. We suggest to 
evaluate the complex stability in a freeze-thawing study at first. If the complexes 
require an even increased excipient to polyplex mass ratio, the 
HP-β-CD/sucrose formulation might be a promising alternative, as the mass of 
HP-β-CD at the expense of the mass of sucrose can be easily increased without 
exceeding isotonicity. In addition to the suitability of the lactosucrose and 
HP-β-CD/sucrose for the manufacturing of lyophilized non-viral vector 
formulations, we suggest that these formulations are beneficial in all cases in 
which a high excipient amount is required but isotonicity levels should not be 
exceeded e.g. for high concentrated protein formulations or other 
nanoparticulate systems. Furthermore, the high Tg′ and Tg values are 
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promising. The increased Tg′ will allow primary drying at elevated shelf 
temperatures resulting in shorter, less expensive freeze-drying cycles. The high 
Tg values will positively influence storage stability.  
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5 Conclusion 
To summarize, by changing the initial HBG buffer to a more acidic L-histidine 
buffer system smaller, more homogeneous and more positively charged 
polyplexes with potentially higher stability due to increased repulsion are 
obtained. Prior to lyophilization, freeze-thawing studies were performed to 
select the most effective cryoprotectant. Using lactosucrose, HP-β-CD /sucrose 
and PVP/sucrose at isotonic concentrations, effective protection against freeze-
thawing induced aggregation of the polyplexes was observed. By using these 
formulations the polyplex size can also be far better preserved upon 
lyophilization and storage compared to previous studies. All samples met the 
current standard limits for particulate contamination for small volume 
parenterals. However, turbidity and number of subvisible particles are 
influenced by the formation of excipient particles. The lyophilized and stored 
polyplexes formulated with lactosucrose or HP-β-CD /sucrose show comparable 
transfection efficiencies and metabolic activities in cell culture. However, 
transfection efficiency along with metabolic activity decreases when using 
PVP/sucrose as stabilizers. Lyophilized and stored samples showed low 
residual moistures and high glass transition temperatures and were found to be 
totally amorphous. The lactosucrose and HP-β-CD sucrose formulations are not 
only promising for the stabilization of non-viral gene delivery systems in general 
but also for their applications like highly concentrated protein formulations. 
In conclusion, in this study we could show that lyophilization is an excellent 
method to achieve stable polyplex formulations with maintained particle size 
and transfection potential. Lyophilized formulations are not only ideal for 
shipping and storage they also reduce the risk of critical batch to batch 
variations in clinical studies if freshly prepared samples prior to administration 
are required. Moreover, lyophilization allows the concentration of non-viral gene 
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delivery formulations by reconstitution of the lyophilized samples with reduced 
quantities of water [19]. 
The possibility to reproducibly produce large standardized batches of well-
defined, transfection efficient polyplexes with long-term stability by using a 
micro-mixer preparation method followed by lyophilization is an important step 
closer from a promising technology to application 
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Abstract 
Lyophilization has proven to be an attractive way to achieve long-term stable 
nanoparticulate gene delivery formulations. However, freezing induced stresses 
are known to induce particle aggregation, unless particles are formulated at a 
sufficient stabilizer/DNA mass ratio.  
The “preferential exclusion hypothesis”, the “vitrification hypothesis”, and the 
“particle isolation hypothesis” mechanisms have been discussed, but are not 
capable to fully explain the stabilization of gene delivery particles during 
freezing. Thus, this study was aimed to comprehensively investigate the 
influence of the freezing step on the stability of gene delivery particles. 
Plasmid/LPEI were formulated at two DNA concentrations (10 µg/mL or 
50 µg/mL) and at increasing sucrose/DNA ratio from 1200 to 14000. At first, 
particle size of polyplexes after freezing by the “standard” depressurization 
method in comparison to conventional shelf-ramp freezing was investigated. In 
a next, step the influence of ice nucleation temperature, residence time of the 
particles in an unstable frozen state, or proceeding freezing was investigated 
separately. Moreover, the increase in sucrose concentration and system 
viscosity during freeze-concentration and corresponding bimolecular reaction 
rates were theoretically modeled. 
The “standard” depressurization method was more stressful to particles 
compared to shelf-ramp freezing, but comparable results were achieved when 
temperature equilibration after ice nucleation was omitted. The ice nucleation 
temperature only affected the stability at low DNA concentrations. But in 
general, particle stability during freezing was highly temperature- and time-
dependent. Particle stability was markedly affected during the early part of 
freezing (< −3°C). In this phase freeze-concentration is already far progressed 
leading to high particle concentration and an increase in bimolecular reaction 
rate which cannot be inhibited by the still very low system viscosity. Low shelf-
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ramp rates negatively affect particle stability. In general, below a critical 
temperature (~≤ −18°C) no further particle aggregation occurred due to the 
drastic increase in sample viscosity that strongly reduce the reaction rates. 
Moreover, an initially high sucrose/DNA ratio and sample viscosity is capable to 
fully inhibit an increase in bimolecular reaction rates during freezing.  
Thus, it can be concluded that the initial sample viscosity rather than the 
unfrozen volume is the predominant factor in particle stabilization. In addition, 
the residence time of particles in the low viscous state is of importance. This 
extended understanding of the underlying stabilization mechanisms during 
freezing of nanoparticles will facilitate the development of improved formulations 
and optimized lyophilization processes.  
 
Keywords 
Non-viral gene delivery, lyophilization, freezing, stabilization, cryoprotection, 
viscosity 
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1 Introduction 
Nucleic acid-based therapeutics are a promising new class of 
biopharmaceuticals [1]. The most common non-viral carriers for the nucleic 
acids are lipoplexes and polyplexes [1]. These nanoparticulate carriers are 
based on cationic lipids or cationic polymers which form condensed complexes 
with the negatively charged nucleic acids via electrostatic interaction [1]. One 
general limitation is the poor long-term stability of nanoparticles, specifically 
non-viral vectors tend to aggregate in aqueous solutions, which is known to 
correlate with a loss in transfection efficiency of nucleic acid based systems [2]. 
Consequently, lyophilization has proven to be an attractive way for the 
production of long-term stable, transfection efficient gene delivery formulations. 
Although lyophilization is a very gentle drying process it involves two potential 
stresses: freezing and drying [3]. These stresses typically cause damage of 
macromolecules and nanoparticles, unless appropriate stabilizers are added to 
the formulation [4].  
In a previous study we found that the undesirable aggregation of plasmid/LPEI 
polyplexes occurs predominantly during the freezing and not during the drying 
step of the lyophilization process [5] (see Chapter 5). Similar observations were 
also reported for lipid/DNA complexes [6-8]. In general sugars, especially 
disaccharides like sucrose, are very efficient cryoprotectants [9-11]. But the 
choice of excipient is not the predominant factor in particle stabilization, unless 
crystallization or phase separation of the excipient occurs [5, 7]. Instead, it was 
observed that the mass ratio of stabilizer to gene delivery particle is critical in 
order to provide sufficient stabilization during the freezing step [5-7].  
During freezing, the product temperature is lowered and samples experience 
supercooling until ice nucleation occurs [12-13]. As the freezing process 
continues, more and more water is converted into ice. This leads to 
cryoconcentration of the samples until a critical concentration is exceeded, and 
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vitrification of amorphous or eutectic crystallization of crystalline excipients 
occurs [12-13]. Thus, there are two main stress factors that could potentially 
impact the stability of gene delivery particles during freezing: ice formation and 
cryoconcentration [14]. Ice formation can threaten particle stability via their 
exposure to ice-liquid interfaces or due to mechanical damage by growing ice 
crystals [14]. Cryoconcentration leads to both solute and particle rich liquid 
phase and might facilitate particle aggregation due to an increase in ionic 
strength, pH shifts or simply particle crowding [4, 7, 14]. 
Several mechanisms how cryoprotectants may stabilize non-viral gene delivery 
particles during freezing have been discussed [2, 15]. The “preferential 
exclusion hypothesis”, which was established to explain protein stabilization, 
states that solutes are preferentially excluded from a protein surface leading to 
the formation of a stabilizing solvent layer [2, 15-16]. However, it is doubtful 
whether the “preferential exclusion hypothesis” can be adapted to non-viral 
vectors, as this hypothesis requires exclusion of the sugar, but for non-viral 
vectors direct interaction of sugar molecules with the particles is reported [15]. 
According to the “glass formation or vitrification hypothesis”, non-viral vectors 
are entrapped in the amorphous glassy matrix that is formed when the sample 
is cooled below the glass transition temperature of the maximally freeze-
concentrated system (Tg`) [2, 15]. The high viscosity of the glassy matrix 
immobilizes gene-delivery particles and, thus, prevents particle aggregation 
[2, 15]. However, the “vitrification hypothesis” is not capable to explain the 
requirement of a critical mass ratio of stabilizer to gene delivery particle, as 
glass formation during freezing is independent of the initial stabilizer 
concentration [15].  
In a study on the freeze-thaw stability of lipid/DNA complexes, Allison et al. [7] 
demonstrated that glass formation is not obligatory as sugars like glucose are 
also capable to preserve particle size at temperatures above Tg`. 
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Consequently, the “particle isolation hypothesis” was proposed [7]. This 
hypothesis is based on the fact that crowding of particles facilitates particle 
aggregation and that the separation of individual particles in the unfrozen 
fraction prevents particle collision during freezing [7]. At higher stabilizer/particle 
mass ratios, the volume of the unfrozen fraction increases, leading to a more 
distinct dilution and more effective separation of the particles in the freeze-
concentrate [7]. In a further study, Armstrong et al. [17] showed that particle 
aggregation can result from the formation of ice as well as from prolonged 
incubation in the frozen state above, but not below, a critical temperature well 
above Tg`. Therefore, they concluded that below this critical temperature 
particles are already sufficiently immobilized in the freeze-concentrate 
preventing particle aggregation [17]. 
Until now, no detailed study on the influence of different freezing parameters, 
such as ice nucleation temperature or freezing rate, on the stability of non-viral 
gene delivery particles is available. These parameters highly affect the freezing 
behavior and the structure of the non-frozen fraction and thus, might also highly 
impact particle stability during freezing. Literature is focused on the influence of 
the freezing process on protein stability or performance of the lyophilization 
process [13]. With regard to the stability of non-viral gene delivery particles, it is 
only reported that fast freezing in a dry ice/alcohol bath, in liquid nitrogen, or in 
a −70 °C freezer resulted in a better preservation of lipoplexes compared to 
slow freezing in a −20 °C freezer or at −2.5 °C/min to −40 °C [6, 18].  
But these difficult to control fast freezing methods are not practical on large 
scale. Instead shelf-ramp freezing, where the filled vials are placed on the 
shelves of the freeze-drier and the shelf temperature is decreased linearly (with 
−0.1 °C/min to −5 °C/min, depending on the capacity of the freeze-drier) with 
time, is the most commonly used freezing method [13]. During shelf-ramp 
freezing, ice nucleation occurs stochastically, resulting in vial-to-vial or batch-to-
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batch heterogeneity and up-scaling issues [13]. Therefore, different methods 
based on ultrasound, electro-freezing, vacuum-induced surface freezing, an ice 
fog or depressurization have been developed in order to control nucleation at 
the desired nucleation temperature [13]. Depressurization is a rather newly 
established method which has gained substantial attraction. Nucleation is 
induced by suddenly depressurizing the freeze-drier chamber that was 
pressurized with argon gas before [19-20]. Bursac et al. [19] reported larger 
pores, lower surface area and improved lactate dehydrogenase recovery for 
samples frozen by depressurization at ~ −3 °C with an ~ 15 min hold step 
compared to samples produced by shelf-ramp freezing. 
The objective of this study was to investigate the influence of different freezing 
procedures on the stability of plasmid/LPEI polyplexes, in order to get an 
extended understanding of critical freezing parameters and the underlying 
stabilization mechanisms during freezing of non-viral gene delivery particles. 
Plasmid/LPEI polyplexes were formulated at different plasmid DNA 
concentrations and at increasing sucrose/polyplex mass ratios. In a first step, 
the influence of the “standard” depressurization method in comparison to 
conventional shelf-ramp freezing on polyplex particle size was investigated. 
Secondly, the influence of the ice nucleation temperature and the residence 
time of the particles above Tg` during freezing were studied individually with the 
aid of the depressurization method. In a next step, the influence of the 
proceeding of freezing on polyplex particle size was investigated. Furthermore, 
the increase in sucrose concentration and sample viscosity during freezing was 
theoretically calculated and correlated with bimolecular reactions rates. These 
theoretical results were then compared to the obtained experimental data. The 
identification of critical parameters and a better understanding of the 
stabilization mechanisms involved during freezing should help to design less 
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stressful lyophilization processes and lyophilized products with improved 
quality.  
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2 Materials and methods 
2.1 Materials 
The plasmid (pCMVLuc) was produced by PlasmidFactory (Bielefeld, 
Germany). 22 kDA linear polyethylenimine (LPEI) was synthesized by acid-
catalyzed hydrolyses from poly(2-ethyl-2-oxazoline) (Sigma Aldrich, Steinheim, 
Germany) as described in [21]. L-histidine was obtained from Merck 
(Darmstadt, Germany) and sucrose from Sigma Aldrich (St Louis, MO, USA). 
3 mL glass vials (glass type: 8412-G) with their according LyoTecTM stoppers 
were used (West Pharmaceutical Services, Lionville, PA, USA). 
2.2 Sample preparation 
Plasmid/LPEI polyplexes were prepared at a N/P ratio (molar ratio of LPEI 
nitrogen (N) to DNA phosphate (P)) of 6:1 and at a DNA concentration of 
100 µg/ml in 10 mM L-histidine buffer pH 6.0 with an established micro-mixer 
method [22] using a 5.0 mL syringe and a plunger speed of 1.0 cm/min. 
Polyplexes were incubated for 30 min at room temperature in order to ensure 
complete polyplex formation.  
Table 6-1: Overview on polyplex formulations tested. 
10 µg/mL DNA 50 µg/mL DNA 
sucrose/DNA 
mass ratio 
sucrose conc. 
[% w/v] 
sucrose/DNA 
mass ratio 
sucrose conc. 
[% w/v] 
2000 2 1200 6 
4000 4 1600 8 
6000 6 2000 10 
8000 8 2400 12 
10000 10 2800 14 
12000 12 3200 16 
14000 14 3600 18 
  4000 20 
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Sucrose stock solutions at various concentrations [% w/v] were prepared in 
10 mM L-histidine buffer pH 6.0. Polyplex formulations at DNA concentrations of 
10 or 50 µg/mL and at various sucrose/DNA mass ratios (Table 6-1) were 
prepared by adequately mixing the polyplex stock solution with the sucrose 
stock solutions.  
2.3 Freeze-thaw studies using different freezing protocols 
Freeze-thawing studies were performed on a pilot scale freeze-drier (FTS 
LyoStarTM 3, SP Scientific, Stone Ridge, NY, USA) equipped with the 
ControLyoTM technology (Praxair, Burr Ridge, IL, USA) for ice nucleation 
temperature control. 500 µL of each polyplex formulation in 3 mL vials were 
investigated in triplicates in each freeze-thawing experiment. Vials were placed 
on the middle of the shelf in a hexagonal array and all edge vials were 
surrounded by placebo vials containing 5% sucrose solution. All samples were 
equilibrated at 20 °C for 15 min prior to freezing. In all complete freeze-thaw 
experiments, samples were frozen to a final shelf temperature of −45 °C and 
held at this temperature over night for 10 h. Thawing was always performed by 
a shelf ramp rate to 20 °C at 2.5 °C/min with a 60 min hold at 20 °C. In order to 
monitor product temperature profiles during freezing, thin wire T-type 
thermocouples (Omega, Stamford, CT, USA) were dipped into thermal grease 
and fixed with tape on the outside of selected vials close to the vial bottom. 
Product temperature data and shelf inlet temperature data were collected every 
minute.  
2.3.1 Conventional shelf-ramp freezing 
Conventional shelf-ramp freezing was performed at a shelf ramp rate of 
−1 °C/min or −5 °C/min to −45 °C. 
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2.3.2 “Standard” depressurization method 
The “standard” depressurization method for controlled ice nucleation was 
performed according to the method described by Konstantinidis et al. [20]. 
Samples were cooled at a shelf ramp rate of −1 °C/min to 5 °C and equilibrated 
at that temperature for 15 min. Air from the product chamber was purged once 
by pressurizing at 10 psig (171 kPa) for 2 min with argon gas and 
depressurizing to a final pressure of 2 psig (115 kPa) within 20 s. The product 
chamber was pressurized with argon gas to approximately 28 psig (294 kPa). 
Subsequently, samples were cooled at −1 °C/min to −4 °C and equilibrated at 
that temperature for 30 min. In order to induce ice nucleation, the chamber 
pressure was quickly released to 2 psig (115 kPa). After ice nucleation, the 
shelf temperature was held for another 15 min at −4 °C. Subsequently, samples 
were cooled at a shelf ramp rate of −1 °C/min to −45 °C. The aforementioned 
parameters applied during purging, pressurization, and depressurization of the 
product chamber were used in all further freeze-thaw experiments. 
2.3.3 Varying ice nucleation temperatures via controlled ice nucleation 
In order to vary ice nucleation temperature during freezing, samples were 
cooled at −1 °C/min to −4 °C, −8 °C or −12°C after pressurization and 
equilibrated at that temperature for 30 min, before ice nucleation was induced. 
Subsequently, samples were directly cooled at −5 °C/min to −45 °C without any 
further equilibration step.  
2.3.4 Varying shelf-ramp rates after controlled ice nucleation  
After pressurization, samples were cooled at −1 °C/min to −12 °C and 
equilibrated at that temperature for 30 min before ice nucleation was induced. 
Subsequently, samples were directly cooled at varying shelf-ramp rates of 
−0.1 °C/min, −0.5 °C/min, −1.0 °C/min or −5.0 °C/min to −45 °C without any 
further equilibration step.  
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2.3.5 Interruption of the freezing process after controlled ice nucleation 
Samples were cooled at −1 °C/min to −12°C after pressurization and 
equilibrated at that temperature for 30 min before ice nucleation was induced. 
Then, samples were directly cooled at −0.1 °C/min to a shelf temperature of 
−12.5 °C, −14.0 °C, −20.0 °C and −26.0 °C. Subsequently, thawing at 
2.5 °C/min was started.  
2.4 Lyophilization 
Lyophilization was performed on the same pilot scale freeze-drier as described 
in 2.3. 500 µL of selected polyplex formulations in 3 mL vials were frozen to 
−45.0 °C using different freezing protocols, and held at −45.0 °C for 60 min. For 
primary drying, the shelf temperature was increased at 0.2 °C/min to −30.0 °C 
and the pressure was reduced to 65 mTorr (8.7 Pa). After ~18 h, the endpoint of 
primary drying was confirmed by manometric endpoint determination. 
Secondary drying was performed at 40 °C (shelf ramp rate of 0.1 °C/min) and 
65 mtorr (8.7 Pa) for 6 h. Samples were stoppered under vacuum. 
2.5 Polyplex characterization 
Size determination of siRNA polyplexes was performed by dynamic light 
scattering (DLS) using the Nanosizer ZS (Malvern Instruments, Westborough, 
MA, USA). The samples were diluted 1:20 with 10 mM L-histidine buffer pH 6.0 
to a final volume of 1 mL. The diluted samples were analyzed in single-use 
polystyrene semi-micro PMMA cuvettes (Brand, Wertheim, Germany) with a 
path length of 10 mm. After an equilibration time of 1 min at 20 °C, each sample 
was recorded three times with 5 subruns of 10 s using the multimodal mode. 
The z-average diameter was calculated from the correlation function using the 
Zetasizer Software 6.20 (Malvern Instruments).  
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2.6 Specific surface area determination 
The specific surface area (SSA) of selected lyophilisates was determined via 
BET surface area analysis using a Flowsorb II 2300 instrument (Micromeritics, 
Norcross, GA, USA). Prior to each measurement, the instrument was calibrated 
via injection of 1 mL of 100% krypton gas at known ambient temperature and 
pressure. Approximately 100 mg of the lyophilisates were transferred into the 
sample holder and sealed with sealing film in a dry bag, purged with nitrogen, 
and then, connected to the instrument. For out gassing samples were heated on 
a heating mantle at 40 °C for 2 hours in a gas flow of a helium and krypton 
mixture. No difference in SSA results was observed for out gassing for more 
than 2 hours. Subsequently, samples were exposed to a mixture of helium (inert 
carrier gas) and krypton (adsorbate) (0.1 mol % krypton in helium). The 
adsorption at 0.1 mol% krypton was determined in single point measurements 
and analyzed with the BET equation. For each formulation and freezing 
condition three samples from independent vials were analyzed at least twice. 
From these results the average SSA [m2/g] along with the standard deviation 
was calculated. In order to include the effect of variable ice surface area in 
samples of variable sucrose levels, the absolute SSA [m2/100mL] was 
calculated by [23]: 
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2.7 Karl-Fischer titration 
The residual moisture content of the lyophilisates was determined by 
coulometric Karl Fischer titration using a Metrohm 756 KF Coulometer 
(Metrohm, Herisau, Switzerland). About 500 µL dried Methanol (HydranalTM-
Methanol, Sigma-Aldrich, Germany) was injected into the sealed vial through 
the stopper and the lyophilized samples were dissolved by slightly shaking the 
vial. The water content was determined by injecting about 300 µL of the 
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methanol samples into the titration solution (HydranalTM-Coulomat AG, Riedel-
de Haen, Seelze, Germany) and was calculated in mass percentage water per 
mg lyophilized sample [% w/w]. HydranalTM Water Standard 0.10 (Sigma-
Aldrich, Steinheim, Germany) was used as reference. For each selected 
formulation and freezing condition three vials were analyzed.  
2.8 Theoretical modeling of the change in sucrose concentration or 
viscosity during freeze-concentration and correlation to reaction 
rates  
The change in sucrose concentration and viscosity during freeze-concentration 
and corresponding relative reaction rates were theoretically modeled as 
previously published [24]. As in our study the weight ratio of L-histidine buffer to 
sucrose was very small, the effect of buffer was neglected. At first, the reduction 
of product temperature with each minute time increment was simulated via 
estimation of the heat transfer from the shelf to the product and subsequent 
evaluation of the amount of ice formed.  
The heat transfer rate form the shelf to the product, Qs [cal/s], is given by, 
)()( psPvvs TTKAQ −⋅⋅=          (6-2) 
where Av and Kv are the cross sectional area and heat transfer coefficient at a 
defined pressure (P) of the vial, respectively, and Ts and Tp are shelf 
temperature and product temperature [25]. Av was ~ 2.19 cm2. The vial heat 
transfer coefficient Kv [cal/(m2Ks)] is composed of three terms: the contact, Kc, 
the radiation, Kr, and the gas conduction term, Kg. The following constants for 
typical tubing vials were used: 104Kc ~ 1.0, 104Kr ~ 1.5 and 104Kg ~ 4.3 (at 
atmospheric pressure, with a mean separation distance of 1 mm).  
The ratio R of the heat transfer rate needed to remove heat created by the 
phase change (Qpc) (i.e. forming of ∆Xw grams of water) to the heat transfer 
rate needed to cool both the solution and the ice formed (Qcool) by the 
temperature change in the time interval ∆t is calculated by: 
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The heat transfer rate needed to freeze ∆Xw grams of water is given by, 
fwpc HXtQ ∆⋅∆=∆⋅           (6-4) 
where ∆Hf is the heat fusion of ice (79.72 cal/g). The heat transfer rate for 
cooling both the solution and the ice formed is given by, 
tglassvialicewwwaterwcool TCmCXXCXtQ ∆∆⋅⋅+⋅−+⋅=∆⋅ ))(( 0    (6-5) 
where Xw0 is the initial mass of water and Xw is the mass of water that is still 
present. Cwater, Cice and Cglass are the specific heats of water, ice and the glass 
vials with 0.99 cal/gK, 0.49 cal/gK and 0.20 cal/gK, respectively. The mass of 
the vials (mvial) was ~5.15 g. ∆T∆t is the change in temperature of the sample in 
the time interval ∆t, and was calculated from the difference in the freezing point 
depression ∆Tf between each time interval. The freezing point depression ∆Tf is 
given by an empirical equation found to fit the data in [26]: 
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where msolute is the mass of sucrose in g per vial. 
Using the calculated factor R (equation 3), the heat provided from the shelf in 
order to form ice was determined. Thus, the amount of formed ice ∆Xw during 
each time interval could be calculated from equation 4, and the amount of 
unfrozen water Xw in the sample at each time point could be determined. For 
each sample composition the temperature of the solution could be calculated 
from equation 6. From that, the concentration of sucrose at each time point, 
until the maximum freeze-concentration of sucrose of ~80.9% [27] is reached, 
was calculated. 
In a next step, a relationship between the variables, product temperature and 
sucrose concentration and the viscosity of the sucrose sample was developed. 
Therefore, viscosity data of sucrose solutions at various concentrations and 
temperatures given in [26] and quoted by C.A. Angell [28] were used. In order to 
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obtain an accurate viscosity estimation outside the available data range, the 
data was fitted with a Vogel-Tammann-Fulcher (VTF) type equation: 
0
)ln()ln(
TT
KA
−
+=η           (6-7) 
This equation relates viscosity (η[poise]) to the absolute temperature (T) and the 
“zero mobility” temperature T0, where A is a constant, which should be 1*10-4 
[28]. T0 depends on the composition of the system as T0 is related to the glass 
transition temperature Tg. It was assumed that the relationship between T0 and 
the systems composition in a binary system is similar to the relationship 
between Tg and the system composition. Thus, a variation of the Fox equation 
was used to represent the composition dependence of T0, 
2
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where T00 is the “zero mobility” temperature for pure water (i.e., when c=0). 
According to C.A. Angell T00=125 K [28]. Moreover, b1 and b2 are pure 
constants to be determined by a fit to the data. For the constant K, which may 
also be dependent of the system composition, a simple linear relation to the 
concentration c was assumed: 
ckKK ⋅+= 10             (6-9) 
Thus, using the last three equations with the fit parameters K0=751, k1=855, 
b1=0.001551 and b2=-0.00617, viscosity over the entire range of concentrations 
and temperatures during freeze-concentration could be calculated.  
In order to estimate the dependence between reaction rate and viscosity, a 
second-order reaction, with an Arrhenius temperature dependence and an 
activation energy of 20 kcal/mol, was assumed. Moreover, reaction rate was 
coupled inversely proportional to the relative increase in viscosity, as a 
diffusion-controlled reaction was assumed, with the diffusion constant being 
inversely proportional, as in the Stokes-Einstein equation. Polyplex 
concentration was calculated based on the assumption that one polyplex 
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contains five plasmid strands each consisting of 6233 base pairs. The relative 
reaction rate was related to the reaction rate at the point of ice nucleation at a 
DNA concentration of 50 µg/mL, which was defined as 1. 
2.9 Statistical analysis 
Differences between mean particle sizes were statistically challenged by 
performing a two-tailed student t test using the QuickCalcs, GraphPad Software 
(La Jolla, CA, USA). Mean values with a p value < 0.05 were judged as 
significantly different. 
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3 Results 
3.1 Influence of the “standard” depressurization method in 
comparison to conventional shelf-ramp freezing on polyplex 
stability  
As aforementioned, it is reported that a better protein recovery of lactate 
dehydrogenase was observed for samples frozen with the “standard” 
depressurization technique compared to stochastic shelf-ramp freezing [19]. 
Thus, in a first step, the influence of the “standard” controlled nucleation in 
comparison to conventional shelf-ramped freezing on polyplex stability was 
investigated. Therefore, polyplex samples formulated at 10 µg/mL and 50 µg/mL 
DNA, and at increasing sucrose/DNA mass ratio (Table 6-1) were frozen via 
depressurization at −4 °C with a 15 min equilibration step and at a subsequent 
shelf ramp rate of −1 °C/min, or via conventional shelf-ramp freezing at a shelf 
ramp rate of −1 °C/min or −5 °C/min. After thawing, plasmid/LPEI polyplex 
samples were analyzed for particle size. 
The two most divergent product temperature profiles obtained during these 
three different freezing procedures, are displayed in Figure 6-1A. Using 
conventional shelf-ramp freezing, ice nucleation occurs very stochastically at 
random product temperatures (−12.4 ± 1.0 °C or −9.7 ± 1.6 °C) and random 
points in time. In contrast, when ice nucleation is induced in a controlled 
manner, using the depressurization technique, ice nucleation occurs at almost 
the same product temperature (−2.3 ± 0.1 °C) and at the same point in time. 
Moreover, the different ramp rates or the application of a 15 min equilibration 
step after depressurization result in different residence times. Here, the 
residence time was defined as time period between ice nucleation and the point 
at which a product temperature of −30 °C is reached. The residence time was 
7.8 ± 0.5 min when samples were frozen at a shelf-ramp rate of −5 °C/min and 
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increased to 14.8 ± 3.6 min at a slower shelf-ramp rate of −1 °C/min. In 
contrast, a markedly prolonged residence time of 51.8 ± 0.8 min was observed 
when the samples were frozen via the “standard” depressurization method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1: Product temperature profiles of 10% sucrose samples monitored with 
thermocouples (TC) and inlet temperatures of the shelf (shelf) during freezing using various 
freezing procedures. A) Conventional shelf ramping (SR) at −1°C/min or −5°C/min or via the 
“standard” depressurization method (DP) at −4°C with a subsequent 15 min equilibration step 
and a shelf ramp rate of -1°C/min. The displayed product temperature data represent the two 
most divergent profiles obtained during the varying freezing procedures. B) Nucleation induced 
by depressurization at a shelf temperature of −4 °C, −8 °C or −12 °C and a subsequent shelf 
ramp rate of −5 °C/min. C) Nucleation induced by depressurization at a shelf temperature of 
−12 °C and subsequent varying shelf ramp rates of −0.1 °C/min, −0.5 °C/min, −1.0 °C/min or 
−5.0 °C/min. D) Nucleation induced by depressurization at a shelf temperature of −12 °C and 
subsequent shelf ramp rate of −0.1 °C/min. The freezing procedure was stopped at a product 
temperature of −3.7 °C, −11.1 °C, −17.8 °C and −23.6 °C. 
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The z-average diameter of the plasmid/LPEI polyplexes after freeze-thawing 
using the three different freezing procedures is displayed in Figure 6-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2: Z-average diameter of plasmid DNA/LPEI polyplexes after freeze-thawing when 
formulated at a DNA concentration of 50 µg/ml (A) or 10 µg/ml (B) and at increasing 
sucrose/DNA mass ratio. Samples were frozen via conventional shelf ramping (SR) at 
−1 °C/min or −5 °C/min or via the “standard” depressurization method (DP) at −4 °C with a 
15 min equilibration step and a subsequent shelf ramp rate of −1 °C/min. The dotted lines 
represent the mean + SD and mean – SD of the Z-average diameter of freshly prepared (T0) 
polyplexes. Each value represents the mean ± SD of three measurements on triplicate samples. 
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 In general, particle size becomes better preserved with increasing 
sucrose/DNA ratio. At a fixed sucrose/DNA ratio the “standard” depressurization 
method had a more negative impact on particle size compared to conventional 
shelf-ramp freezing. For instance, the size of plasmid/LPEI polyplexes at a 
concentration of 50 µg/mL and at a sucrose/DNA ratio of 2000 increased from 
~113 nm to ~153 nm or ~146 nm when frozen at a shelf-ramp rate of −1 °C/min 
or −5 °C/min, respectively (Figure 6-2A). However, when frozen with the 
“standard” depressurization method, the increase in particle size to ~205 nm 
was significantly (p < 0.05) more pronounced. Moreover, the freezing procedure 
also impacts the critical sucrose/DNA ratio, at which full retention of the particle 
size is achieved. At a DNA concentration of 50 µg/ml, significant (p > 0.05) 
retention of particle size was observed at a sucrose/DNA ratio of 3200 or 2800, 
when frozen at a shelf-ramp rate of −1 °C/min or −5 °C/min, respectively. In 
comparison, a sucrose/DNA ratio of 4000 was required to significantly 
(p > 0.05) preserve particle size, when samples were frozen with the “standard” 
depressurization method. Analogous trends were observed for plasmid/LPEI 
polyplexes at a DNA concentration of 10 µg/mL. However, at this DNA 
concentration full retention of particle size could not be achieved in any 
formulation and freezing protocol. As described above, there are two important 
factors that can be used to discriminate between freezing procedures: 
nucleation temperature and residence time. Thus, the influence of these two 
factors on polyplex particle size was investigated separately in the following 
experiments. 
 
 
 
 
 
188                                                                                                         Chapter 6 
 
3.2 Influence of ice nucleation temperature on polyplex stability 
In order to investigate the influence of ice nucleation temperature on polyplex 
stability, the samples were equilibrated at various temperatures (−4 °C, −8 °C or 
−12 °C) prior to depressurization. This resulted in product temperatures of 
−2.2 ± 0.2 °C, −6.3 ± 0.3 °C or −10.4 ± 0.2 °C at the time of ice nucleation. 
Subsequently, samples were directly cooled at −5 °C/min, in order to achieve 
residence times which do not significantly differ (p > 0.05) (13.2 ± 1.0 min, 
12.8 ± 0.9 min and 12.3 ± 0.6 min resp.). The difference in ice nucleation 
temperature and the consistency in residence time is reflected by the monitored 
temperature profiles (exemplarily shown for 10% sucrose samples in 
Figure 6-1B). 
At a DNA concentration of 50 µg/mL (Figure 6-3A), no significance difference 
(p > 0.05) in particle size was observed at fixed sucrose/DNA ratios. For all ice 
nucleation temperatures a complete retention of particle size was achieved at a 
sucrose/DNA ratio of 3200. At the lower DNA concentration of 10 µg/mL 
(Figure 6-3B), the trend, that particle size was slightly better preserved when 
freezing was induced at lower ice nucleation temperatures, was observed. 
However, this trend was only significant (p < 0.05) for all three ice nucleation 
temperatures at sucrose/DNA ratios of 8000 and 10000. Again, at the lower 
DNA concentration no complete particle stabilization could be achieved. 
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Figure 6-3: Z-average diameter of plasmid DNA/LPEI polyplexes after freeze-thawing when 
formulated at a DNA concentration of 50 µg/ml (A) or 10 µg/ml (B) and at increasing 
sucrose/DNA mass ratio. Samples were frozen at varying ice nucleation temperatures induced 
by depressurization (DP) at a shelf temperature of −4 °C, −8 °C or −12°C and a subsequent 
shelf ramp rate of −5 °C/min. The dotted line represents the mean + SD and mean – SD of the 
Z-average diameter of freshly prepared (T0) polyplexes. Each value represents the mean ± SD 
of three measurements on triplicate samples. 
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3.3 Influence of residence time on polyplex stability 
In addition, the influence of residence time on polyplex stability was 
investigated. Therefore, ice nucleation of all polyplex samples was induced via 
depressurization after equilibration at a shelf temperature of −12 °C. 
Subsequently, samples were frozen at varying shelf ramp rates of −0.1 °C/min, 
−0.5 °C/min, −1.0 °C/min or −5.0 °C/min. The obtained temperature profiles are 
displayed in Figure 6-1C. The varying shelf ramp rates after controlled ice 
nucleation resulted in highly different residence times of 206.0 ± 3.4 min, 
48.5 ± 1.7 min, 29.0 ± 0.8 min or 12.8 ± 0.5 min, respectively.  
At a DNA concentration of 50 µg/mL (Figure 6-4A) polyplex particle size did not 
significantly (p > 0.05) differ when frozen with shelf ramp rates of −1 °C/min or 
−5 °C/min after controlled ice nucleation. At fixed sucrose/DNA ratios, particle 
size increased with decreasing shelf ramp rate from −1 °C/min to −0.5 °C/min or 
−0.1 °C/min. But the variations between all of these three different freezing 
rates were only significant (p < 0.05) for the samples formulated at 
sucrose/DNA ratios between 2000 and 3200. Significant preservation (p > 0.05) 
of particle size was achieved at a sucrose/DNA ratio of 3200, when frozen at 
−1 °C/min or −5 °C/min. At the lower shelf ramp rate of −0.5 °C/min a 
sucrose/DNA ratio of 4000 was required for the significant (p < 0.05) 
stabilization of particle size. However, when samples were frozen at 
−0.1 °C/min, particle size could not completely be maintained within the 
investigated range of sucrose/DNA ratios.  
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Figure 6-4: Z-average diameter of plasmid DNA/LPEI polyplexes after freeze-thawing when 
formulated at a DNA concentration of 50 µg/ml (A) or 10 µg/ml (B) and at increasing 
sucrose/DNA mass ratios. Samples were frozen with controlled ice nucleation via 
depressurization (DP) at −12°C and subsequent varying shelf ramp rates of −0.1 °C/min, −0.5 
°C/min, −1.0 °C/min or −5.0 °C/min. The dotted line represents the mean + SD and mean – SD 
of the Z-average diameter of freshly prepared (T0) polyplexes. Each value represents the mean 
± SD of three measurements on triplicate samples. 
At a lower DNA concentration of 10 µg/mL particle size did also not significantly 
(p > 0.05) differ between samples prepared at shelf ramp rates of −1 °C/min or 
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−5 °C/min (Figure 6-4B). Moreover, an analogous trend with an increase in 
particle size when shelf ramp rates are decreased was observed at the lower 
DNA concentration. This variation in particle size with differing shelf ramp rates 
was only significant between samples that were frozen at −1/−5 °C/min or 
−0.1 °C/min, when formulated at sucrose/DNA ratios ≥ 6000. For instance, the 
decrease in the freezing rate from −1 °C/min to −0.1 °C/min resulted in an 
120 nm increase in particle size after freeze-thawing from 162 ± 12 nm to 
282 ± 27 nm, when formulated at a sucrose/DNA ratio of 14000. In general, for 
both DNA concentrations, the increase in polyplex particle size was comparable 
when samples were frozen with the depressurization technique in combination 
with a fast shelf ramp rate of −1 °C/min or −5 °C/min or by conventional shelf-
ramp freezing at shelf ramp rates of −1 °C/min or −5 °C/min (see 3.1). 
3.4 Influence of the proceeding of freezing on polyplex stability  
In order to investigate the influence of the proceeding of freezing, samples were 
directly cooled at −0.1 °C/min after controlled ice nucleation at −12°C and the 
freezing process was stopped by subsequent thawing at shelf temperatures of 
−12.5 °C, −14.0 °C, −20.0 °C or −26.0 °C. This approach resulted in freezing of 
the samples down to a product temperature of −3.7 °C, −11.1 °C, −17.8 °C or 
−23.6 °C before thawing was started. The corresponding product temperature 
and shelf inlet temperature profiles are displayed in Figure 6-1D.  
At a DNA concentration of 50 µg/mL, particle size did not significantly (p > 0.05) 
differ, except for a sucrose/DNA ratio of 2400, when samples were frozen at a 
shelf ramp rate of −0.1 °C/min to a product temperature of −3.7 °C or when 
samples were frozen at a shelf ramp rate of −5 °C/min to −45 °C (Figure 6-5A).  
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Figure 6-5: Z-average diameter of plasmid DNA/LPEI polyplexes after freeze-thawing when 
formulated at a DNA concentration of 50 µg/mL (A) or 10 µg/mL (B) and at increasing 
sucrose/DNA mass ratio. Samples were frozen with controlled ice nucleation via 
depressurization (DP) at −12 °C and with a subsequent shelf ramp rate of −0.1 °C/min. The 
freezing procedure was stopped at a product temperature of −3.7 °C, −11.1 °C, −17.8 °C and 
−23.6 °C. For comparison reasons, data obtained for samples frozen with controlled ice 
nucleation via depressurization (DP) at -12 °C and subsequent shelf ramp rates of −0.1 °C/min 
and −5.0 °C/min are also displayed. The dotted line represents the mean + SD and mean – SD 
of the Z-average diameter of freshly prepared (T0) polyplexes. Each value represents the mean 
± SD of three measurements on triplicate samples. 
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In these two cases, complete preservation of particle size was achieved at a 
sucrose/DNA ratio of 3200. When the samples were further frozen at a shelf 
ramp rate of −0.1 °C/min to −11.1 °C particle size significantly further increased 
(p < 0.05) for all formulations at a sucrose/DNA ratios ≥ 1600, and full recovery 
of particle size was observed at a sucrose/DNA ratio of 4000. The proceeding of 
freezing from -11.1 °C to a product temperature of −17.8 °C resulted in a further 
significant raise (p < 0.05) in particle size. However, when freezing further 
proceeded from -17.8 °C to product temperatures ≤ −23.6 °C no significant 
(p > 0.05) further change in particle size was observed. For the latter two cases, 
no complete polyplex stabilization could be obtained within the investigated 
range of sucrose/DNA ratios. At the lower DNA concentration of 10 µg/mL this 
clear correlation could not be observed (Figure 6-5B). Again, freezing at a shelf 
ramp rate of −0.1 °C/min to a product temperature of −3.7 °C or freezing at a 
shelf ramp rate of −5 °C/min to −45 °C resulted in comparable particles sizes 
after freeze-thawing. For all other investigated freezing procedures an increase 
in particle sizes, but no significant correlation to the proceeding of freezing was 
found. But a clear trend to further destabilization with freezing was observed 
when comparing the particle size at a product temperature of -3.7°C to all other 
lower product temperatures. 
3.5 Surface area and residual moisture content of selected 
lyophilized samples 
Moreover, selected samples (6%, 10%, 14% and 20% sucrose) were lyophilized 
using different freezing procedures, in order to establish a correlation between 
the freezing procedure and the resulting SSA or residual moisture content of the 
lyophilisates (Table 6-2).  
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Table 6-2: Specific surface area (SSA) [m2/g] or absolute SSA [m2/100 mL] and residual 
moisture contents (RM) [%w/w] of selected lyophilized formulations (6%, 10%, 14% and 20% 
sucrose). The samples were frozen via depressurization (DP) at −12 °C or −4 °C at a 
subsequent ramp rate of −5 °C/min or −0.1 °C/min or via depressurization at −4 °C with a 
15 min equilibration step and a ramp rate of −1 °C/min.  
  6% sucrose 10% sucrose 14% sucrose 20% sucrose 
SSA [m2/g] 0.82 ± 0.07 0.78 ± 0.04 0.58 ± 0.02 0.51 ± 0.03 
SSA [m2/100ml] 4.92 ± 0.42 7.80 ± 0.40 8.12  ± 0.28 10.20 ± 0.60 
DP −12 °C, 
−5 °C/min 
RM [%w/w] 0.19 ± 0.03 0.23 ± 0.04 0.35 ± 0.04 0.40 ± 0.04 
SSA [m2/g] 0.62 ± 0.03 0.44 ± 0.02 0.32 ± 0.01 0.30 ± 0.01 
SSA [m2/100ml] 3.72 ± 0.18 4.40 ± 0.20 4.48 ± 0.28 6.00 ± 0.20 
DP −4 °C, 
−5 °C/min 
RM [%w/w] 0.20 ± 0.04 0.28 ± 0.02 0.42 ± 0.05 0.55 ± 0.02 
SSA [m2/g] 0.73 ± 0.04 0.59 ± 0.04 0.43 ± 0.03 0.40 ± 0.02 
SSA [m2/100ml] 4.38 ± 0.16 5.90 ± 0.40 6.02 ± 0.42 8.00 ± 0.40 
DP −12 °C, 
−0.1 °C/min 
RM [%w/w] 0.38 ± 0.04 0.43 ± 0.09 0.44 ± 0.06 0.52 ± 0.05 
SSA [m2/g] 0.51 ± 0.02 0.30 ± 0.01 0.23 ± 0.01 0.19 ± 0.01 
SSA [m2/100ml] 3.06 ± 0.12 3.00 ± 0.10 3.22 ± 0.14 3.80 ± 0.20 
DP -4 °C, 
15 min, 
−1 °C/min RM [%w/w] 0.46 ± 0.03 0.49 ± 0.06 0.75 ± 0.02 0.83 ± 0.10 
 
For all formulations, the SSA [m2/g] decreased, the absolute SSA [m2/100 mL] 
increased and the residual moisture content increased with increasing sucrose 
concentration. In general, the freezing procedure highly influenced SSA and 
residual moisture. The increase in ice nucleation temperature by 8 °C (from 
−12 °C to −4 °C) at consistent subsequent shelf-ramp rates of −5 °C/min 
resulted in a significant (p < 0.05) decrease in both SSA [m2/g] and absolute 
SSA [m2/100 mL] and a slight, but not significant increase (p > 0.05, except for 
the 20% sucrose sample) in residual moisture for all formulations. The decrease 
in the shelf-ramp rate from −5 °C/min to −0.1 °C/min after controlled nucleation 
at −12 °C led to significantly (p < 0.05) lowered SSA [m2/g] and absolute SSA 
[m2/100 mL] as well as a significantly (p < 0.05) higher residual moisture content 
for all formulations. Freezing of the samples using the “standard” 
depressurization method rendered the lowest SSA [m2/g] and absolute SSA 
[m2/100 mL] and the highest residual moisture content for all formulations.  
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3.6 Theoretical modeling of the change in sucrose concentration or 
viscosity during freeze-concentration and correlation to reaction 
rates  
In order to correlate the experimental observations with the increase in viscosity 
of the samples during freeze-concentration, theoretical product temperature 
profiles were modeled and used to calculate the change in sucrose 
concentration and sample viscosity over time. In addition relative reaction rates 
were estimated assuming a second-order reaction with an Arrhenius 
temperature dependence and relative reaction rates over time were estimated. 
The simulated temperature profiles and the calculated sucrose concentrations 
and viscosities of a 10% sucrose sample, that was nucleated at −12°C and 
subsequently frozen at a shelf ramp rate of −5 °C/min or −0.1 °C/min, are 
displayed in Figure 6-6. In general, the theoretically modeled temperature 
profiles showed rather good agreement to real product temperature data. When 
the initial ice nucleation occurs product temperature rises rapidly to the 
equilibrium freezing point. Further ice crystal growth is then controlled by the 
latent heat release due to ice formation and the cooling rate of the shelf which 
the sample is exposed to. At first, heat release and cooling are at equilibrium, 
leading to a temperature plateau. Later, when cooling of the shelf dominates, 
product temperature drops and further decreases depending on the shelf ramp 
rate used. During the first part of the freezing step, when ice formation and heat 
release is still in equilibrium, most ice is formed. In this temperature region the 
sucrose concentration of the sample sharply increases followed by a further 
slower increase until the maximum freeze-concentration is reached at Tg`. For 
instance, a more than 5 fold increase in the sucrose concentration from 10% to 
~55% is already reached when the product temperature falls below −4 °C after 
ice nucleation. When freezing proceeds to product temperatures of ~−12 °C, 
sucrose concentration further increases to ~72%. At the product temperature of 
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~−18 °C, at which no further increase in particle size is observed during slow 
freezing, sucrose concentration accounted for ~76%. Analogously, viscosity 
also tremendously increases during the first part of freezing. Due to the 
temperature dependence of the viscosity, a further pronounced increase is seen 
also at temperatures well below Tg`. For instance, viscosity values increase to 
~ 0.14 Pa*s, 20.2 Pa*s, 741.0 Pa*s, 53.3*106 Pa*s or 1.5*1012 Pa*s when a 
product temperature of ~ −4 °C, −12 °C, −18 °C, −32 °C or −45 °C is reached, 
respectively. Obviously, a faster increase in sucrose concentration and samples 
viscosity is observed, when samples are frozen at a shelf ramp rate of 
−5 °C/min compared to freezing at a shelf ramp rate of −0.1 °C/min. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-6: Theoretical simulation of product temperature (Tp), sucrose concentration (suc) and 
viscosity (η) of 500 µL 10% sucrose solution in a 3 mL vial during shelf-ramp freezing at a shelf 
ramp rate of −5°C/min or −0.1 °C/min.  
Figure 7 displays the estimated relative reaction rate over time and the 
corresponding viscosity at different shelf ramp rates or different initial sucrose 
concentrations.  
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Figure 6-7: Theoretical relative bimolecular reaction rate (rr) of a second order reaction of 
polyplexes during shelf-ramp freezing at a sample volume of 500 µL in a 3 mL vial. 
Corresponding simulated viscosity values (η) are also displayed. Reaction rates were calculated 
with Arrhenius temperature dependence and inversely proportional correlated to modeled 
viscosity values. A) Freezing of a 10% sucrose formulation at a DNA concentration of 50 µg/mL 
at a shelf ramp rate of -5 °C/min or -0.1 °C/min. B) Freezing of a 6%, 10% or 20% sucrose 
formulation at a DNA concentration of 50 µg/mL or of a “half concentrated” 10% sucrose 
formulation at a DNA concentration of 25 µg/mL at a shelf ramp rate of -1 °C/min. 
During freezing of a 10% sucrose formulation (Figure 6-7A) the reaction rate 
already increases five fold at the point of ice nucleation and increases more 
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than ten fold during further freezing. The maximum relative reaction rate is 
reached when the sample viscosity is ~7 mPa*s at a product temperature of 
~−1 °C. When a sample viscosity of ~50 mPa*s is reached at a product 
temperature of ~−3 °C the relative reaction rate falls below the initial reaction 
rate in the liquid formulation at the point of ice nucleation. Subsequently, the 
relative reactions rate converges against zero (< 0.01) at a viscosity of 
~16500 mPa*s at a product temperature of ~−12°C. When samples are frozen 
at a shelf ramp rate of −5 °C/min, the initial reaction rate level is regained 
already after ~12 min, whereas it takes ~30 min to reach this point when 
samples are frozen at −0.1 °C/min.  
When 50 µg/mL DNA samples with different initial sucrose concentration are 
frozen at −1 °C/min (Figure 6-7B), the reaction rate also increases ~5 fold 
during initial ice nucleation for all formulations. During further freezing the 
reaction rate increased drastically in presence of 6% and 10% to a maximum of 
relative reaction rate of 26.0 and 11.7 respectively. In contrast, the reaction rate 
did not further increase when samples contained 20% sucrose. This might be 
related to the already ~2.4 fold higher viscosity of 20% sucrose formulations 
compared to the 6% samples at the point of ice nucleation. When polyplexes 
were formulated at higher sucrose concentrations relative reaction rates 
returned to 1 much earlier during freezing. But for all formulations reaction rates 
close to zero (< 0.01) were found at almost the same time point ~24 min after 
ice nucleation. Additionally, the reaction rate for a polyplex formulation at half of 
the original DNA concentration containing 10% sucrose was modeled. In this 
case, the initial reaction rate was lower due to the reduced polyplex 
concentration. The maximum in reaction rate was reached at the same point in 
time, as observed for the original 10% sucrose formulation. But the level of the 
maximum reaction rate was comparable to the 20% sucrose formulation which 
has the same initial sucrose/DNA ratio. 
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4 Discussion 
Several studies have demonstrated that stable transfection rates of non-viral 
gene delivery particles are closely correlated with the maintenance of particle 
size [6, 29]. Even in the absence of reduced in-vitro transfection rates with a 
change in particle size, the parameter particle size is a critical quality attribute 
for in-vivo application and overall for a pharmaceutical product [30]. Therefore, 
this study focused solely on particle size as an indicator of aggregation 
reflecting physicochemical instability which can be affected by freeze-thawing 
and lyophilization. In general, aggregation of gene delivery particles originates 
from colloidal mechanisms, involving electrostatic and/or van-der-Waals 
interactions [2, 31].  
 
In accordance with previous studies [5-7, 10], it was observed that the particle 
size of plasmid/LPEI polyplexes is drastically affected by freeze-thawing and 
that, particle size became better preserved as the ratio of sucrose to plasmid 
DNA was increased. It is well known from literature, that maintenance of particle 
size requires a critical stabilizer/DNA ratio, which is highly dependent on the 
type of non-viral gene delivery particle. For instance, the maintenance of 
particle size of LPEI [5], PEI [8], transferrin-PEI [9], or DMAEMA [29] polyplexes 
could be achieved at sucrose/DNA ratios of 4000, 7500, 10000, or 1250, 
respectively. In contrast, it is well known, that lipid-based complexes require 
much lower excipient/DNA ratios for size protection compared to polymer-based 
complexes [8]. For example, DOTAP-DOPE [8], DOTAP-Chol [8], or DMRIE-C 
[7] lipoplexes could be stabilized at sucrose/DNA ratios of 1250, 900, or 500, 
respectively. This existence of a critical stabilizer/DNA ratio led to the 
development of the “particle isolation hypothesis” by Allison et al. [7]. These 
authors concluded that the volume of the unfrozen fraction, in which particles 
are suspended during freezing, must be only high enough to isolate the 
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complexes in order to prevent particle collision. There is no doubt that particle 
crowding promotes aggregation during freezing, and that particles have to be 
separated in order to inhibit particle aggregation. However, there are two 
observations in our study that indicate that the “particle isolation hypothesis”, 
based on the availability of a large enough volume of the unfrozen fraction, is 
not suitable to solely explain the stabilization of non-viral gene delivery particles 
during freezing.  
 
At first, it was observed that the stability of non-viral vectors upon freeze-
thawing is not only dependent on the type of vector, but also on the initial DNA 
or particle concentration of the sample. Moreover, it was found that the increase 
in particle size of plasmid/LPEI polyplexes was more pronounced in more dilute 
samples (10 µg DNA/ mL) compared to more concentrated samples (50 µg 
DNA/ mL) at the same sucrose/DNA ratio. In contrast to the more concentrated 
samples, for which complete particle stabilization could be achieved at a 
sucrose/DNA ratio of more than 2800, the complete preservation of particle size 
of more diluted plasmid/LPEI polyplexes was even not possible at very high 
sucrose/DNA ratios of 14000. Similarly, Allison et al. [7] reported that the 
freezing of more dilute samples of lipoplexes (8 µg DNA/mL) resulted in 
significantly larger particle sizes than freezing of more concentrated samples 
(160 µg DNA/mL), when formulated at the same sucrose/DNA ratio [7]. 
However, in this case, the doubling of the sucrose/DNA ratio to 1000 was 
sufficient to stabilize the more diluted lipoplex samples [7].  
As in our study the size of an individual gene delivery particle was always 
consistent in the initial solution, independent of the DNA concentration, a lower 
DNA concentration can be equated with a lower particle concentration. As an 
estimate one would assume that a five fold decrease in the number of gene 
delivery particles per sample volume would result in a five fold lower absolute 
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amount of stabilizer necessary to achieve an identical volume per particle in the 
freeze-concentrate. Thus, the stabilizer/DNA ratio required for particle 
stabilization is expected to stay constant in accordance to the “particle isolation 
hypothesis”, independently of the initial particle concentration. However, this 
was not the case for plasmid/LPEI polyplexes, in our study, nor for 
plasmid/DMRIE-C lipoplexes, as reported by Allison et al. [7]. Other 
hypotheses, that might explain the observed lowered particle stability in more 
diluted samples and the inability to completely stabilize low-concentrated 
plasmid/LPEI polyplexes, will be discussed below. 
Secondly, besides the dependence of particle stability on the type of gene 
delivery particle or on the initial DNA concentration, it was observed that the 
freezing procedure highly influences the freeze-thaw stability of plasmid/LPEI 
polyplexes. For instance, we found that freezing of plasmid/LPEI polyplexes by 
conventional shelf-ramp freezing resulted in a less pronounced increase in 
particle size compared to freezing by the “standard” depressurization method. 
Moreover, the critical sucrose/DNA ratio, at which complete preservation of 
particle size can be achieved, was significantly lower when high-concentrated 
samples were frozen by conventional shelf-ramp freezing in comparison to the 
“standard” depressurization method. However, the volume of the unfrozen 
fraction is independent of the freezing procedure and only controlled by the 
initial excipient concentration prior to freezing and the concentration of the 
maximum freeze-concentrate, which is reported to be ~81% for sucrose [27]. 
Thus, particle stabilization during freezing cannot only be explained by the 
available volume of the unfrozen fraction, but other parameters during freezing 
might be involved in the stabilization mechanism. 
 
When comparing the conventional shelf-ramp freezing with the “standard” 
depressurization method, two freezing parameters were identified, that could 
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explain the observed differences in particle stability: ice nucleation temperature 
and residence time of the particles in the freeze-concentrate until glass 
formation occurs. These two parameters were investigated separately by the 
aid of the “depressurization method” which enables to dictate ice nucleation 
temperature. Moreover, various shelf-ramp rates after controlled ice nucleation 
were used in order to achieve different residence times. In general, the 
depressurization method is a very elegant, easy to apply method that can be 
used to guarantee homogeneous ice formation at a defined ice nucleation 
temperature, in comparison to conventional shelf-ramp freezing, during which 
ice nucleation occurs stochastically. This was also approved by the temperature 
profiles that were collected during the different freezing procedures. In addition, 
in this study, the depressurization method was highly useful in order to 
discriminate between the effect of ice nucleation temperature and subsequent 
freezing rates on the stability of an active pharmaceutical ingredient. Previously, 
only a few, but more intricate and unhandy methods were available to study the 
effect of ice nucleation temperature on protein activity, such as seeding with ice 
crystals [23], ultrasound-controlled ice nucleation [32], or the ice fog 
technique [33].  
 
When different ice nucleation temperatures at constant residence times were 
applied during freezing, no effect on particle stability in high-concentrated 
plasmid/LPEI polyplex formulations was observed. In contrast, for the low-
concentrated plasmid/LPEI polyplex formulations the trend that particle size was 
slightly better maintained, when freezing was induced at lower ice nucleation 
temperatures, was noticed. In general, as the ice nucleation temperature 
decreases, the number of formed ice crystals increases, thereby resulting in the 
formation of an increased ice-water interfacial area [13]. For example, in our 
study, SSA measurements showed that the decrease of ice nucleation 
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temperature from −4 °C to −12 °C results in an increase of the absolute ice 
surface per vial between 32% and 81%, depending on the initial sucrose 
concentration. This is in accordance with literature, in which an increase in the 
ice surface area by nearly 50% is reported, when the ice nucleation temperature 
was decreased from −1 °C to −11 °C [34]. Moreover, the observed increase of 
the SSA per sample vial with increasing solid content, agrees also well with 
literature [23]. For proteins, it is well known, that surface-induced denaturation 
can be damaging [35] and that the difference in ice nucleation temperature can 
highly influence protein stability [23, 36]. Here, it is assumed that proteins 
adsorb on the ice crystals and thus, suffer a loss of conformational stability [24]. 
But still, there is a lack of understanding of the source of surface-induced 
denaturation. It is speculated that the mechanism involves very strong electric 
fields [24]. These electric fields might be generated during ice crystallization in 
dilute electrolyte solutions due to preferential incorporation of one ionic species 
into the ice, while the other ionic species remain in the freeze-concentrate 
[24, 37]. The strength of the electric field depends on the freezing rate, the type 
of solvent, and the type and concentration of ionic species present in solution 
[24, 38-39]. As in our study an improved particle preservation was observed at 
lower ice nucleation temperatures, which induces the formation of large ice-
water interfaces, the sole presence of a certain amount of additional interfaces 
can not explain the observed trend in particle destabilization. Rather, it is 
assumed that the aforementioned process dependent generation of electric 
fields on the ice surface might contribute to the destabilization of the 
plasmid/LPEI particles, as these particles are only based on electrostatic 
interactions of the negatively charged nucleic acid and the positively charged 
polymer. However, it is arguable why the generation of electrically charged ice 
surfaces should only predominantly influence non-viral gene delivery particles in 
diluted formulations when formulated at the same absolute amount of stabilizer 
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(e.g. 14% sucrose). Speculatively, it might be assumed that only a certain 
amount of gene delivery particles interacts with the ice-water surface during 
freezing, and that thus, this interaction plays a relatively larger role in more 
dilute samples in comparison to more concentrated samples.  
Consequently, one can conclude that for dilute samples ice formation is one 
destabilizing factor for gene delivery particles during freezing. In this case, it is 
not unexpected, that non-surface active excipients, like sucrose, are not 
capable to fully stabilize against this surface-induced stress, even at very high 
sucrose/DNA ratios. Analogously, Allison et al. [7] stated that the reduced 
stability of lipoplexes in more dilute samples could be explained in general by 
an increased interaction with the ice crystal surface area. In contrast to our 
study, Allison et al. [7] could achieve a complete preservation of particle size for 
more dilute lipoplex samples. Presumably, as polyplexes are only based on 
electrostatic interactions, whereas lipoplexes are additionally stabilized by 
hydrophobic interactions, polyplex stability might be more disturbed during the 
formation of charged ice interfaces as compared to the integrity of lipoplexes. 
Furthermore, our results give experimental evidence, that, in the case of more 
concentrated formulations, other factors than ice formation are responsible for 
the destabilization of gene delivery particles during freezing. 
 
In order to investigate the time-dependence of particle stability during freezing, 
plasmid/LPEI polyplexes were frozen at different shelf ramp rates after ice 
nucleation at a constant temperature. In general, particle size of the polyplexes 
strongly increased with increasing residence times. Moreover, the critical 
sugar/DNA ratio, that is required for full particle size protection, is highly 
elevated for prolonged residence times. Both observations hold true for high- 
and low-concentrated polyplex formulations. Thus, not only the volume of the 
unfrozen fraction but also the time span during which a particle is exposed to 
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freezing induced stresses is of high importance for particle stability during 
freezing. Moreover, these results give experimental evidence that particle 
stability is not only time-dependent during incubation in the frozen state as 
reported by Armstrong et al. [17], but is highly time-dependent already during 
the freezing process, as well. This negative effect of prolonged residence times 
in the critical temperature region during freezing also explains why the 
“standard depressurization technique”, which involves a temperature 
equilibration step after ice nucleation as described in [20], led to a more 
pronounced increase in particle size compared to conventional shelf-ramp 
freezing at fast freezing rates. However, the combination of the depressurization 
technique with subsequent fast freezing rates resulted in comparable particles 
size after freezing as shelf-ramp freezing. 
It was found that the decrease in the shelf ramp rate after controlled nucleation 
resulted in a decrease in the SSA, although ice nucleation temperature was 
kept constantly. Theoretically, the number of ice crystals that is initially formed 
during nucleation is defined by the ice nucleation temperature and thus, 
determines the resulting ice surface area. But our results show that, besides ice 
nucleation temperature, also the freezing rate influences the dimension of the 
resulting surface area. It can be speculated that the slow freezing rate leads to 
a situation that is comparable to a short annealing phase, during which larger 
crystals grow at the expense of smaller ones [40], leading to a reduced specific 
surface area of the product [41].  
At first, we defined the residence time as the period of time between ice 
nucleation and the point at which a product temperature of −30 °C is reached. 
The latter temperature is around the Tg` of the glassy sucrose matrix [42], 
below which particle mobility should be highly limited. However, further 
experiments showed that freezing at very slow shelf ramp rates is only critical 
with regard to particle stability until a product temperature of ~−18 °C is 
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reached. Thus, besides the aforementioned time-dependence, stabilization of 
non-viral gene delivery particles during freezing seems also to be highly 
temperature dependent. Similarly, Armstrong et al. [17] showed that particle 
aggregation does not occur during prolonged incubation in the frozen state at 
temperatures ≤  −22 °C. Moreover, these results suggest that glass formation or 
vitrification of the sample is not required for gene delivery particle stabilization 
during freezing, which is in accordance with literature [7]. However, although 
vitrification is not necessary for particle stabilization in the frozen state, the 
maintenance of the glassy state might be essential for the long-term storage 
stability of lyophilized formulations [2, 43]. 
Furthermore, it was, interestingly, observed that the initial proceeding of slow 
freezing to a product temperature of ~ −3 °C was as stressful as fast freezing to 
−45 °C. This indicates that particle aggregation essentially occurs during initial 
ice formation and that the further proceeding of freezing is negligible as long as 
a fast enough freezing rate is used.  
 
This observed time-dependence of particle destabilization during freezing 
indicates that destabilization of non-viral particles during freezing is to a marked 
degree kinetically controlled. As particle aggregation originates from colloidal 
interaction, particle mobility is a prerequisite for this bimolecular reaction. 
Particle mobility during freezing is strongly coupled with system viscosity and 
thus, particle stabilization can be achieved by a viscosity-driven decrease in the 
reaction rate constants [14]. In general, according to Arrhenius kinetics, a 
decrease in temperature would decrease the bimolecular reaction rates [14]. 
However, when ice formation occurs during freezing, solutes and particles 
present in the starting solution will experience a high increase in concentration. 
By the aid of our theoretical modeling, it could be illustrated that sucrose 
concentration and consequently viscosity strongly increases especially in the 
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initial part of freezing during which the product temperature almost remains 
constant. This increase in the concentration of the solutes and particles in the 
freeze-concentrate causes an increase in the rate of bimolecular reactions [14] 
and, thus, competes with the Arrhenius dependent decrease in reaction rate. In 
order to estimate the course of the bimolecular reaction rate of gene delivery 
particles during freezing, a second order reaction with Arrhenius temperature 
dependence was assumed. Moreover, the reaction rate was coupled to 
viscosity assuming a diffusion-controlled reaction with the diffusion constant 
being inversely proportional, as in the Stokes-Einstein equation [24]. It is 
undisputable that hereby calculated reaction rates are only rough estimations. 
But nevertheless this model might help to illustrate the interrelation between 
bimolecular reaction rate and system viscosity, which is dependent on the 
freezing protocol and on initial solute concentration. During ice nucleation a ~5 
fold increase in the relative reaction rate was observed for all samples. 
However, here, one has to keep in mind that all reaction rates are presented as 
relative reaction rates, which are related to the reaction rate at the point of ice 
nucleation at a DNA concentration of 50 µg/mL. At this point, the liquid, ice-free 
sample has reached the lowest temperature during cooling before ice formation 
starts. Thus, the reaction rate that was used as reference is low compared for 
example to the reaction rate in the liquid state at room temperature. The 
reaction rate in a liquid sample at 20 °C was determined to be ~5 fold higher 
compared to the reaction rate at −12 °C.  
When 50 µg/mL polyplexes were formulated at 10% sucrose, which is below the 
critical sucrose/DNA ratio, reaction rates increased during proceeding of 
freezing. However, in all cases, the maximum rate was reached already at a 
rather high product temperature of ~ −1 °C and a very low system viscosity of 
~7 mPa*s. Thus, when polyplexes are formulated at a too low initial sucrose 
concentration, bimolecular reactions will be accelerated during the very early 
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part of freezing as the particle concentration increases and the viscosity 
increase cannot compensate for this. However, as the product temperature 
further decreases viscosity increases substantially limiting particle diffusion and 
collision. At a certain point during freezing this latter effect becomes dominant 
resulting in decreased bimolecular reaction rates. In our model, the initial 
reaction rate was reached at a product temperature of ~−3 °C and viscosity of 
~50 mPa*s, indicating that the period before is the most critical temperature 
region during freezing. This is in very good agreement with our experimental 
observations. Moreover, our model indicates that the bimolecular reaction rates 
converge against zero at a temperature of −12°C and a viscosity of 
~16500 mPa*s. This is also in good accordance to our experimental results as 
no further particle aggregation, even at very slow shelf ramp rates, was found 
when the product temperature fell below a critical temperature between −11°C 
and −18°C. This highlights, that in this temperature region the system viscosity 
is already high enough in order to almost completely inhibit particle mobility and 
that glass formation is not required. Armstrong et al. [17] reported that a 
viscosity of the freeze-concentrate of 2.10*104 Pa*s was required to prevent 
particle interaction when samples were incubated at −22°C for 24h. But this 
study was performed at a quite low sucrose/DNA ratio of 200 that was not 
capable to completely inhibit particle aggregation during initial freezing. By the 
aid of our model, we could show that the point, beyond which no further 
aggregation occurs, is reached much earlier when freezing is performed at 
accelerated shelf ramp rates, as was expected. Furthermore, we could show 
that the initial stabilizer concentration strongly impacts the maximum reaction 
rates during freezing. When a sufficiently high initial excipient concentration is 
chosen, the increase in the bimolecular reaction rate during freezing after initial 
ice formation may be suppressed completely. This indicates that the initial 
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system viscosity, which is directly related to the initial excipient concentration, is 
decisive for the course of the reaction rate during freezing. 
Allison et al. [7] also mentioned that the high viscosity of the unfrozen fraction 
may serve to immobilize complexes and prevent aggregation. However, they 
reported that viscosity is not capable to explain the observed critical sugar/DNA 
ratio, as the solute concentration in the freeze-concentrate is only dependent on 
the sample temperature but not on the initial solute concentration. Thus, finally, 
they concluded that the distance between complexes in the unfrozen fraction, 
which is defined by the initial solute concentration, determines whether particles 
can physically interact or not [7]. Besides the aforementioned results that do not 
fit to this theory, this hypothesis can be reinvestigated by the aid of our modeled 
data. For instance, the sucrose concentration in the unfrozen fraction of a 6% 
and a 20% sucrose formulation is doubled to 12% and 40% at product 
temperatures of − 0.4 °C and −2.2 °C, respectively. This small difference in 
product temperature leads to a substantial difference in the viscosity of this 
unfrozen fraction (3.2 mPa*s versus 29.4 mPa*s) and in the reaction rate (~16 
versus ~3). Thus, although the same volume of the unfrozen fraction is given, 
particle stability considerably differs mainly due to the clear difference in sample 
viscosity at a minute difference in product temperature. 
In conclusion, these results confirm, that the initial excipient concentration and, 
accordingly, the excipient/DNA ratio are of high importance for particle stability. 
To some degree this is due to the volume of the unfrozen fraction provided by 
the stabilizer. But the positive effect of higher stabilizer concentrations is to a 
great extent related to the fact that a high initial stabilizer concentration provides 
a higher viscosity in the initial phase of freezing. This increase in viscosity 
compensates the increase in particle concentration which drives the reaction 
rate up. Thus, the choice of the excipient is of minor importance as long as 
comparable viscosity is achieved and no phase separation or crystallization 
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occurs, which is the case for sucrose or glucose, but not for mannitol or 
hydroxyethyl starch [2, 7, 44].  
 
In contrast to our observations on the stability of polyplexes, a better stability of 
lactate dehydrogenase was reported when samples were frozen with the 
“standard” depressurization method in comparison to shelf-ramp freezing [19]. 
However, Bhatnagar et al. [23] could show that ice formation and not freeze-
concentration is the critical destabilizing factor during freezing of lactate 
dehydrogenase. Thus, this comparison shows that an optimized freezing 
procedure cannot just simply be transferred to another pharmaceutical active 
ingredient. Rather, an extended understanding of the involved destabilization 
mechanism has to be accomplished in order to design an optimal freezing 
process during lyophilization, varying from case to case.  
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5 Summary and conclusion 
The aim of the study was to provide an extended understanding of the critical 
freezing parameters and the mechanisms by which non-viral gene delivery 
particles are stabilized during the freezing step of lyophilization. In general, it 
was observed that the particle size of plasmid/LPEI polyplexes is better 
preserved with an increase in sucrose/DNA ratio, but that the critical ratio above 
which particle aggregation is completely suppressed is highly dependent on the 
freezing process used, e.g. the “standard” depressurization method was more 
stressful to plasmid/LPEI polyplexes in comparison to conventional shelf-ramp 
freezing. In order to explain this discrepancy, the influence of ice nucleation 
temperature and residence time was investigated separately by the aid of the 
depressurization method. Only the stability of particles at low concentration 
correlated negatively with an increase in ice nucleation temperature 
corresponding to a decrease in SSA. This observation can potentially be related 
to the generation of electric fields at the ice interface. For both DNA 
concentrations, a more distinct increase in particle size was detected when 
samples were frozen at decreased shelf-ramp rates after controlled ice 
nucleation. Depressurization in combination with fast subsequent ramp-rates 
resulted in comparable particle sizes as conventional shelf-ramp freezing, 
indicating that an equilibration step after ice nucleation is critical with regard to 
particle stability. Destabilization of particles during freezing occurs 
predominantly during the initial temperature decrease down to ~ −3 °C after ice 
nucleation. In this phase, cryoconcentration has already advanced but sample 
viscosity is still too low in order to fully inhibit particle mobility. This experimental 
observation matched well with our theoretical model. Here, a maximum of the 
reaction rates was found at a product temperature of ~-1 °C and reaction rates 
reached their initial levels at product temperatures of ~ −3 °C. No further particle 
aggregation was observed at temperatures below ~ ≤ −18 °C indicating that, 
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despite of the absence of glassy state, particle mobility is sufficiently inhibited 
with reaction rates close to zero due to the high sample viscosity. Furthermore, 
our modeled data showed that the level of the maximum reaction rate is 
determined by the initial sucrose/DNA ratio. This fully explains the need of a 
critical sucrose/DNA for complete particle stabilization.  
In conclusion our results show that the time span that a particle spends in the 
low viscous state after ice nucleation is decisive for the stability of non-viral 
gene delivery particles during freezing. This phase of low viscosity but 
increased particle concentration is strongly affected by the initial sample 
viscosity, which is directly related to the initial excipient concentration, but also 
by the applied freezing rate. This extended understanding of the involved 
stabilization mechanisms during freezing will facilitate the development of 
optimized formulations and less stressful lyophilization processes, always to be 
performed hand in hand.  
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Abstract 
Polyplexes based on precise oligoaminoamides exhibited promising results in 
non-viral siRNA delivery. However, one serious limitation is insufficient stability 
of polyplexes in liquid, raising the demand for lyophilized, long-term stable 
formulations. 
Two different siRNA/oligoaminoamide polyplexes were prepared. Freeze-thaw 
experiments were performed, in order to test various formulations containing 
sucrose, trehalose, lactosucrose and hydroxypropyl-β-cyclodextrin for their 
cryoprotective potential, and to investigate the influence of the oligomer 
structure on particle stability. Selected formulations were lyophilized and tested 
for storage stability up to 6 months. Moreover, reconstitution of the lyophilisates 
in reduced volume was studied. Samples were analyzed for particle size, gene 
silencing, cytotoxicity, turbidity, sub-visible particles, osmolarity, residual 
moisture content, glass transition temperature and morphology.  
Depending on the oligomer, siRNA polyplexes maintained particle size and 
gene silencing efficiency in the absence or presence of low amounts (7%) of 
stabilizers after freeze-thawing, lyophilization and reconstitution. The difference 
in formulation stability was not related to covalent disulfide bridges internally 
stabilizing the polyplexes. Hydroxypropyl-β-cyclodextrin did not provide 
sufficient stability. For lyophilized 5%/10% sucrose and 7% lactosucrose 
formulations, long-term stability was demonstrated even at 40°C with constant 
turbidity values, low numbers of subvisible particles at low residual moisture 
levels and sufficiently high glass transition temperatures. 
 
Keywords 
Freeze-drying, lyophilization, non-viral RNA delivery, polyplexes, siRNA 
delivery, stability testing 
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1 Introduction 
Gene therapy offers significant promise to cure, treat or prevent diseases, such 
as cancer, cardiovascular or inherited monogenic diseases, by altering or 
manipulating genes [1-2]. In traditional gene therapy, gene substitutes (DNA) 
are introduced into cells in order to replace defective genes [1]. Within the last 
few years, RNA interference by which harmful genes can be “silenced” [3], has 
provided promising therapeutic opportunities [4]. In this case, small interfering 
RNA (siRNA) with a length of only 21-23 base pairs [5] induces specific 
posttranscriptional gene silencing upon delivery into the cytoplasm [6].  
Under in vivo conditions, “naked” nucleic acid is rapidly degraded by serum 
nucleases [4] and is only inefficiently taken up by target cells, because of its 
negative charge and large size [6]. Thus, in vivo gene therapy necessitates 
gene delivery vectors that ideally protect nucleic acids in the extracellular 
environment and mediate their delivery to the target site [7]. Currently, viral 
vectors are still the most efficient delivery systems, but possess several 
drawbacks, such as immunogenic and toxic reactions or the potential for viral 
recombination [7-8]. Due to these concerns, non-viral vectors are attractive 
alternatives [7-8]. Most non-viral vectors are composed of cationic lipids or 
cationic polymers, which form electrostatic nano-sized complexes (lipo-/ 
polyplexes) with the negatively charged nucleic acids  [1]. Among many 
polycations, polyethylenimine (PEI) is considered as the “gold standard”, 
because of its high transfection efficiency [9-10]. PEI exhibits polydispersity, 
significant toxicity, limited degradability [9], and in the case of siRNA transfer 
only modest delivery efficiency [11-12]. Therefore, modified polymers, which 
allow to establish structure activity relationships, are required for efficient and 
safe clinical siRNA delivery [13-14]. Currently, a library of more than 300 
sequence-defined, monodisperse, precisely tailored oligomers has been 
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generated by solid-phase assisted synthesis, including a number of oligomers 
that were highly efficient in siRNA transfer [15].  
A major drawback that holds true for most non-viral vectors is their poor long-
term stability in aqueous systems, including the tendency to form aggregates, 
which is often correlated with a loss in transfection efficiency [16-18]. However, 
the mandatorily repeated fresh preparation of the non-viral complexes, prior to 
administration in clinical application, possess the risk of batch to batch 
variations and is highly afflicted with safety concerns [19-20]. Thus, for 
successful therapeutic use, one major requirement is the development of 
formulations, which can be reproducibly manufactured and stored for an 
extended period of time with full retention of particle integrity and biological 
activity. 
Previously, it was shown that lyophilization of non-viral vectors is an attractive 
way in order to achieve long-term stable gene delivery formulations [17], with 
most of the literature describing systems based on plasmid DNA or 
oligonucleotides [19-27]. Although lyophilization is a rather gentle drying 
process, it involves two main stress factors, freezing and water removal, which 
can result in nanoparticle damage unless appropriate stabilizers are added [28]. 
Suitable stabilizers were for example monosaccharides (glucose), 
disaccharides (sucrose, trehalose), oligosaccharides (inulin, lactosucrose), or 
polysaccharides/polymers (cyclodextrins, dextrans, povidone).  
Unfortunately, only limited information is available with regard to lyophilization of 
non-viral siRNA delivery systems. Wu et al. [29] showed that siRNA-loaded lipid 
particles could be prepared by hydration of a stable freeze-dried matrix, 
containing siRNA and lipids. However, they only compared this preparation 
method to an established direct preparation procedure and did not investigate 
the influence of the lyophilization process itself on particle size and biological 
activity. Kundu et al. [30] determined particle size and gene silencing efficiency 
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of a lyophilized lipid-based siRNA nanosome formulation upon storage, but also 
did not investigate the influence of the lyophilization process. Moreover, 
Andersen et al. [31] described lyophilized chitosan or lipid siRNA formulations 
that are coated on cell culture plates as high-throughput screening tool and 
showed that 10% sucrose was required to adequately retain particle size and 
gene silencing activity. Additionally, Yadava et al. [32] reported that siRNA 
lipoplexes could only be lyophilized without loss of transfection efficacy and with 
only a slight increase in particle size in the presence of lyoprotectants, such as 
glucose or sucrose. Similar results were published by Werth et al. [33], who 
required 5% glucose to preserve the transfection efficacy of low molecular 
weight polyethylenimine based siRNA polyplexes, but atomic force microscopy 
demonstrated a broadening of the polyplex particle size.  
In most studies, the main focus was on the preservation of the transfection 
efficiency of non-viral complexes after lyophilization. However, other crucial 
quality control parameters have been ignored. For example, retention of particle 
size, number of subvisible particles in a formulation, or relevant characteristics 
of the lyophilisates, such as physical state, glass transition temperature or water 
content, which can highly influence storage stability. In a previous work [25], we 
focused on the improvement of a lyophilized plasmid/LPEI polyplex formulation. 
The aim of the present study was to transfer this approach to the formulation 
development of lyophilized, long-term stable siRNA polyplexes based on novel 
oligoaminoamides. Due to the smaller size and the limited number of negative 
charges of siRNA, siRNA forms more rigid and less electrostatically stabilized 
complexes [4, 13]. Thus, siRNA complexes were assumed to be more 
susceptible to freezing and drying induced stresses, compared to plasmid DNA 
complexes. The availability of long-term stable, lyophilized siRNA polyplex 
formulations would highly facilitate the application of siRNA technology in 
clinical trials. 
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In a first step, a micro-mixer method [34] was transferred to up-scale the 
preparation of siRNA/oligoaminoamide polyplexes. Secondly, freeze-thaw 
studies were performed to select the most effective cryoprotectants in particle 
stabilization. In order to provide a better understanding of the correlation 
between the chemical structure of the used oligomers and the freeze-thaw 
stability of the corresponding siRNA polyplexes, oligomer analogs were 
synthesized and tested in a further freeze-thaw experiment. Selected 
formulations were lyophilized and the possibility to achieve higher concentrated 
siRNA polyplex formulations by reconstitution to reduced volumes was 
investigated. Moreover, stability of selected lyophilized formulations was tested 
up to 6 months. The siRNA/oligoaminoamide polyplexes were analyzed with 
respect to their particle size using dynamic light scattering (DLS), as well as 
their metabolic activity and gene silencing efficiency in cell culture. Furthermore, 
liquid formulations were characterized for their osmotic pressure, turbidity and 
number of subvisible particles. Lyophilisates were examined by Karl Fischer 
titration, differential scanning calorimetry (DSC) and X-ray powder diffraction 
(XRD). 
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2 Materials and methods 
2.1 Materials 
Oligoaminoamides 49 and 460 were synthesized analogously as described in 
[15] and [35], respectively. The oligotyrosine containing T-shape 
oligoaminoamides 332 and 454 were also obtained by solid-phase assisted 
synthesis (unpublished results; C. Troiber and E. Wagner, manuscript in 
preparation). When indicated, free terminal cysteines of oligomer 49 were 
blocked by incubation with a 10-fold molar excess of N-ethylmaleimide (NEM) 
(Sigma-Aldrich, Steinheim, Germany) overnight, followed by a saturation of the 
excessive NEM with a 10-fold molar surplus of acetylcysteine (Sigma-Aldrich, 
Steinheim, Germany). The chemical sequences of the used oligoaminoamides 
are listed in Table 7-1. 
Table 7-1: Chemical sequences of the used polymers 49, 332, 454 and 460. S: succinic 
anhydride, tp: tetraethylenpentamine, OleA: oleic acid, C: cysteine, Y: tyrosine, A: alanine, ]K: 
lysine with branching at α,ε–amino groups.  
 
 
 
 
 
 
 
GFP-siRNA (sense: 5'-AuAucAuGGccGAcAAGcAdTsdT-3'; antisense: 5'-
UGCUUGUCGGCcAUGAuAUdTsdT-3'; small letters: 2’methoxy-RNA; s: 
phosphorothioate) and control-siRNA siCtrl (sense: 5’-
AuGuAuuGGccuGuAuuAGdTsdT-3’; antisense 5‘-
CuAAuAcAGGCcAAuAcAUdTsdT-3‘) were kindly provided by Axolabs GmbH 
(Kulmbach, Germany; formerly Roche Kulmbach GmbH).  
Oligomer Sequence 
49 C-Stp2-(OleA)2K]K-Stp2-C 
332 Y3-Stp2-(OleA)2K]K-Stp2-Y3 
454 C-Y3-Stp2-(OleA)2K]K-Stp2-Y3-C 
460 A-Stp2-(OleA)2K]K-Stp2-A 
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Purified water (ELGA LabWater, Celle, Germany) served as solvent for all 
solutions. siRNA and oligomer stock solutions were diluted in 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Merck, Darmstadt, 
Germany) buffer pH 7.4, so that mixing equal volumes of the two solutions 
resulted in a N/P ratio of 12:1 (molar ratio of protonable oligomer nitrogen (N) to 
siRNA phosphor (P)) and a siRNA concentration of 200 µg/mL, which is referred 
to the siRNA concentration of the sample. 
Stabilizer stock solutions at various concentrations [% w/v] of sucrose 
(Südzucker, Mannheim, Germany), trehalose 100 (Hayashibara, Okayama, 
Japan), hydroxypropylbetadex (HP-β-CD) (CavasolTM W7 HP, Wacker Chemie, 
Munich, Germany), lactosucrose (Nyuka-OligaTM LS-90P, Hayashibara, 
Okayama, Japan) and polysorbate 20 (Tween 20TM, Merck, Darmstadt, 
Germany) were prepared in 20 mM HEPES buffer pH 7.4 without any further 
purification. Stabilizer stock solutions were filtered with a 0.2 µm cellulose 
acetate membrane syringe filters (VWR International, Ismaning, Germany) and 
mixed 1:1 with the formed siRNA polyplexes. For cell culture experiments all 
samples were prepared under aseptic conditions. 
2R glass vials (Fiolax® clear, Schott AG, Müllheim, Germany) with their 
according rubber stoppers (West Pharmaceutical Services, Eschweiler, 
Germany) with a filling volume of 150 µL or 500 µL were used. 
2.2 Preparation of siRNA polyplexes 
The siRNA polyplexes were prepared by a micro mixer method that was 
originally established for plasmid/LPEI polyplexes [34]. 5.0 mL syringes with 
luer lock tip (Terumo, Leuven, Belgium) and a plunger speed of 1.0 cm/min 
were used for this mixing process. After mixing, the polyplexes were incubated 
for 30 min at room temperature. In order to ensure the suitability of the micro 
mixer method for the preparation of siRNA polyplexes, polyplexes were also 
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prepared via admixing 75 µL siRNA stock solution into the same volume of 
oligomer stock solution in 1.5 mL Eppendorf tubes in comparison.  
2.3 Freeze-thawing studies 
For the freeze-thawing studies, 75 µL siRNA polyplex solution at a 
concentration of 200 µg/mL was mixed with 75 µL stabilizer solution at various 
concentrations in 2R vials resulting in a polyplex concentration of 100 µg/ml and 
various stabilizer concentrations (5%, 10% and 20% sucrose, 10% sucrose/ 
0.01% polysorbate 80, 5% and 10% trehalose, 7% and 14% lactosucrose, 10% 
HP-β-CD/ 6.3% sucrose). Freeze-thawing experiments were performed on a 
pilot-scale freeze-drier (Lyostar II, FTS Systems, SP Industries, Stone Ridge, 
USA). The samples were equilibrated at 20 °C for 10 min, frozen at −1 °C/min to 
−45 °C with a 30 min hold at −45°C. Thawing was performed at 1 °C/min to 
20°C with a 30 min hold at 20°C. This procedure was performed three times.  
2.4 Lyophilization of siRNA polyplexes 
500 µL of the selected samples (5% and 10% sucrose, 5% and 10% trehalose, 
7% and 14% lactosucrose) were lyophilized in 2R vials. Samples were prepared 
by mixing 250 µL siRNA polyplex solution with 250 µL stabilizer solution at 
various concentrations. Lyophilization was performed on a pilot scale freeze-
drier (Lyostar II). Samples were frozen at −1 °C/min to −45 °C and held for 
120 min. Primary drying was performed at −20 °C and 34 mTorr with 
manometric endpoint determination. Secondary drying was performed at 
reduced pressure of 8 mTorr at 20 °C. Samples were stoppered under slight 
vacuum at 600 Torr nitrogen and vials were crimped with aluminum seals. 
2.5 Long-term stability testing of lyophilized samples 
For long-term stability testing, selected lyophilisates (5% and 10% sucrose, 7% 
lactosucrose) were stored at 2-8 °C, 25 °C and 40 °C over a period of 1 month 
and 6 months. 
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2.6 Reconstitution of lyophilized samples 
Lyophilized samples were reconstituted with 250 µL (5% sucrose, 5% trehalose 
and 7% lactosucrose samples) or 500 µL (10% sucrose, 10% trehalose and 
14% lactosucrose samples) purified water. This resulted in samples with siRNA 
concentrations of 200 µg/ml or 100 µg/mL, respectively.  
2.7 siRNA polyplex characterization 
Size determination of siRNA polyplexes was performed by DLS using the 
Nanosizer ZS (Malvern, Herrenberg, Germany). The samples were diluted 1:20 
with 20 mM HEPES buffer pH 7.4 to a final volume of 1 mL. The diluted 
samples were measured in single-use polystyrene semi-micro PMMA cuvettes 
(Brand, Wertheim, Germany) with a path length of 10 mm after an equilibration 
time of 1 min at 20 °C. Each sample was recorded three times with 3 subruns of 
10 s using the multimodal mode. The z-average diameter (Zave) or the number 
mean diameter, and the polydispersity index (pdi) were calculated from the 
correlation function using the Zetasizer Software 6.20 (Malvern). 
Freshly prepared siRNA polyplexes were analyzed for their zeta-potential with 
laser Doppler anemometry using the Zetasizer Nano ZS (Malvern). Each 
sample was analyzed in a DTS 1060c cell (Malvern) with 10 up to 100 subruns 
of 10 s at 20 °C (n=3). The zeta-potential was calculated by the Smoluchowski 
equation.  
2.8 Cell culture: metabolic activity and gene silencing  
Freshly prepared, freeze-thaw stressed, lyophilized, and lyophilized and stored 
GFP-siRNA polyplex formulations were diluted to 25 µg/mL with HBG (5% 
glucose, 20 mM HEPES pH 7.4) for cell culture experiments. Control-siRNA 
polyplexes were freshly prepared and treated in exactly the same manner.  
Mouse neuroblastoma cells (Neuro2A/EGFPLuc cells), stably transfected with 
the EGFPLuc gene, were grown in Dulbecco’s modified Eagle’s medium 
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(DMEM), supplemented with 10% FCS, 4 mM glutamine, 100 U/mL penicillin, 
and 100 µg/mL streptomycin and incubated at 37 °C and 5% CO2. In order to 
determine the metabolic activity or the knock down efficiency of the siRNA 
polyplexes, Neuro2A/EGFPLuc cells were seeded into 96-well plates at a 
density of 5000 cells/well 24 h prior to transfection. Subsequently, cell culture 
medium was replaced with 80 μL fresh medium containing 10% FCS. 20 µL of 
the diluted transfection complexes in HBG were added to each well and 
incubated for 48 hours at 37 °C and 5% CO2. 20 µL HBG buffer was used as 
negative control. All experiments were performed in triplicates, respectively. 
Subsequently, metabolic activity was evaluated. Therefore, 10 μL MTT 
(5 mg/ml) were added to each well, reaching a final concentration of 0.5 mg 
MTT/mL. After an incubation time of 2 h, unreacted dye and medium were 
removed and the plates were frozen at -80 °C for at least 1 h. The purple 
formazan product was dissolved in 80 μL/well dimethyl sulfoxide and quantified 
by a UV plate reader (Tecan, Groedig, Austria) at 590 nm with background 
correction at 630 nm. The metabolic activity (%) was calculated relative to HBG 
controls.  
To determine gene knock down efficiency, the transfected cells were treated 
with 100 µL lysis buffer (0.5x) 48 h post transfection. Subsequently, luciferase 
activity in the cell lysate was determined with a Centro 960 plate reader 
luminometer (Berthold Technologies, Bad Wildbad, Germany). The relative light 
units (RLU) were presented as percentage of the luciferase gene expression 
obtained with only HBG treated control cells.  
2.9 Osmometry 
The osmotic pressure of 150 µL of each lyophilized and reconstituted sample 
was determined in triplicates with an automatic semi-micro osmometer (Knauer, 
Berlin, Germany). The instrument was checked with aqueous NaCl solutions of 
75, 150 and 300 mM.  
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2.10 Turbidimetry 
Turbidity of the samples in formazine nephelometric units (FNU) was 
determined by using a NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany). 
Samples were analyzed in triplicates in LUMIstoxTM glass cuvettes (Dr. Lange, 
Düsseldorf, Germany). Prior to the measurement, the instrument was checked 
by measuring the turbidity of purified water.  
2.11 Light obscuration  
Light obscuration tests were carried out according to Ph.Eur. 2.9.19. The 
particle counting of subvisible particles in a size range between 1 and 200 µm 
was conducted using a SVSS-C instrument and associated analysis software 
(PAMAS GmbH, Rutesheim, Germany). For each sample (n=3) four 
measurements of a volume of 0.3 mL with a pre-run volume of 0.3 mL at fixed 
fill rate, emptying rate and rinse rate of 5 mL/min were performed. Prior to each 
measurement the system was rinsed with 0.2 µm filtered purified water until 
particle counts of less than 100 particles/mL ≥ 1 µm and less than 
10 particles/mL ≥ 10 µm were determined. The obtained results represented the 
mean value of the particle counts of three measurements, referred to a sample 
volume of 1.0 mL.  
2.12 Karl Fischer titration 
The residual moisture of the lyophilisates directly after lyophilization and after 
storage was determined in triplicates by coulometric Karl Fischer titration using 
a Metrohm 756 KF Coulometer (Metrohm, Herisau, Switzerland). The 
lyophilisates were dissolved in 0.5 mL dried Methanol (HydranalTM-Methanol 
Dry, Sigma-Aldrich, Steinheim, Germany). The water content of the samples 
was determined by injecting 0.3 mL of the methanol samples into the titration 
solution (HydranalTM-Coulomat AG, Sigma-Aldrich) and the water content was 
calculated as % w/w. Empty vials were treated identically throughout 
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preparation and storage to obtain comparable blank values. HydranalTM Water 
Standard 0.10 (Sigma-Aldrich) was used as reference.  
2.13 Differential scanning calorimetry (DSC) 
DSC experiments were performed in 40 µL aluminum crucibles using a Mettler 
Toledo DSC 821e (Mettler-Toledo GmbH, Giessen, D). In order to determine 
the glass transition temperature of the maximally freeze-concentrated solution 
(Tg`), 30 µL of the liquid samples were cooled at − 5 °C/min from 20 °C to 
− 40 °C, and subsequently, at − 2 °C/min from − 40 °C to − 50 °C, held at 
− 50 °C for 10 min and reheated at 10 °C/min to 20 °C. For the determination of 
the glass transition temperature of the lyophilisates (Tg), approximately 10 mg 
were weighed into the aluminum crucibles in a glove box purged with dry air. 
Samples were equilibrated at 25 °C for 5 min and heated at 10 °C/min to 
110 °C. Tg and Tg` were defined as the midpoint of the glass transition in the 
heat heating scan of the DSC experiment. All analyses were performed in 
triplicates. 
2.14 X-ray powder diffraction (XRD) 
The morphology of the lyophilisates directly after lyophilization and after storage 
was analyzed by XRD on an X-ray diffractometer XRD 3000 TT (Seifert, 
Ahrensburg, Germany). Samples were fixed on a copper sample holder with 
1 mm fill depth, exposed to CuKa radiation (U =  40 kV, I = 30 mA, 
λ = 154.17 pm), and scanned from 5 to 45° 2-Θ with steps of 0.1° 2-Θ and a 
duration of 1 s per step.  
2.15. Statistical analysis 
Results were determined to be statistically different by performing a two-tailed 
student t test using the QuickCalcs, GraphPad Software (La Jolla, CA, USA). 
Mean values with a p value < 0.05 are considered as significantly different. 
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3 Results 
3.1 Up-scaled preparation and characterization of the siRNA 
polyplexes 
In order to guarantee a standardized and reproducible preparation of 
siRNA/oligoaminoamide polyplexes at a larger scale, a micro-mixer method 
established for the preparation of plasmid/LPEI polyplexes [34] was transferred 
to the siRNA polyplexes. Therefore, siRNA/oligomer 332 and siRNA/oligomer 
49 polyplexes were prepared by classical pipetting and by the micro mixer 
method. In a preliminary study (Troiber et al., unpublished results, manuscript in 
preparation), polyplex size obtained by DLS, fluorescence correlation 
spectroscopy, AFM and nanoparticle tracking analysis were compared. For 
siRNA/oligomer 332 polyplexes the Zave and for siRNA/oligomer 49 polyplexes 
the volume or number mean diameter in DLS provided the most realistic and 
representative size results. Consequently, these parameters were employed for 
size characterization of polyplexes prepared by the different methods. 
For siRNA/oligomer 332 polyplexes, Zave and pdi were not significantly 
(p > 0.05) influenced by the preparation method (pipetting Zave: 131.0 ± 
7.1 nm, pdi: 0.17 ± 0.02; micro-mixer Zave 122.0 ± 1.4 nm, pdi: 0.17 ± 0.02). 
Similarly, for siRNA/oligomer 49 polyplexes, no significant difference in the 
mean number diameter (18.4 ± 2.0 nm vs. 18.0 ± 1.2 nm), or the mean volume 
diameter (23.5 ± 4.2 nm vs. 24.9 ± 4.5 nm) was observed. The polydispersity of 
the siRNA/oligomer 49 polyplexes was slightly improved, when prepared with 
the micro-mixer method (0.37 ± 0.13), compared to classical pipetting (0.58 ± 
0.24). Additionally, silencing efficiency of siRNA/oligomer 332 polyplexes in 
mouse neuroblastoma cells was significantly independent from the preparation 
method, at comparable metabolic activities. The luciferase activity was 4.0 ± 
0.5% after pipetting and 3.8 ± 0.5% using the micro-mixer method. The 
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siRNA/oligomer 49 polyplexes prepared by the micro-mixer method showed a 
significantly better gene silencing efficiency (luciferase activity of 34.8 ± 3.8%), 
compared to polyplexes prepared via classical pipetting (luciferase activity of 
47.8 ± 4.0%). Moreover, in 20 mM HEPES buffer pH 7.4, the zeta-potential of 
siRNA/oligomer 332 or siRNA/oligomer 49 polyplexes was 38.1 ± 0.8 mV or 
20.8 ± 0.6 mV, respectively. For all further formulation studies, polyplexes were 
prepared with the micro-mixer method. 
3.2 Freeze-thawing studies 
Prior to lyophilization, freeze-thawing studies were performed, in order to select 
the most effective cryoprotectant at its required concentration. The 
siRNA/oligoaminoamide polyplexes were freeze-thawed three times in 20 mM 
HEPES buffer pH 7.4 without or with the addition of 5%, 10% and 20% sucrose, 
10% sucrose/ 0.01% polysorbate 80, 5% and 10% trehalose, 7% and 14% 
lactosucrose, or 10% HP-β-CD/ 6.3% sucrose. As aforementioned, 
siRNA/oligomer 332 polyplexes were characterized by the Zave and 
siRNA/oligomer 49 polyplexes were characterized by the number mean 
diameter, as the volume mean diameter results were for technical reasons 
highly influenced by the presence of stabilizer molecules. 
After freeze-thawing in absence of stabilizers, Zave and pdi of siRNA/oligomer 
332 polyplexes drastically increased up to 1068 ± 170 nm and 0.9 ± 0.1, 
respectively (Figure 7-1A). This drastic particle formation and precipitation was 
easily observable by visual inspection. The presence of low amounts of 
disaccharides, such as 5% sucrose or 5% trehalose, was capable to limit this 
high increase in particle size. Nevertheless, the particle size after freeze-
thawing was significantly increased for these formulations, when compared to 
freshly prepared particles. Higher amounts of sucrose (10% and 20%) with or 
without polysorbate, trehalose (10%), or lactosucrose (7% and 14%) completely 
preserved the particle size upon freeze-thawing.  
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Figure 7-1: A) Z-average diameter (oligomer 332) or B) number mean diameter (oligomer 49) 
and polydispersity index of freshly prepared or three times freeze-thaw stressed (3xFT) siRNA 
polyplexes. Polyplexes were formulated in 20 mM HEPES buffer pH 7.4 without (HEPES) or 
with the addition of stabilizers (5%, 10% and 20% sucrose, 10% sucrose/0.01% polysorbate 80, 
5% and 10% trehalose, 7% and 14% lactosucrose, 10% HP-β-CD/ 6.3% sucrose). 
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However, the presence of HP-β-CD led to a pronounced increase in particle 
size and polydispersity already in freshly prepared formulations. After freeze-
thawing, these high values further persisted. In contrast, the addition of 
stabilizers was not necessary for the maintenance of particle size after freeze-
thawing for siRNA/oligomer 49 polyplexes (Figure 7-1B). All formulations, 
except for the HP-β-CD/sucrose formulation, showed no significance difference 
in particle size after freeze-thawing compared to freshly prepared formulations. 
In the case of siRNA/oligomer 49 polyplexes the HP-β-CD/sucrose samples, 
both freshly prepared and freeze-thawed, did not show particle aggregation, but 
dissociation of the particles with a mean number diameter of around 1 nm. 
Cell culture experiments in mouse neuroblastoma cells (data not shown) did not 
show an influence of the different formulations on metabolic activity (~80%). 
Gene silencing activity of siRNA/oligomer 332 polyplexes was slightly 
decreased after freeze-thawing, when formulated in HEPES buffer without the 
addition of stabilizers. In this case, the luciferase activity was only reduced by 
~80%. In contrast, the luciferase activity was decreased by ~92% for all other 
effective formulations. For HP-β-CD/sucrose formulations gene silencing activity 
of the siRNA/oligomer 332 polyplexes was strongly reduced with a reduction in 
luciferase activity of only ~40%. In contrast, siRNA/oligomer 49 polyplexes 
formulated in HEPES buffer and with stabilizers showed comparable gene 
silencing activity after freeze-thawing with a decrease in luciferase activity of 
~75%. Only the HP-β-CD/sucrose formulations showed a distinctive reduction in 
biological activity with a reduced luciferase expression by only ~15%. 
All freshly prepared or freeze-thawed placebo formulations (without polyplexes) 
displayed low turbidity values of ~0.6 FNU, close to the turbidity of purified 
water. A high turbidity of ~10 FNU was observed in the case of freshly prepared 
siRNA/oligomer 332 polyplexes in buffer. This high turbidity was also detected 
for almost all freshly prepared and freeze-thawed formulations. A decreased 
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turbidity to ~1 FNU was observed for the freeze-thawed buffer formulation and 
both fresh and freeze-thawed HP-β-CD/sucrose formulations. In these cases, 
huge aggregates were formed, which led to particle precipitation. All 
siRNA/oligomer 49 polyplex formulations showed very low turbidity values in the 
range of 0.6 to 0.8 FNU, except for the HP-β-CD/sucrose formulations, which 
exhibited a turbidity of ~3.5 FNU after preparation, but which completely 
vanished after freeze-thawing as complexes precipitated.  
Similar trends were observed for the number of subvisible particles of the 
various samples. An increased number of particles ≥ 1 µm was detected for 
freshly prepared siRNA/oligomer 332 polyplexes, compared to the 
corresponding placebo samples. All siRNA/oligomer 332 polyplex formulations 
showed a slight increase in the number of particles ≥ 1 µm after freeze-thawing 
from ~250 to ~2000 particles/mL, except the HP-β-CD/sucrose formulation, 
which showed a decrease in the number of particles ≥ 1 µm from 1700 to 
1000 particles/mL as polyplexes precipitated. All siRNA/oligomer 332 polyplex 
formulations exhibited low numbers of subvisible particles ≥ 10 µm (≤ 
5 particles/mL) and ≥ 25 µm (≤ 3 particles/mL). In comparison, only the 
siRNA/oligomer 49 polyplexes, formulated in HP-β-CD/sucrose, showed 
increased numbers of particles (~2000 particles/mL ≥ 1 µm; ~ 600 particles ≥ 
10 µm, ~80 particles ≥ 25 µm). All other siRNA/oligomer 49 polyplex 
formulations exhibited only a small gain in the number of particles ≥ 1 µm after 
freeze-thawing (from ~100 to ~500 particles/mL) and showed low numbers of 
subvisible particles ≥ 10 µm (≤ 8 particles/mL) and ≥ 25 µm (≤ 2 particles/mL). 
 
Thus interestingly, siRNA/oligomer 49 polyplexes were resistant against 
freezing and thawing without addition of stabilizer. In contrast, 
siRNA/oligomer 332 polyplexes required at least small amounts of stabilizers. It 
was assumed that the unexpectedly high freeze-thaw stability of 
Lyophilization of siRNA/oligoaminoamide polyplexes                                      237 
 
 
siRNA/oligomer 49 polyplexes might be associated with the terminal cysteine 
groups of oligomer 49, which are known to form internal cross-linking disulfide 
bonds after siRNA complexation that may stabilize the polyplexes. In order to 
test this hypothesis, oligomer 454 and oligomer 460 were synthesized. In 
comparison to oligomer 332, oligomer 454 had additional terminal cysteines, 
whereas in oligomer 460 the terminal cysteines of oligomer 49 were substituted 
with alanine residues. Additionally, the terminal cysteines of oligomer 49 were 
blocked with N-ethylmaleimide (NEM) prior to polyplex formation. Polyplexes 
using these variants were prepared in 20 mM HEPES buffer pH 7.4 via pipetting 
and exposed to freeze-thaw stress without addition of stabilizers.  
 
Figure 7-2: A) Z-average diameter (oligomer 332 and oligomer 454) and B) number mean 
diameter (oligomer 49, oligomer 49/NEM and oligomer 460) of freshly prepared or three times 
freeze-thaw stressed (3xFT) siRNA polyplexes formulated in 20 mM HEPES buffer pH 7.4.  
Despite of the additional cysteines, siRNA/oligomer 454 polyplexes showed the 
same distinctive increase in Zave and pdi as the siRNA/oligomer 332 
polyplexes (Figure 7-2A). In contrast, neither the blockage of the free cysteine 
groups of oligomer 49 by NEM, nor the substitution of the free cysteines of 
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oligomer 49 by alanines (oligomer 460) influenced the mean number diameter 
of the polyplexes significantly (p > 0.05) (Figure 7-2B). 
3.3 Lyophilization of siRNA/oligoaminoamide polyplexes 
Selected formulations of the siRNA/oligoaminoamide polyplexes in pure buffer, 
5% or 10% sucrose, 5% or 10% trehalose, or 7% or 14% lactosucrose were 
lyophilized using a conservative lyophilization process. The product temperature 
was maintained below the Tg` of the samples (Table 7-2) at least in the first 
two-thirds of the primary drying step. All lyophilisates, except the samples 
without stabilizers, exhibited good cake appearance.  
Table 7-2: Glass transition temperature of the maximally freeze concentrate (Tg`) prior to 
lyophilization (prior to lyo) and glass transition temperature (Tg) and residual moisture content 
(RM) of solid lyophilized formulations directly after lyophilization (after lyo) and after storage for 
1 month (1 m) or 6 months (6 m) at 2-8 °C, 25 °C, and 40 °C (n=3). 
 
The possibility to concentrate siRNA polyplex formulations, by reconstitution to 
reduced volumes after lyophilization, was investigated. Therefore, the 10% 
sucrose, 10% trehalose and 14% lactosucrose formulations were reconstituted 
in the original volume, whereas the 5% sucrose, 5% trehalose and 7% 
 5% sucrose 10% sucrose 7% lactosucrose 
 Tg`/Tg [°C] RM [%w/w] Tg`/Tg [°C] RM [%w/w] Tg`/Tg [°C] RM [%w/w] 
Prior to lyo -33.4 ± 0.1  -31.7 ± 0.5  -25.9 ± 0.1  
After lyo 58.4 ± 0.5 0.21 ± 0.01 56.2 ± 2.7 0.56 ± 0.02 97.8 ± 2.0 0.14 ± 0.03 
1m 2-8°C 57.3 ± 1.5 0.31 ± 0.03 56.3 ± 1.5 0.56 ± 0.04 92.0 ± 2.3 0.17 ± 0.01 
1m 25°C 57.0 ± 0.2 0.37 ± 0.02 50.8 ± 1.0 0.73 ± 0.05 91.0 ± 1.0 0.21 ± 0.01 
1m 40°C 55.0 ± 1.8 0.54 ± 0.02 49.8 ± 1.9 0.75 ± 0.03 89.7 ± 2.7 0.36 ± 0.03 
6m 2-8°C 55.7 ± 0.9 0.53 ± 0.04 52.4 ± 0.7 0.60 ± 0.06 91.1 ± 0.8 0.16 ± 0.01 
6m 25°C 55.3 ± 1.3 0.68 ± 0.06 49.4 ± 0.7 0.75 ± 0.03 89.4 ± 0.7 0.22 ± 0.01 
6m 40°C 52.4 ± 0.8 0.70 ± 0.07 47.9 ± 0.4 0.80 ± 0.06 86.5 ± 0.7 0.41 ± 0.03 
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lactosucrose were reconstituted in only half of the original volume. All 
lyophilisates, except the siRNA/oligomer 332 polyplex samples without 
stabilizers, instantly (< 5 s) dissolved upon reconstitution. After reconstitution, 
few large, visible particles were observed for the non-stabilized siRNA/oligomer 
332 polyplexes. All other reconstituted lyophilisates showed no particle 
formation or turbidity that was visible by the naked eye. After reconstitution, the 
osmolarity of the sucrose, trehalose or lactosucrose samples was 318 ± 7, 313 
± 8 or 308 ± 5 mOsm/kg, if reconstituted in the original volume, and 347 ± 11, 
341 ± 8 or 321 ± 13 mOsm/kg, if reconstituted in half of the original volume, 
respectively. 
After lyophilization and reconstitution, Zave and pdi of siRNA/oligomer 332 
polyplexes was substantially increased in the absence of any stabilizer 
(Figure 7-3A). All other siRNA/oligomer 332 polyplex formulations showed only 
a marginal change in particle size after lyophilization and reconstitution 
(Figure 7-3A). This change in particle size of less than 6% between freshly 
prepared and lyophilized samples was significant (p ≤ 0.05), for all formulations, 
except for the 7% lactosucrose formulations. Unexpectedly, for siRNA/oligomer 
49 polyplexes (Figure 7-3B) no significant change in particle size was caused 
by lyophilization in the absence of any stabilizers or in the presence of sucrose. 
For the siRNA/oligomer 49 polyplexes formulated with trehalose or lactosucrose 
a slight difference was observed. Furthermore, samples that were reconstituted 
in the original volume and samples that were reconstituted in only half of the 
original volume did not significantly differ in size for both, siRNA/oligomer 332 
polyplexes and siRNA/oligomer 49 polyplexes. 
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Figure 7-3: A) Z-average diameter (oligomer 332) and B) number mean diameter (oligomer 49) 
of siRNA polyplexes formulated in 20 mM HEPES buffer pH 7.4 with 5% or 10% sucrose or 7% 
lactosucrose. Samples were freshly prepared (fresh) and lyophilized (lyo). The 5% sucrose, 5% 
trehalose and 7% sucrose formulations were reconstituted in half of the original volume after 
lyophilization (*).  
In cell culture experiments, siRNA/oligomer 332 polyplexes lyophilized in pure 
HEPES showed a decreased gene silencing activity with a limited reduction of 
the luciferase activity by ~75% (data not shown). All other lyophilized and 
reconstituted formulations for both siRNA polyplexes, siRNA/oligomer 332 and 
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siRNA/oligomer 49, retained their initial gene silencing activity at comparable 
metabolic activity. 
Similar to placebo formulation, turbidity of all siRNA/oligomer 332 polyplex 
formulations (data partly shown in Figure 7-6) was not increased after 
lyophilization and reconstitution in the original volume. A nearly doubled 
turbidity was detected for the samples that were reconstituted with only half of 
the original volume. All siRNA/oligomer 49 formulations showed a slight 
increase in turbidity after lyophilization and reconstitution from ~0.6 FNU to 
maximally 1.0 FNU.  
For both, siRNA/oligomer 332 and siRNA/oligomer 49, polyplex formulations, a 
distinctive increase in the number of subvisible particles ≥ 1 µm from 
< 500 particles/mL to up to 9000 particles/mL was monitored (data partly shown 
in Figure 7-7A). However, an increase in the number of subvisible particles ≥ 
1 µm up to 3500 particles/mL was also observed for the placebo formulations. 
In general, for all lyophilized and reconstituted siRNA formulations, very low 
numbers of subvisible particles ≥ 10 µm (≤ 30 particles/mL) and ≥ 25 µm 
(≤ 5 particles/mL) were found (data partly shown in Figure 7-7B and Figure 
7-7C).  
3.4 Long-term stability of lyophilized siRNA/oligoaminoamide 
polyplexes 
Consequently, formulations containing 5% sucrose, 10% sucrose, or 7% 
lactosucrose, were investigated for long-term stability over 6 months at 2-8 °C, 
25 °C, or 40 °C. After reconstitution of the 5% sucrose and 7% lactosucrose 
formulations with half of the original volume and of the 10% sucrose formulation 
with the original volume, samples were characterized for particle size, biological 
and metabolic activity, turbidity and number of subvisible particles. In addition, 
lyophilisates were analyzed for residual moisture content, Tg and amorphous 
state. 
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Figure 7-4: A) Z-average diameter (oligomer 332) and B) number mean diameter (oligomer 49) 
of siRNA polyplexes formulated in 20 mM HEPES buffer pH 7.4 with 5% or 10% sucrose or 7% 
lactosucrose. Samples were freshly prepared (fresh), lyophilized (lyo) or lyophilized and stored 
at 2-8 °C, 25 °C or 40 °C for 1 month (1 m) or 6 months (6 m). The 5% sucrose and 7% sucrose 
were reconstituted only in half of the original volume after lyophilization (*). 
Zave and pdi of siRNA/oligomer 332 polyplexes did not significantly change 
over time compared to the samples that were directly analyzed after 
lyophilization, independent of the formulation or storage temperature 
(Figure 7-4A). Comparable results were observed for siRNA/oligomer 49 
polyplexes, as no significant change in the mean number diameter was found 
over storage; only for the 5% sucrose formulation stored for 1 month at 40 °C 
and the 10% sucrose formulations stored for 6 months at 2-8 °C or 25 °C a 
slight increase in pdi was observed (Figure 7-4B).  
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Figure 7-5: Influence of the formulation of siRNA/oligomer 332 and siRNA/oligomer 49 
polyplexes and corresponding placebo samples on (A) the luciferase activity of Neuro-2A cells 
and (B) the metabolic activity in Neuro-2A cells (n=3). Samples were formulated in 20 mM 
HEPES buffer pH 7.4 with the addition 5% sucrose, 10% sucrose or 7% lactosucrose. Samples 
were freshly prepared (fresh), lyophilized (lyo) or lyophilized and stored at 2-8 °C, 25 °C or 
40 °C for 1 month (1 m) or 6 months (6 m). The 5% sucrose and 7% sucrose were reconstituted 
in half of the original volume after lyophilization (*). Freshly prepared siCtrl polyplexes in HEPES 
buffer were used as controls.  
Cell culture experiments in Neuro2A/EGFPLuc cells (Figure 7-5A and 7-5B) 
showed similar results for luciferase activity and metabolic activity for all 
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placebo samples, independently from the storage conditions. Control 
experiments with fresh siCtrl/oligomer 332 or siCtrl/oligomer 49 polyplexes, 
which were tested along with fresh or 6 months stored polyplexes, revealed 
luciferase activities of ~120% for the siCtrl/oligomer 332 polyplexes and ~95% 
for the siCtrl/oligomer 49 polyplexes at comparable metabolic activities of ~75%. 
Slight differences in the knock down efficiency were found for the 
siRNA/oligomer 332 polyplexes, which varied between 97.4% and 87.9%, and 
for siRNA/oligomer 49 polyplexes, which varied between 15.6% and 30.8%. 
However, no correlation with storage time or storage temperature were 
identified. The same holds true for metabolic activities which ranged between 
55% and 93%. 
Turbidity values of all formulations including placebo did not change significantly 
(p > 0.05) over 6 months (Figure 7-6).  
 
Figure 7-6: Turbidity in formazine nephelometric units (FNU) of siRNA/oligomer 332 polyplexes, 
siRNA/oligomer 49 polyplexes and corresponding placebo samples formulated in 20 mM 
HEPES buffer pH 7.4 with the addition 5% sucrose, 10% sucrose or 7% lactosucrose. Samples 
were freshly prepared (fresh), lyophilized (lyo) or lyophilized and stored at 2-8 °C, 25 °C or 
40 °C for 1 month (1 m) or 6 months (6 m). The 5% sucrose and 7% sucrose were reconstituted 
in half of the original volume after lyophilization (*). 
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Figure 7-7: Number of sub-visible particles/mL with a particle diameter ≥ 1 μm (A), ≥ 10 μm (B) 
or ≥ 25 μm (C) of /oligomer 332 and siRNA/oligomer 49 polyplexes and corresponding placebo 
samples formulated in 20 mM HEPES buffer pH 7.4 with the addition 5% sucrose, 10% sucrose 
or 7% lactosucrose. Samples were freshly prepared (fresh), lyophilized (lyo) or lyophilized and 
stored at 2-8 °C, 25 °C or 40 °C for 1 month (1 m) or 6 months (6 m). The 5% sucrose and 7% 
sucrose were reconstituted in half of the original volume after lyophilization (*). 
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In general, no trend in the number of particles ≥ 1 µm was observed in the long-
term stability study (Figure 7-7A). In general, the formulations containing 
lactosucrose showed higher particle numbers. The number of subvisible 
particles ≥ 10 µm (≤ 40 particles/mL) and ≥ 25 µm (≤ 8 particles/mL) was very 
low for all samples and again no trend could be assessed with storage time or 
storage temperature (Figure 7-7B and 7-7C). 
The residual moisture levels of all lyophilisates increased with proceeding 
storage time and increasing storage temperature (Table 7-2). The lowest 
residual moisture was observed for lactosucrose formulations, which increased 
from 0.14% directly after lyophilization to 0.41% when stored for 6 months at 
40 °C. In general, 10% sucrose formulations showed higher water content 
(0.56% to 0.8%) compared to 5% sucrose formulations (0.21% to 0.70%). 
Correspondingly, the Tg values decreased with proceeding storage time and 
increasing storage temperature (Table 7-2). Lactosucrose formulations yielded 
the highest Tg values between 97.8 °C and 86.5 °C. In accordance with the 
observed water content, 5% sucrose formulations showed slightly higher Tg 
(58.4 °C to 52.4 °C), compared to 10% sucrose formulations (56.2 °C to 
47.9 °C). All lyophilisates were completely amorphous after storage over 
6 month as no signs of crystallinity were observed by X-ray powder diffraction 
(data not shown). 
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4 Discussion 
The standard method to prepare siRNA polyplexes is to mix siRNA and polymer 
solutions via pipetting at small volumes. The quality of the particles obtained via 
this poorly controlled and standardized process highly depends on the 
preparation conditions, like the way of admixing, or pipette handling 
inconsistencies among different operators [16, 34, 36-37]. Therefore, a 
controlled and easily up-scalable micro-mixer method that had recently been 
established for the preparation of plasmid/LPEI polyplexes [34], was 
successfully transferred to the preparation of siRNA polyplexes. Both 
siRNA/oligomer 332 and siRNA/oligomer 49 polyplexes, prepared with the 
micro-mixer method at large volume (5 mL), showed similar particle size, 
slightly improved polydispersity and similar gene silencing efficiency, as 
compared to systems prepared via pipetting at common small volumes 
(150 µL). It is known from our previous study [34] that at larger volumes, the 
heterogeneity of polymer-based gene delivery particles is even more 
pronounced, when prepared via pipetting. But larger sample volumes of 
polyplexes with a defined quality are necessary for adequate formulation 
development, preclinical and clinical studies. Moreover, our results showed that 
the micro-mixer method is well suited for the standardized and reproducible 
preparation of plasmid DNA, siRNA and thus, presumably, also oligonucleotide 
polyplexes. Analogous methods have also been successfully introduced for the 
preparation of cationic lipoplexes [20, 36]. 
 
It is known that particle stability can be negatively influenced during freezing 
[28, 38]. This results from cryoconcentration as ice separates, rendering a 
complex and solute rich liquid phase with increased risk of particle association 
at reduced interparticle distance [28, 39-40]. Moreover, interaction of the 
particles with the formed ice-liquid interfaces [41], selective crystallization of 
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buffer components, leading to a pH shift [42], or mechanical damage of the 
particles by the growing ice or excipient crystals [40], can affect particle stability. 
Freeze-thawing experiments demonstrated a drastic increase in particle size 
and polydispersity of siRNA/oligomer 332 polyplexes in the absence of 
stabilizers. A similar effect is also reported for DNA-based DOTAP/DOPE [43] 
or PEGylated lipoplexes [24], and PDMAEMA [23, 44] or LPEI [25] polyplexes, if 
formulated without stabilizer. In contrast, in the absence of stabilizers 
siRNA/oligomer 49 polyplexes were completely stable against freezing induced 
stresses. The preservation of particle size upon freeze-thawing is also reported 
for siRNA-based DOTAP/DOPE lipoplexes [32] and in addition for DNA- and 
siRNA- low molecular weight PEI complexes [45]. Thus, the question arises on 
what causes this substantial difference in particle stability upon freezing. 
In order to approve or disapprove the hypothesis that the polyplex-stabilizing 
intermolecular disulfide bridges between the cysteines of oligomer 49 might be 
responsible for the unexpectedly high colloidal stability, oligomer analogs were 
investigated. It is well-established that the presence of cysteine groups in the 
systems is essential for efficient DNA and siRNA delivery [15, 35]. In this case, 
intra-particulate disulfide bridge formation increases the polyplex stability and 
inhibits particle dissociation during cellular uptake. However, neither blockage 
nor substitution of the cysteines in oligomer 49 reduced the high colloidal 
stability of the particles. Thus the presence of disulfide bridges was not 
essential for the polyplex formulation stability. Moreover, the addition of 
cysteines to oligomer 332 did not improve colloidal particle stability upon freeze-
thawing. This indicates that different mechanisms are involved regarding the 
stabilization of an individual polyplex particle and the inter-particulate colloidal 
stability of polyplex particles.  
Besides the general discrepancy in the chemical structure of the two oligomers, 
the particle size of the corresponding polyplexes significantly differs, with 
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~150 nm for siRNA/oligomer  332 polyplexes and ~20nm for siRNA/oligomer 49 
polyplexes. This might be one important factor governing particle stability upon 
freeze-thawing. This hypothesis is supported by the afore cited literature, where 
an increase in particle size upon freeze-thawing was observed for all particles 
with sizes of ~ 125 to 250 nm [23-25, 43-44], whereas particle size was 
maintained for all complexes with ~ 30 to 60 nm [32, 45]. During freezing, the 
formation and the further growth of ice crystals results in cryoconcentration of 
the sample within the interstitial region. Depending on the initial solute 
concentration of the sample and the presence or absence of microcollapse the 
thickness of the interstitial region roughly varies between ~100 nm and ~1 µm 
[46]. Although the absolute number of particles with an increase in diameter is 
reduced at a fixed ratio of polymer to siRNA, the general probability of particle 
collision in these narrow channels might be increased for larger particles. 
Moreover, it could be possible that larger particles could get stuck at very 
narrow parts of the interstitial region, which might promote particle 
agglomeration. 
Another possible explanation for the different aggregation behavior of the two 
siRNA polyplexes might be their potential to stabilize interactions among 
individual particles. In the case of the oligotyrosine containing oligomer 332, the 
interaction between individual particles and the stabilization of these inter-
particulate interactions might be favored due to the strong pi interactions among 
the aromatic amino acid residues, known as pi-pi stacking [47-48]. siRNA 
oligomer 49 polyplexes might also get into contact with each other during 
cryoconcentration, but in this case, the stabilization of the inter-particulate 
interactions to “stable” agglomerates might not be favored and the 
agglomerates might dissociate again to the original particles size upon thawing.  
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In order to stabilize siRNA/oligomer 332 polyplexes against freezing induced 
stresses, only low amounts of sucrose, trehalose and lactosucrose were 
necessary and these stabilizers showed similar potential. In contrast, HP-β-CD 
significantly affected the polyplexes, which is discussed below. Thus, in 
accordance with literature [21, 28], the mass ratio of polyplex to amorphous 
matrix material is more critical than the choice of stabilizer, apart from 
cyclodextrins. For the stabilization of siRNA/oligomer 332 polyplexes, 7% [m/V] 
of stabilizer was required to fully maintain particle size, corresponding to a 
stabilizer/siRNA ratio of 700. In comparison, a stabilizer/DNA mass ratio of 4000 
was necessary to stabilize plasmid/LPEI polyplexes [25]. Even higher 
stabilizer/DNA ratios of 7500 [49] or 10000 [19] were reported for the adequate 
protection of DNA/PEI polyplexes. However, a comparable stabilizer/DNA ratio 
of 1250 was sufficient for the preservation of DMAEMA polyplexes [23]. 
However, until now, no detailed studies on stabilizer to siRNA ratios in order to 
retain the particle size of siRNA based gene delivery complexes were available.  
Various mechanisms, such as preferential exclusion [50], vitrification [50] and 
particle isolation [51], are discussed in order to explain how cryoprotectants can 
preserve non-viral gene delivery particles during freezing. It is still not clear, 
whether the preferential exclusion hypothesis [52], according to which proteins 
are stabilized by a solvent layer that is formed around the macromolecules, can 
be transferred to the stabilization of non-viral gene delivery particles [50]. 
According to the vitrification hypothesis, non-viral gene delivery particles are 
immobilized in the highly viscous glassy matrix, when samples are cooled below 
Tg` [17, 53-54]. Additionally the particles may be stabilized by isolation as 
crowding of particles favors their aggregation and a critical stabilizer/particle 
ratio that leads to a certain degree of spatial separation of the particles is 
necessary for full particle protection [51].  
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The high stabilizer/particle ratios that are required for certain gene delivery 
particles initiated the introduction of higher molecular weight excipients [22, 
24-25, 55], in order to ensure low osmolarity, when applying formulation 
containing higher masses of stabilizer. For example, stabilization of 
plasmid/LPEI polyplexes in isotonic formulations could only be achieved by 
using oligosaccharides, such as lactosucrose or a combination of HP-β-CD with 
sucrose [25]. siRNA/oligomer 332 polyplexes were also well protected against 
freeze-thawing stress using lactosucrose. However, comparable particle 
stabilization could also be achieved with the commonly used disaccharides 
sucrose and trehalose, without markedly exceeding the isotonicity level.  
The presence of HP-β-CD strongly influenced particle size and polydispersity of 
both, fresh and freeze-thawed, siRNA polyplexes. For siRNA/oligomer 332 
polyplexes a pronounced increase in particle size was induced, whereas 
siRNA/oligomer 49 polyplexes dissociated. Both formulations displayed an 
increase in polydispersity. The effect might be caused by the insertion of the 
lipophilic oleic acid moiety of the oligomer into the lipophilic cavities of the 
cyclodextrin molecules. In the case of siRNA/oligomer 332 polyplexes, the 
remaining tyrosines supporting strong and attractive pi-pi interactions [47-48] 
outside the cavity, may lead to the formation of large aggregates. In the case of 
siRNA/oligomer 49 polyplexes, the formation of cyclodextrin inclusion of the 
oleic acid chains induces the disruption of the polyplexes into small fragments. 
Thus, interactions based on the poorly water soluble lipophilic moiety appear to 
be essential for particle formation and stability. In this freeze-thaw study the 
cyclodextrin stock solution was added to the siRNA/oligomer 49 polyplexes after 
incubation for 30 min, when still about 75% of the free thiol groups were present 
[15] and the formed disulfide bonds do not provide sufficient stabilization of the 
polyplexes. 
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Tg` values for the selected sucrose and lactosucrose samples were in good 
accordance with literature [34, 56]. The higher Tg` for lactosucrose 
formulations, compared to sucrose formulations, can be explained by the Fox-
Flory theory [57], according to which the Tg` increases with increasing 
molecular weight of the excipient. This increased Tg` would allow primary drying 
at elevated temperatures, reducing time and cost of lyophilization processes. 
 
Lyophilization experiments confirmed the need of small amounts of stabilizers, 
in order to maintain the particle size of siRNA/oligomer 332 polyplexes. It is well 
established that stabilizers act not only in the course of freezing, but stabilize 
particles in the dry state via entrapment of the particles in a glassy matrix, which 
allows particle separation and inhibits particle collision, known as “vitrification 
hypothesis” [50]. Additionally, the “water replacement hypothesis” is discussed 
for protection against dehydration induced stresses, according to which the 
stabilizer molecules replace the escaping water by direct interaction with the 
particle surface [50]. Again, siRNA/oligomer 49 polyplexes showed 
unexpectedly high stability and even in the case of gross collapse due to 
absence of any stabilizer, the polyplexes did not show any tendency to 
aggregate. However, all samples lyophilized without stabilizers did not form a 
proper cake, which is required for pharmaceutically acceptable lyophilized 
products, and exhibited longer reconstitution times. 
For all formulations, the polyplex particle size was not significantly changed 
after lyophilization, compared to samples analyzed after freeze-thawing. This 
indicates that the predominant stress factor for siRNA polyplexes during 
lyophilization is the freezing step, and not the drying phase. This is in 
accordance with literature on DNA lipoplexes [51] and DNA/LPEI polyplexes 
[25]. In contrast, Yadava et al. [32] reported a dramatic increase in size for 
siRNA lipoplexes after lyophilization in the absence of stabilizers and a slight 
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increase in presence of sucrose or glucose, whereas in none of the formulations 
the particle size was affected by freeze-thawing. 
In comparison, Yadava et al. [32] could limit the size increase only to 43% or 
320% for their lyophilized lipoplex formulations, when formulated with 5% 
glucose or 9.5% sucrose, respectively. Andersen et al. [31] showed that 10% 
sucrose was required for sufficient stabilization of siRNA/chitosan particles 
during lyophilization. Werth et al. [33] reported that siRNA polyplexes, based a 
low molecular weight PEI, can be lyophilized in the presence of 5% glucose, but 
a slight broadening of particle size distribution was observed based on AFM 
measurements. Thus, in our study, it is the first time that non-viral siRNA gene 
delivery particles could be successfully lyophilized without any limitation. 
Lyophilization of formulations at initial “half-isotonic” concentrations, in 
combination with reconstitution in only half of the initial volume, allowed 
doubling of the siRNA polyplex concentration for in-vivo and clinical studies, 
where high concentrations are required, without affecting particle size and gene 
silencing activity. It is well known that particle size and polydispersity of gene 
delivery particles increase, when the particles are prepared at higher 
concentrations [34, 58]. Similarly, the possibility to concentrate plasmid/PEI 
polyplexes, formulated with low molecular weight dextrans by a factor of four, 
was described by Anchordoquy et al. [22]. Zillies et al. [27] proved that 
oligonucleotide-loaded gelatin nanoparticles, which required only a rather low 
stabilizer to particle ratio, could be concentrated even 30-fold without an 
increase in particle size. 
 
In general, particle size is not only an important quality criterion, but can also 
affect gene silencing efficiency in vitro and in vivo. In our study, the size of 
siRNA/oligomer 332 polyplexes drastically increased after freeze-thawing and 
lyophilization in the absence of any stabilizer. This correlated with a 2.5 fold 
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decrease in gene silencing activity. In literature, it is reported that the uptake of 
larger particles in cell culture experiments might be even increased, due to 
sedimentation of the larger particles onto the cells [59]. However, in order to 
achieve successful gene transfer in vivo, preservation of particle size is crucial, 
as large aggregated particles are in general ineffective in vivo and can even be 
toxic due to embolism in the lung [10]. 
All tested polyplex formulations in the presence of stabilizers were able to 
maintain gene silencing efficiency after freeze-thawing and lyophilization. This 
demonstrates that the addition of stabilizers to siRNA/oligomer 332 polyplexes 
is required not only to maintain particle size, but also to retain gene silencing 
efficiency. Similar results are reported in literature for siRNA/chitosan particles 
[31], siRNA/low molecular weight PEI complexes [33] and siRNA lipoplexes 
[32]. SiRNA/oligomer 49 polyplexes could be lyophilized with preserved gene 
silencing efficiency in the absence of stabilizers. This can be directly correlated 
to the maintenance of particle size after lyophilization. Andersen et al. [31] 
reported that siRNA/TransIT-TKO lipoplexes could also effectively induce 
knockdown after lyophilization in the absence of stabilizer, but did not report the 
particle size. 
For all HP-β-CD/sucrose formulations the changes in particle size for both 
particle types led to a highly pronounced decrease in gene silencing activity. 
This effect may not only be ascribed to the change in particle size, but also to 
the structural alterations within the particles or the perturbed interactions 
between siRNA and the oligomer [17].  
In our storage stability study, variations in gene silencing efficiency and 
metabolic activity were observed, which did not correlate with storage time or 
temperature, but instead reflected the common differences between 
independent cell culture experiments, as the samples were analyzed separately 
after lyophilization, after 1 month and after 6 months of storage.  
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The results indicate that the initial sizes and gene silencing efficiencies of both 
siRNA/oligoaminoamide polyplex formulations could be maintained during 
storage for 6 months at up to 40 °C, when samples were lyophilized in the 
presence of appropriate stabilizers. Only Andersen et al. [31] investigated 
storage stability of lyophilized siRNA gene delivery particles with gene silencing 
efficiency, but without particle size as quality criterion. The knockdown 
efficiency of siRNA/TransIT-TKA lipoplexes completely vanished and the 
knockdown efficiency of siRNA/chitoson particles decreased from 67% to 32%, 
when stored for 2 month at 25 °C.  
 
Moreover, turbidity and number of subvisible particles were investigated to 
provide a more comprehensive characterization of the formulations. Due to the 
larger size of the siRNA/oligomer 332 polyplexes, high turbidity values were 
already observed for fresh preparations, as turbidity scales as the radii to the 
sixth power [22]. A low turbidity of siRNA/oligomer 332 polyplex samples was 
only observed after freeze-thawing and lyophilization in the absence of any 
stabilizer, as in this case polyplexes precipitated. When siRNA/oligomer 332 
polyplex lyophilisates were reconstituted in reduced volume, turbidity values 
approximately doubled. Turbidity values of siRNA/oligomer 49 polyplex 
formulations were markedly lower at the start and slightly increased after 
lyophilization. This slight increase in turbidity was also observed for 
corresponding placebo samples, suggesting that it is caused by a marginal 
particle formation of the excipients themselves, or due to a particle 
contamination during the non-aseptic lyophilization process as previously 
reported [21, 25]. The changes in particle size observed for the HP-β-CD 
polyplex formulations inversely correlated with the observed turbidity values, 
with a drastic increase in particle size and decrease in the turbidity for 
siRNA/oligomer 332 polyplexes due to particle precipitation and a decrease in 
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particle size and increase in the turbidity of siRNA/oligomer 49 polyplexes due 
to particle dissociation. In general, the increase in turbidity correlated with an 
increase in the number of subvisible particles ≥ 1 µm. All samples met the 
current standard limits for small volume parenterals specified in the Ph.Eur. [60] 
or USP [61].  
The storage stability of lyophilized formulations strongly correlates with other 
relevant characteristics of the lyophilisates, such as Tg, water content, or 
amorphous state. The Tg values of lactosucrose formulations were significantly 
higher as compared to sucrose formulations, and for both sucrose and 
lactosucrose, Tg values compared well to literature [25, 62]. The Tg was slightly 
lower for samples with higher water content as water acts as plasticizer [63]. 
The increase in water content with increasing storage time and temperature is 
in accordance with literature [64]. In general, all water contents were very low 
(< 1%) after storage. Moreover, the investigated storage temperatures did not 
exceed the Tg of the samples or influence the amorphous state of all samples. 
This is important, as product vitrification guarantees particle separation and low 
mobility in the glassy matrix, which is essential for long-term stability [51]. 
Consequently, lactosucrose might be a beneficial lyoprotectant compared to 
sucrose, as it can withstand higher residual moisture contents during storing, 
without the Tg falling below the storage temperature. 
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5 Conclusion 
To summarize, a currently established micro-mixer method was successfully 
applied to the standardized and reproducible preparation of 
siRNA/oligoaminoamide polyplexes. This guarantees a constant and defined 
quality of the particles, especially when prepared at large volumes. Freeze-
thawing and freeze-drying studies showed that siRNA/oligotyrosine-oligomer 
332 polyplexes required only low amounts of stabilizers (mass ratio of ~700). 
The type of stabilizer was of minor importance, as sucrose, trehalose and 
lactosucrose formulations showed similarly good particle preservation. In 
contrast, siRNA/oligomer 49 polyplexes were stable against freezing and drying 
induced stresses, even in the absence of any stabilizer. These results showed 
that siRNA polyplexes are less prone to lyophilization related stresses 
compared to DNA polyplexes. Further freeze-thawing experiments, using 
polyplexes based on oligomer analogs, showed that the presence of cysteines 
which internally stabilize polyplexes by disulfide forming are not responsible for 
the different colloidal stability of the two siRNA/oligoaminoamide polyplexes. 
Cyclodextrin was not suitable as stabilizer; destabilization of particles was 
induced by the formation of inclusion complexes between the lipophilic moieties 
ofoligomers and cyclodextrin cavities. Selected lyophilized formulations 
maintained particle size and gene silencing efficiency, also when reconstituted 
with reduced volumes. Furthermore, long-term stability of both siRNA 
polyplexes, formulated with 5% sucrose, and 10% sucrose, or 7% lactosucrose, 
was demonstrated, when stored over 6 months up to 40 °C. All freeze-thawed, 
lyophilized and stored formulations exhibited only slightly altered turbidity 
values, met the standard limits for particulate contamination for small volume 
parenterals, and did not markedly exceed isotonicity level. In addition, all 
lyophilisates were amorphous with low residual moisture contents and 
sufficiently high glass transition temperature. The well established 
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lyoprotectants sucrose and trehalose were appropriate for successful 
lyophilization of siRNA polyplexes. However, the use of oligosaccharides might 
be advantageous with respect to the achievable concentration level of the 
samples, the potential of time-, and thus cost-reduction in the lyophilization 
process, and the potentially better storage stability at higher temperature and 
moisture levels. In conclusion, lyophilization is a promising approach to achieve 
long-term stable siRNA polyplexes with maintenance of particle size and gene 
silencing efficiency at pharmaceutically defined high quality. 
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Abstract 
Lyophilization is an important and well-established pharmaceutical drying 
process. Product temperature is the most critical process parameter during 
lyophilization as it impacts both product quality and process efficiency. 
Traditionally, thermocouples (TC) or resistance temperature detectors (RTD) 
and recently, manometric temperatures measurements (MTM) have been used 
to monitor the product temperature. But all of these techniques have several 
drawbacks. The objective of this study was the implementation and evaluation 
of an optical fiber system as novel process monitoring tool during lyophilization. 
Therefore, temperature profiles of mannitol, sucrose or trehalose were recorded 
with various prototypes of the optical fiber sensors (OFS) and compared to data 
obtained with conventional TCs or Pirani/capacitance manometry with respect 
to the endpoint of primary drying. The OFS allowed easy handling and easy 
center bottom positioning. Data obtained with the OFS in contact with product 
were in good agreement with data obtained via TCs or Pirani/capacitance 
manometry. The OFSs showed significantly higher sensitivity, faster response 
and better resolution compared to TCs. This allowed for the detection of 
additional excipient crystallization events. It was found that force effects on 
unshielded sensors enabled to detect glass transitions. Three-dimensional 
temperature profiles were obtained with an OFS helix configuration. The 
possible integration of a glass fiber with several OFSs in series into the shelf 
surface enables non-invasive, automatic loading compatible monitoring of the 
drying process. In conclusion, these advantages turn the novel optical fiber 
systems into a highly attractive process monitoring tool during lyophilization. 
 
Keywords 
Freeze-drying, lyophilization, PAT, process monitoring, optical fiber sensors 
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1 Introduction 
Freeze-drying also known as lyophilization is a common, well-established drying 
process to improve the long-term stability of labile pharmaceuticals, such as 
proteins or nucleic acids [1-3]. The concept of freeze-drying is based on the 
sublimation of ice from a frozen product at low temperature and reduced 
pressure [4]. A traditional lyophilization process consists of three major steps: 
freezing, primary and secondary drying [5-6]. During freezing, most of the water 
will form ice crystals and the solutes are concentrated until they crystallize or 
transform into a solid amorphous state [5-6]. In the course of primary drying, 
pressure in the product chamber is reduced and shelf temperature is increased 
to provide sufficient energy that is needed for sublimation of the formed ice [1]. 
Primary drying is complete when all frozen water is removed [1]. However, at 
this stage non-frozen water is still absorbed in the interstitial region and has to 
be desorbed in a secondary drying step at elevated shelf temperature und low 
chamber pressure, to finally achieve the desired low residual moisture 
content [5].  
Lyophilization is an extremely time- and thus cost-intensive drying process [4]. 
For that reason, process development efforts aim to design well-understood and 
more efficient lyophilization processes. In a Food and Drug Administration’s 
(FDA) guidance for industry [7] the concept of “Process Analytical Technology” 
(PAT) was established. Its main objective is to enhance scientific understanding 
and control of the manufacturing process through timely measurements of 
critical quality and process attributes, with the goal to consistently ensure a 
predefined final product quality (Quality by Design) [7-8]. In order to fulfill this 
objective the implementation of PAT tools, such as process analyzers or 
process control tools, is required [7, 9]. 
Therefore, various PAT-tools have been implemented to monitor and control the 
lyophilization process. Batch methods comprise spectroscopy based 
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measurements such as tunable diode laser absorption spectroscopy (TDLAS), 
mass spectrometry or other residual gas analyzers, manometric temperature 
measurement (MTM), and Pirani/capacitance manometry [9-11]. Single vial 
methods comprise near infrared (NIR) or Raman spectroscopy, temperature, 
conductivity or moisture sensors, microbalance technique, and offline analytics 
after sampling [9-11]. 
As product temperature is undisputable the main critical parameter during 
lyophilization, product temperature monitoring is the most important and most 
often applied technique [11]. In general, product temperature, which depends 
on the shelf temperature, the chamber pressure, the container system and other 
formulation properties, cannot be directly controlled [12]. In order to prevent 
product collapse product temperature is maintained below the critical 
temperature of the formulation. This is the glass transition temperature (Tg`) or 
the collapse temperature (Tc) for amorphous systems, and the eutectic 
temperature (Teu) for crystalline systems [1, 3]. Product collapse may 
negatively influence product properties such as residual moisture content, 
reconstitution time or stability of the active pharmaceutical ingredient (API) but 
will also lead to product rejections because of unaesthetic appearance [2, 13].  
Traditionally, 100-ohm platinum resistance temperature detectors (RTDs) or 
type T copper-constantan thermocouples (TCs) have been used to measure 
product temperature in a few selected vials [11, 14]. RTDs, that are preferred in 
manufacturing because of their chemical inertness and mechanical robustness, 
disadvantageously require an electrical current for measurement of the 
temperature dependent electrical resistance, which might cause elevated heat 
transfer to the product. Moreover, the large mass of the sensing tip results in an 
average temperature across the length of the tip rather than at a precise 
location, which might be troublesome with small product container or low fill 
volumes [14-15]. TCs, which are more frequently used in laboratory scale 
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freeze-dryers, have the advantage that they allow temperature measurements 
at the precise location of the junction of the two dissimilar metal wires, where a 
temperature related voltage is generated. However, TCs pose the risk of 
chemical erosion leading to sterility concerns [14].  
One main disadvantage for product temperature measurements with RTDs or 
TCs is the fact that these sensors are not compatible with automatic loading 
systems during manufacturing scale freeze-drying [8]. Therefore, wireless 
temperature sensors have been developed [15-18]. “Active sensors” require 
batteries and data is only available after the run [17], or they are connected to a 
power module inside the product chamber [16]. “Passive transponders” allow to 
circumvent these problems but the number of available sensors is limited and 
their distance from the receiver can become critical in large freeze-driers 
[15, 18]. Another main disadvantage that holds true for any invasive thermo-
sensor is its influence on ice nucleation and heat transfer, thereby causing bias 
in both freezing and drying behavior relative to vials not containing sensors. 
Thus vials bearing sensors may not be representative for the entire batch 
[8, 11]. 
Manometric temperature measurement (MTM) is capable of non-invasive 
prediction of the product temperature at the sublimation interface of a vial 
reflecting the batch average. With this technique, the valve connecting the 
chamber and the condenser is closed momentarily (~25s) and the pressure rise 
in the chamber is recorded over time [11]. By fitting a MTM equation to the 
pressure data [19], an average temperature of the entire batch can be obtained. 
But MTM delivers data that is often biased towards colder running vials [20] and 
only representative in the first 2/3 of primary drying [21]. Furthermore, MTM is 
not reliable when processing high concentration amorphous samples [22], is 
currently only available on production scale [22], and cannot be used for 
monitoring of heterogeneities in a batch like “edge vial effects” [23].  
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Besides the ensurance that the critical product temperature will not be 
exceeded during drying, product temperature measurements are also used to 
detect the endpoint of drying [11]. The endpoint is commonly defined by the 
time point when product temperature is equivalent to the shelf temperature or 
(in case of elevated radiative heat transfer to the product) when the temperature 
reading is higher than the shelf temperature and constant over time [15]. 
More recently, researchers more and more stress the importance of the freezing 
step in lyophilization [24-29]. The freezing step does not only influence process 
performance during primary and secondary drying, but also sample 
morphology, stability of the API as well as physical state of the product [25]. 
Product temperature measurement is one of the few direct, in-line analytical 
tools in order to get a deeper insight into the freezing behavior.  
In conclusion, product temperature measurements during lyophilization are of 
high importance. However, all available techniques exhibit certain 
disadvantages such as invasive sample placement, lack of sensitivity, risk of 
corrosion, sterility concerns, incompatibility with automatic loading systems, or 
measurement inaccuracies. Consequently, there is an urgent need for new 
temperature measurement technologies that overcome at least one or some of 
the disadvantages of the aforementioned temperature monitoring devices.  
The objective of this study was the implementation of an optical fiber system 
[30], that is based on fiber Bragg gratings (FBGs), as a novel process 
monitoring tool during lyophilization. Several different design variations of the 
optical fiber sensors (OFSs) were created and evaluated for their potential use 
in product temperature monitoring during lyophilization and freezing 
experiments in comparison to conventional T-type thermocouples. At first, the 
general suitability of the OFSs for product temperature measurements and end 
point detection during lyophilization was investigated. Moreover, the sensitivity 
of the OFS to detect physico-chemical events during freezing such as ice 
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nucleation, crystallization of crystalline or glass formation of amorphous 
excipients was examined. In addition, the influence of the shielding or 
unshielding of the OFS on temperature profiles was studied. An OFS helix was 
tested for the detection of three-dimensional temperature profiles. Furthermore, 
two additional design variations of the OFS were evaluated for their use as non-
invasive temperature measurement devices. 
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2 Materials and methods 
2.1 Materials 
5, 10 or 20 % [m/V] solutions of the common lyophilization excipients 
D(-)-mannitol (Riedel-de Haën, Seelze, Germany), trehalose (Hayashibara, 
Okayama, Japan) or sucrose (Südzucker, Mannheim, Germany), were used as 
model formulations. Purified water (ELGA LabWater, Celle, Germany) served 
as solvent for all solutions. All model formulations were filtered with 0.2 µm 
cellulose acetate membrane syringe filters (VWR International GmbH, 
Ismaning, Germany). 2R or 6R glass vials (FiolaxTM clear, Schott, Müllheim, 
Germany) with corresponding rubber stoppers (West, Eschweiler, Germany) at 
1, 2 or 4 mL filling volume were used.  
2.2 The optical fiber system  
The optical fiber system [30] consists of a FBG suitable optical fiber that is 
guided via a connection fiber through one of the flanges on the top of the 
freeze-drier into the product chamber. Outside the freeze-drier, the fiber is 
connected to an interrogation unit, which acts as laser light source and detector 
at the same time. The interrogator is coupled to a computer with special 
software for in process data evaluation. 
2.2.1 Optical fiber sensor (OFS) structure and characteristics 
The heart of the novel system is the optical fiber itself. The optical fiber is a hair-
thin cylindrical filament made of glass that is able to guide light by its assembly 
of three different regions with different refractive indices (Figure 8-1A). In the 
central position is the fiber core (6 µm in diameter) made of highly transparent 
germanium-doped silicate. A region having a lower refractive index, the 
cladding (125 µm in diameter), surrounds the fiber core. Due to this lower 
refractive index of the cladding light is entrapped inside the fiber core and is 
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guided along the fiber via total internal reflection. A coating made of OrmocerTM, 
an inorganic polymer material that is obtained by controlled hydrolysis and 
condensation of organically modified silicium alkoxides, surrounds the cladding 
(195 µm in diameter), resulting in high tensile strength of the fiber [31]. 
The key element of the OFS is the FBG, which represents a wavelength-
dependent reflector generated by adding a periodic variation to the refractive 
index within the fiber core (Figure 8-1B). 
 
Figure 8-1: Schematic representation of the structure and characteristics of the optical fiber 
sensor: A) The optical fiber consists of the fiber core (1), the cladding (2) and the coating (3). 
The laser light (4) is guided by total internal reflection inside the fiber core. B) A Fiber Bragg 
Grating (FBG) is achieved by adding a periodic variation to the refractive index of the fiber core. 
This figure was modified from [31]. 
This is usually achieved by irradiation with spatially-varying pattern of intensive 
UV-light. The high content of germanium increases the photosensitivity of the 
material and thus allows the creation of gratings with one excimer laser pulse 
only. With this single writing technique FBGs can be manufactured directly 
during the fiber drawing process with excellent reflectivity values (draw tower 
grating (DTG)) [32]. The total length and number of grating periods in a FBG 
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depends on the strength or amplitude of the grating. DTGs typically have a 
sensor length of 5 to 10 mm and a grating period spacing of about 2 mm, which 
ensures a reflectivity of typically more than 15% using a wavelength in the 
range about 1550 nm [33]. 
2.2.2 Operation principle 
The operation principle of an OFS is depicted in Figure 8-2.  
 
 
Figure 8-2: Schematic representation of the operation principle of the optical fiber sensor: most 
of the broad spectrum laser light is transmitted and only a narrow part is reflected at a FBG 
specific, temperature dependent wavelength (λFBG). This figure was modified from [31]. 
The fundamental operation principle is based on Fresnel reflection, where light 
traveling between media of different refractive indices may both reflect and 
refract at the interface. Thus, when a broad spectrum laser light beam reaches 
the FBG most of the light will be transmitted. Only a small portion will be 
reflected, centered at the Bragg wavelength according to Bragg’s law [34]: 
Λ⋅⋅= nFBG 2λ             (8-1) 
where λFBG is the reflected Bragg wavelength, n is the refractive index of the 
grating in the fiber core and Λ is the grating periodic spacing. Any change in the 
refractive index of the grating or in the grating periodic spacing (Λ) that is 
caused by temperature or strain will result in a shift of the Bragg wavelength. In 
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general, the temperature sensitivity of a FBG is primarily based on the 
temperature dependence of the refractive index, and to a lesser extent on the 
thermal expansion of the fiber, changing the grating period spacing. The shift ∆λ 
in the reflected Bragg wavelength at a certain temperature shift (∆T) can be 
specified as 
T
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n
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where 
Tδ
δΛ  is the thermal expansion in the material, which is usually            
~5*10-7 °C-1, and 
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δ  is the thermo-optic coefficient of the material, which is 
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indicating that the shift in the Bragg wavelength is in the order of 10 pm per 1 °C 
[31]. Thus, after a temperature calibration the detected shift in the Bragg 
wavelength can be directly converted into temperature values.  
As each FBG is written at a unique wavelength the use of several FBGs in 
wavelength division multiplexing techniques (WDM) is possible [34]. In this 
case, each FBG in series is encoded at a certain section of the input broad-
band spectrum and the specific Bragg wavelength shift of each FBG can be 
interrogated individually. Most WDM interrogators use high power sweeping 
lasers as light source instead of broadband light. The benefits are a longer 
range due to the high power source, a broader wavelength window for a higher 
sensor capacity and the possibility to simultaneously interrogate several fibers 
with several sensors [31].  
2.2.3 System and design variations 
In this study, a sm130 interrogation unit (Micron Optics, Atlanta, GA, USA) with 
a high power sweeping laser in the wavelength range from 1510 to 1590 nm, 
four optical channels, and a scan frequency up to 1kHz (frequency utilized for 
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measurements was 5 Hz) was used. Data management was performed using 
the ENLIGHTPro Sensing Analysis Software (Micron Optics, Atlanta, GA, USA). 
All raw fibers with DTG achieved FBGs were obtained from FBGS Technologies 
GmbH (Jena, Germany) and are able to operate in a temperature range from 
-180 to 200 °C. A single-ended, metal-embedded OFS was obtained from 
Micron Optics. This OFS has been calibrated (temperature range: -200 to 
300 °C, accuracy: ±0.05 °C, repeatability: ± 0.013 °C) against a NIST traceable 
platinum resistance thermometer.  
 
Figure 8-3: Design variations of the optical fiber sensors (OFSs): A) prototype I (OFS I): glass 
fiber is coated with PTFE and the FBG is fixed in center bottom position (right) or above position 
(left), B) comparative placement of conventional thermocouples (TCs) in center bottom position 
(right) and above position (left), C) prototype II (Fix/Flex): the fixed OFS is embedded into a 
metal tube and a sconed OFS is non-coated and thus very flexible, D) prototype III (Helix): glass 
fiber with ten FBGs in series is formed to the shape of a helix inside a metal tube, D) prototype 
IV (OFS IV): glass fiber is fused into the bottom of a 6R vial with the FBG in center bottom 
position, E) prototype V (Plate): glass fiber with ten FBGs in series is embedded into the surface 
of a metal plate.  
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The different design variations of the OFSs used in our study are displayed in 
Figure 8-3. For prototype I (Figure 8-3A), the glass fiber is covered with a 
tubular holder made of PTFE and the FBG is fixed at the lower tip of the loop in 
center bottom position or above position at the lyophilization stopper through 
metal tubes. In this setup five OFSs (4x center bottom position, 1x above 
position) were used in series. The comparative placement of conventional T-
type thermocouples (PVC insulated, epoxy coated tip, 24 AWG, 36” length) (SP 
Scientific, Stone Ridge, NY, USA) is displayed in Figure 8-3B. For prototype II 
(Figure 8-3C), the aforementioned single-ended, metal-embedded OFS was 
combined with a non-coated, highly flexible OFS in order to investigate the 
effect of the flexibility of the sensors on temperature readouts. For prototype III 
(Figure 8-3D), the glass fiber with ten FBGs in series was formed to the shape 
of a helix inside a metal tube in order to allow the measurement of “three-
dimensional” temperature profiles. For prototype IV (Figure 8-3E), the glass 
fiber was fused into the bottom of a 6R vial with the FBG in center bottom 
position in order to allow non-invasive temperature measurements from beneath 
the glass surface of the vial in center bottom position. For prototype V 
(Figure 8-3F), a glass fiber with ten FBGs in series was embedded into a metal 
plate in order to allow non-invasive temperature measurements below the vials 
“at the shelf”. 
2.3 Temperature calibration  
Prototypes I to IV were calibrated in the temperature range from -50 °C to 
+30°C at 10 °C steps by immersion into an ethanol bath. Therefore, ethanol 
was pre-cooled in a -80 °C freezer and transferred into a Dewar vessel. The 
temperature of the stirred ethanol bath was adjusted by adding pre-heated 
ethanol. The wavelength of the reflected signal of each FBG was recorded after 
temperature equilibration for at least 30 min. The NIST calibrated OFS was 
used as temperature reference.  
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Prototype V was calibrated by placing the OFS plate onto the shelf of the 
freeze-drier. In this case, conventional TCs were used as temperature 
reference. The preset temperature calibration of the conventional T-type 
thermocouples was verified at -20°C, 0°C and 20°C using the aforementioned 
ethanol bath. The TCs were in close contact to the FBGs of the glass fiber using 
heat transfer paste. Subsequently, the shelf temperature was varied from -60 °C 
to 40 °C and after temperature equilibration for at least 30 min the wavelength 
of the reflected signal of each FBG was recorded. 
For all OFSs the recorded wavelengths were plotted against the reference 
temperature and a temperature calibration function was obtained by a second 
order polynomial fit (OriginLab 8.0, Northampton, MA, USA). R2 of the 
polynomial fit was always higher than 0.9980.  
 
2.4 Measurement of product temperature profiles during 
lyophilization and freezing experiments 
Several lyophilization cycles (Table 8-1) were performed on a laboratory scale 
freeze-drier (Lyostar II, FTS Systems, Stone Ridge, NY, USA).  
Table 8-1: Lyophilization cycles used for the lyophilization experiments with the various OFS 
design variations. FV: filling volume, ST 1°: shelf temperature during primary drying, CP 1°: 
chamber pressure during primary drying, ST 2°: shelf temperature during secondary drying, CP 
2°: chamber pressure during secondary drying. 
 
Sample OFS FV [ml] ST 1° [°C] CP  1° [mtorr] ST 2° [°C] CP 2° [mtorr] 
10% sucrose I 1 -15 34 20 8 
10% trehalose III 2 -20 100 30 100 
10% trehalose IV 4 -20 100 30 100 
5% mannitol V 4 -15 34 20 8 
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The endpoint of primary drying was determined via manometric endpoint 
determination using a capacitance manometer (MKS BaratronTM Type, MKS 
Instruments, Wilmington, MA, USA) in combination with a Pirani gauge (Mini-
ConvectronTM vacuum gauge, Helix Technology Corp., Mansfield MA, USA). In 
all experiments secondary drying was performed for 8 to 10 hours. In addition to 
the lyophilization experiments several freezing experiments were performed 
(Table 8-2).  
Table 8-2: Freezing and thawing rates used for the freezing experiments with the various OFS 
design variations. FV: filling volume. 
Sample OFS FV [ml] freezing rate [°C/min] thawing rate [°C/min] 
10% sucrose I 1 -2.5  
5% mannitol I 1 -2.5  
20% trehalose I 4 -2.5 2.5 
5% mannitol II 4 -1 1 
 
In all lyophilization and freezing experiments, samples were placed in a 
hexagonal packing on the shelf. Each sample was surrounded by empty vials in 
order to eliminate influence from the surrounding vials on product temperature 
profiles, especially during the freezing experiments. In the experiments using 
prototype V, samples were directly placed on the ten FBGs of the OFS plate 
surrounded by six empty vials which were fixed with tape on the plate in order to 
ensure exact sample positioning.  
2.5 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was used to confirm thermal events. 
30 µl samples were analyzed in 40 µl aluminum crucibles using a Mettler Toledo 
DSC821 (Mettler Toledo GmbH, Giessen, Germany). Samples were cooled 
from 20 °C to -50 °C at -1 °C/min, held at -50 °C for 10 min and reheated at 
10 °C/min to 20 °C 
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3 Results and discussion 
3.1 Product temperature measurements and end point detection  
In order to evaluate the general suitability of the OFSs for product temperature 
measurements and end point detection, temperature profiles of prototype I 
sensors and conventional T-type TCs obtained in center bottom position during 
lyophilization of 1 mL 10% sucrose samples were compared (Figure 8-4). 
Pirani/capacitance manometry was used to additionally determine the endpoint 
of drying.  
 
Figure 8-4: Temperature profiles of 1 mL 10% [m/V] sucrose samples in 2R vials obtained with 
a conventional thermocouple (TC) or the prototype I of the optical fiber sensors (OFS I) during a 
complete freeze-drying cycle with comparative Pirani/capacitance (CM) manometry. 
The temperature profiles observed with the prototype I OFSs and the TCs were 
in very good agreement. It should be noted that the positioning of the 
prototype I OFSs in the center bottom position could be ensured without any 
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problems as the glass fiber is fixed within a tubular holder made of PTFE at the 
lyophilization stopper. In contrast, the positioning of the TCs in center bottom 
position is rather difficult. Despite the fixation of the TC at a bent cannula, the 
center bottom position could not completely be ensured due to the very rigid 
wires necessary for each individual TC. As in general ice sublimation proceeds 
from the top to the bottom and to a lesser extend, from the side to the center of 
the sample [35], slightly distinctive sensor positioning could in general result in 
varying temperature profiles.  
As aforementioned, the endpoint of primary drying is indicated when product 
temperature is in parallel to the shelf temperature. The product temperature 
profiles observed with the prototype I OFS and the TC indicated the same 
endpoint of primary drying. In addition, manometric endpoint determination was 
performed. Here, the endpoint of primary drying is reached when the reading of 
the Pirani gauge converges with the reading of the capacitance manometer [1]. 
The endpoint determined with manometric endpoint detection was in very good 
agreement with the endpoint determined with the OFS. It is well known from 
literature, that a shorter primary drying time might be observed for vials 
containing invasive temperature probes and that thus a safety margin of primary 
drying time of at least 10% of the primary drying time of the vials containing the 
invasive probe is suggested [1].  
3.2 Sensitivity to physico-chemical events during freezing 
In a next step, the sensitivity of the OFSs to detect physico-chemical events 
such as ice nucleation, crystallization or glass formation of excipients during 
freezing was investigated. 
3.2.1 Supercooling and ice nucleation 
When a solution is cooled during the freezing process, it supercools to 
temperatures well below the equilibrium freezing point before ice starts to 
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nucleate and crystallize [36]. When ice nucleation occurs, the product 
temperature rises rapidly to near the equilibrium freezing point. Subsequently 
the temperature decreases at first slowly until most of the water has crystallized 
and then sharply when the product is cooled to the shelf temperature [25, 37]. 
Figure 8-5 displays the temperature profiles that were obtained with TCs or the 
prototype I of the OFSs in center bottom and above position during freezing of 
10% sucrose samples. Both sensor types showed comparable onsets of ice 
nucleation / supercooling of -8.6 °C for the OFS and -7.8 °C for the TC. The 
OFSs showed a significantly higher sensitivity and faster response in center 
bottom position and in above position in comparison to the TCs.  
 
Figure 8-5: Temperature profiles during ice nucleation of 1 mL 10% [m/V] sucrose samples in 
2R vials obtained with a conventional thermocouple (TC) or the prototype I of the optical fiber 
sensors (OFS I) in center bottom (in) and above (ab) position when cooled at a shelf 
temperature ramp rate of -2.5 °C/min. 
In general, ice nucleation is a random and stochastic event [24]. It is well known 
that ice nucleation can be catalyzed by external factors such as the insertion of 
invasive temperature probes [6]. Therefore, vials holding invasive probes show 
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less supercooling and thus can form larger ice crystals which finally results in 
lower product resistance, faster sublimation and shorter drying time compared 
to the rest of the batch [1]. In the semi-clean environment of the laboratory, this 
freezing bias is negligible, but can become relevant in a particulate free, sterile 
manufacturing environment [11]. It is assumed that the minute size and thus 
small effective surface area of the OFSs (diameter of the glass fiber: 195µm) 
compared to conventional TCs (diameter of the TC tip: 2 mm) which is in 
contact with the sample will decrease the probability of heterogeneous 
nucleation in well controlled manufacturing environment.  
The higher sensitivity and faster response of the OFSs can be explained by the 
high sampling frequency (5 Hz) of the optical system that allows the detection of 
very rapid temperature changes with higher resolution. In addition, the low mass 
of the OFS compared to TCs or even RTDs contributes to the higher response 
rate and sensitivity of the optical system. It was observed that the temperature 
measured with the OFS during ice nucleation exceeds the equilibrium freezing 
point by about 4.5 °C. It is assumed that this “overshoot”, which also contributes 
to the high response rate of the OFSs, is caused by additional effects of strain 
on the FBG during ice crystal formation. Further investigations and discussion 
on this assumption can be found below. However, the general higher sensitivity 
and response rate is additionally confirmed by the non-invasive measurements 
in above position, in which strain effects can be excluded. Here, a much faster 
and better resolved response to ice nucleation was observed with the OFSs 
compared to the TCs, as well. 
3.2.2 Crystallization of excipients 
During freezing, cryocentration of the solute constituents of the sample occurs 
in the interstitial region between the growing ice crystals [6]. Some of the 
solutes will crystallize when a certain solute concentration is reached at the 
eutectic melting temperature. For example, mannitol, glycine, and sodium 
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chloride are known to crystallize upon freezing, if present as the major 
component [38]. Mannitol is widely used as bulking agent in freeze-dried 
formulations as it shows good cake-supporting properties [39]. 
The temperature versus time profile of 5% mannitol samples obtained with 
conventional TCs and the prototype I of the OFSs during freezing is shown in 
Figure 8-6. The conventional TC is only able to detect one broad exothermal 
peak when ice nucleation starts. In contrast, the OFS at first detects one sharp 
ice nucleation peak. But subsequently an additional, less distinctive peak is 
detected, that is not observed for pure water samples. Therefore, this peak was 
ascribed to the crystallization of mannitol. This observation again highlights the 
high sensitivity and resolution of the novel optical fiber system.  
 
Figure 8-6: Temperature profiles of 1 mL 5% [m/V] mannitol samples obtained with a 
conventional thermocouple (TC) or the prototype I of the optical fiber sensors (OFS I) in a 2R 
vial when cooled at a shelf temperature ramp rate of -2.5 °C/min.  
Up to now, mannitol crystallization in such a case could only be detected by off-
line analytics such as X-ray powder diffraction [39] or expensive spectroscopic 
on-line monitoring tools such as Raman or NIR spectroscopy [40]. When 
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dealing with lyophilized formulations incomplete mannitol crystallization or semi-
crystalline mannitol is very critical as the recrystallization of mannitol during 
drying can lead to vial breakage [41] or the crystallization of mannitol during 
storage can influence the long-term storage stability of the product [42]. Thus, 
the general ability to monitor the crystallization behavior of samples during 
freezing is highly desirable. 
3.2.3 Glass formation of excipients 
In the case that solutes do not crystallize during freezing, the solute 
concentration increases until at the glass transition temperature (Tg`) a glass 
forms [6, 25]. This freezing behavior is observed for polyhydroxy compounds 
such as sucrose or trehalose, which are often used in freeze-dried formulations 
due to their high potential to stabilize proteins [2]. 
The temperature versus time profile of 4 mL 20% trehalose samples measured 
with conventional TCs and the prototype I of the OFSs during freezing and 
thawing is shown in Figure 8-7. In contrast to the conventional TCs, during 
freezing the OFS after the ice nucleation peak showed an additional small 
exothermal signal in the temperature region of -30 °C (Figure 8-7A). This event 
was noticeably more pronounced during thawing (Figure 8-7B). At lower solid 
contents (10%) and slower freezing and thawing rates only non-significant 
traces of this event, which was attributed to the glass transition or the collapse 
temperature of the sample, could be detected. Using DSC, the onset of the 
glass transition temperature was determined to be at -31.4 °C and the midpoint 
of the glass transition temperature was determined to be at -30.2 °C, which is in 
very good agreement with our observation. 
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Figure 8-7: Temperature profiles of 4 mL 20% [m/V] trehalose samples in 6R vials obtained with 
a conventional thermocouple (TC) or the prototype I of the optical fiber sensors (OFS I) when 
cooled (A) or thawed (B) at a shelf temperature ramp rate of -/+2.5 °C/min. 
The glass transition temperature Tg` is defined as the temperature at which a 
time or frequency dependent reversible change in the physical state of a 
material from an rigid, amorphous solid to a rubber-like, viscous liquid [43]. In 
the region of the glass transition, which represents a temperature range of a few 
degrees, the viscosity of the freeze-concentrate changes about four orders of 
magnitude up to 1014 Pa s [36, 44]. This transition is related with a temperature 
dependent change in the enthalpy or heat capacity of the sample [43]. This 
property, and not an endo- or exo-thermal event as it is e.g. observed for the 
(re-)/crystallization of mannitol, is used in DSC to determine the Tg’ of a sample. 
Thus, the peaks observed in the temperature profile detected with the OFSs 
cannot be attributed to a change in the product temperature but to viscosity 
related strain effects on the unshielded OFSs. The influence of the unshielding 
of the OFSs on temperature readouts will be discussed below. The OFS was 
only sensitive enough to detect the glass transition at high solid contents of the 
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sample. It is also reported for DSC experiments that a higher solute 
concentration of a sample leads to a higher sensitivity of the measurement as 
the ratio of freeze-concentrate phase to ice is then increased [45]. Similarly, a 
larger portion of the freeze-concentrate is assumed to lead to more pronounced 
force effects which are responsible for the response of the OFSs. In addition, 
the observed response of the sensors at only high freezing and thawing rates 
can be correlated to well-known observations in DSC experiments. In the latter, 
high heating rates are used to enhance the sensitivity by increasing the 
magnitude of the shift in the baseline due to the heat capacity change that 
accompanies the glass transition [45]. In accordance, only a fast change in 
temperature and therefore in sample viscosity leads forces which are high 
enough to be detected by the OFS. Moreover, comparable to DSC 
measurements, in which the heating scan is always used for the determination 
of glass transition temperatures, a higher glass transition sensor readout was 
observed during thawing in our vial experiments. As the detection of this event 
with the OFS is presumably related to a fast change in the viscosity of the 
sample, the OFS may also indicate the collapse temperature (Tc) of a sample. 
In literature [46-47] a Tc of trehalose, determined via freeze-drying microscopy, 
of around -34 °C to -28.5 °C is reported with is close tot the Tg` of trehalose and 
would fit to the transition detected with the OFS in the sample.  
In general, the possibility to detect the glass transition of a sample directly in the 
lyophilization vial inside the freeze-drier during freezing would be an enormous 
advantage as the other typical off-line analytical methods like DSC or freeze-
drying microscopy can never simulate the exact same conditions e.g. 
temperature ramp rate and sample volume, as used in the freeze-drier. 
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3.3 Influence of the shielding or unshielding of the OFSs on 
temperature profiles 
As aforementioned, due to non-realistic, shifted temperature readouts during ice 
crystal formation and due to the detectability of non-temperature related events 
such as glass transition, it is assumed that the OFSs do not only respond to 
temperature but also to strain effects. In order to investigate the influence of the 
shielding or unshielding of the OFSs on the detected temperature profiles, the 
temperature profile of a 5% mannitol sample during freezing and annealing was 
measured with a fixed, metal-embedded OFS in combination with a very 
flexible, completely unshielded OFS in comparison to a conventional TC 
(Figure 8-8).  
 
 
 
 
 
 
 
 
 
 
Figure 8-8: Temperature profiles of 4 mL 5% [m/V] mannitol samples in 6R vials obtained with a 
conventional thermocouple (TC) or the prototype II consisting of a fixed (Fix) and a flexible 
(Flex) optical fiber sensor during cooling (A) or during the heating phase of the annealing step 
(B) at a shelf temperature ramp rate of -/+ 1 °C/min. 
Annealing, where by the product temperature is increased to a temperature 
between the Tg` of the amorphous phase and the Teu of the crystalline phase, 
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is performed to allow efficient crystallization of the crystalline bulking agents, 
such as mannitol, in order to minimize inter-vial heterogeneity or to optimize 
drying performance [48]. 
The temperature readouts of the shielded OFS were in good agreement with 
the TC data. In contrast, especially after ice crystal formation, the unshielded 
sensor showed a drift towards lower temperatures (Figure 8-8A). This indicates 
that shielding of the OFSs is necessary to guarantee correct temperature 
readouts. The crystallization peak for mannitol during freezing could be 
detected with both, the shielded and the unshielded OFSs but not with the 
conventional TC. Thus, the general sensitivity of the OFS towards fast 
temperature changes is high enough and a sensitivity to strain by unshielding of 
the OFS is not required for the detection of exothermic events. However, the 
additional event during heating to the annealing temperature, could only be 
detected with the completely unshielded OFS (Figure 8-8B). This event might 
be related to the glass transition of the meta-stable amorphous mannitol phase,  
which is reported to occur at temperatures between -32°C and -27°C depending 
on the heating rate [45]. Thus, for correct temperature readouts shielded OFS 
are required, which additionally allow for the detection of temperature related 
events such as ice formation or mannitol crystallization. However, in order to 
allow for the detection of force and not temperature related changes of the 
sample unshielded sensors are necessary. 
3.4 Three-dimensional information on temperature profiles in a vial 
In order to obtain three-dimensional information on the temperature profiles of a 
sample during lyophilization, an optical fiber system helix with ten OFSs in 
series (H1 to H10) was used to measure the product temperature at different 
positions in a 10% trehalose sample (Figure 8-9).  
During cooling (Figure 8-9A) a temperature gradient in the sample was 
observed, with the lowest temperature at the OFS closest to the vial bottom and 
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the shelf (H1), and the highest temperature at the OFS closest to the sample 
surface (H10). When ice nucleation started, the temperature increased at the 
same time point for all OFS (H1 to H10). This observation can be explained by 
the fact that a critical mass of ice nuclei is required to initiate ice crystal 
formation [44, 49-50], which then occurs very rapid and simultaneously in the 
entire system, resulting in a temperature increase close to the equilibrium 
freezing point [44, 49-50]. Once stable ice crystals are formed in the entire 
system, ice crystal growth proceeds by the addition of water molecules to the 
interface [49]. However, only a small fraction of the freezable water solidifies 
immediately, as the supercooled water can only absorb a small fraction of the 
heat that is given off by the exothermic ice formation [49]. Therefore, after the 
initial ice network has formed, additional heat has to be removed from the 
solution by further cooling in order to promote further ice crystal growth and thus 
complete solidification of the sample. As released heat in the sample due to ice 
crystal formation is faster removed by the colder shelf in positions close to the 
shelf, ice formation finishes quite early close to the vial bottom. This could be 
seen by the lacking of a temperature plateau and by the early decrease of the 
product temperature for the OFS close to the vial bottom (H1). However, for the 
OFS close to the sample surface (H10) a temperature plateau was observed 
before product temperature decreased. This indicates that at higher positions 
within the sample solidification requires more time to fully complete.  
During further cooling the temperature gradient in the sample persists as 
observed prior to ice nucleation, with lower temperatures on the bottom and 
higher temperatures on the top. The general findings, that ice nucleation occurs 
at the same time throughout the entire system and that complete solidification 
proceeds from the bottom to the top of the sample, are in good accordance with 
the freezing behavior observed by visual recording of the samples in the 
lyophilizer during freezing via shelf-ramping [51]. Moreover, the product 
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temperature data obtained with the OFSs during freezing are in excellent 
agreement with the temperature profiles that were obtained for eight different 
vial positions via mathematical simulations by Nakagawa et al. [52]. However, 
this is now the first time that such freezing profiles could be experimentally 
approved with a high number of measurements points.  
 
Figure 8-9: Three-dimensional temperature profile of 2ml 10% trehalose solution in a 2R vial 
obtained with the OFS helix (prototype III) during the freezing step (A) when cooled at a shelf 
temperature ramp rate of -1 °C/min and during the primary drying step (B).  
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During primary drying (Figure 8-9B) the observed temperature gradient was 
opposite to the one during freezing. Now, product temperature is higher close to 
the bottom of the sample and lower close to the top of the sample, as during 
primary drying the shelf, in this case set to -20°C, does not provide cooling of 
the samples but instead heat for ice sublimation. In general, when primary 
drying comes to its end, the product temperature increases first at the top and 
later at the bottom of the sample. This indicates that ice sublimation processes 
in general from the top to the bottom of the sample, which is also described in 
literature [53]. For the OFS closest to the sample surface (H10) the increase in 
product temperature during primary drying already starts after 16 hours with a 
moderate slope. In comparison, the OFS close to the vial bottom (H1) product 
temperature starts to increase quite sharply after 25 hours. But in both cases, 
the plateau at the endpoint of primary drying is reached at the same time (after 
~31 hours). Traditionally, the endpoint of primary drying is defined by the time 
point when product temperature is equivalent or in parallel to the shelf 
temperature and constant over time [15]. However, from our experiment, it is 
obvious that primary drying in the upper parts of the sample is completed earlier 
compared to lower parts of the sample and that thus the traditional definition of 
the endpoint of primary drying holds only true for the section of the sample 
where drying is completed the latest. The time point at which the final plateau in 
product temperature is reached is the same for all sensor points. This effect is 
due to the fact that the energy provided by the shelf is needed for the 
sublimation of the still frozen part of the sample. The energy consequently does 
not reach the upper part of the sample, but the energy loss at the sublimation 
front is high enough to cool the already dry, upper part of the sample. In more 
detail, it was observed that the OFS closest to the sample surface (H10) 
indicated the first increase in product temperature at the end of primary drying. 
However, it was not the OFS closest to the vial bottom (H1) but the OFS almost 
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in the middle of the helix (H4) that showed the latest increase in product 
temperature. These results experimentally support the theory that the ice-vapor 
interface does not follow an “ideal” planar geometry, where drying is finished at 
the vial bottom, but that the ice-vapor interface follows an “actual” curved 
geometry, where drying is finished somewhere in the center of the vial [35]. 
According to Jennings [35], sublimation occurs first from a planar surface. As 
the sublimation process commences, sublimation occurs preferentially with 
respect to the walls of the vial, and the ice is mound-like shaped. The formation 
of the mound is an indication that the rate of sublimation in this region is lower 
than near the vial walls because this region obtained less energy for the 
sublimation process [35]. Near completion of the sublimation process, a small 
mound is formed and located in the center of the vial [35]. This change in the 
configuration of the ice during drying was also supported by Pikal and Shah 
[54]. They suggested that drying is faster along the vial walls than in the core 
region, resulting in a highly curved ice–vapor interface. They proposed that the 
reason for this observation might be a low resistance pathway for vapor escape 
along the vial wall as a result of product shrinkage close to the wall during 
drying.  
When the endpoint of primary drying is reached, the same temperature gradient 
as in the beginning of primary drying is observed, with higher temperatures 
closer to the bottom and lower temperatures closer to the top, because of 
sample heating via the shelf. This small temperature gradient subsequently 
further persisted during secondary drying (data not shown).  
3.5 Non-invasive temperature profiling during lyophilization 
As aforementioned, invasive temperature measurements come with the 
disadvantageous that the obtained data are not fully representative for samples 
that do not contain any temperature probe. Therefore, non-invasive temperature 
measurements were performed using two additional OFS prototypes in order to 
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test whether due to the high sensitivity the OFS could provide adequate 
information on sample temperature or endpoint of primary and secondary 
drying.  
At first, a non-invasive temperature profile during lyophilization of a 10% 
trehalose sample was measured with the prototype IV of the OFSs, for which 
the glass fiber was fused into the bottom of a 6R vial with the FBG in center 
bottom position (Figure 8-10).  
 
Figure 8-10: Temperature profiles of 4 mL 10% [m/V] trehalose samples in 6R vials obtained 
with a conventional thermocouple (TC) or the prototype IV of the optical fiber sensors (OFS IV) 
during a complete freeze-drying cycle with comparative Pirani/capacitance (CM) manometry. 
During the freezing and secondary drying step product temperature behavior of 
the OFS was in very good agreement with TC data. Here, only a small 
temperature gradient was observed between the TC and the OFS 
temperatures. During primary drying the OFS showed a delayed increase in 
product temperature compared to the TC. This is due to the difference in sensor 
positioning, with the TC inside the sample in center bottom position and the 
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OFS fused into the vial bottom. However, the endpoint of primary drying 
(constant product temperature) with the OFS and the TC was observed at the 
same time (~32h) and was additionally in very good agreement with manometric 
endpoint determination. Consequently, this setup does not detect real product 
temperature, as always a temperature gradient between sample and vial bottom 
will be observed. However, Barresi et al. [55-56] showed that the measured 
external temperature at the bottom of the vial is suitable in order to calculate 
parameters such as the sublimating interface temperature, product temperature 
profile, heat and mass transfer coefficients using a mathematical model. But the 
data show that the aforementioned drawbacks that are related to invasive 
temperature probes can be overcome. 
As the setup with the glass fiber on the bottom of the vial does not allow for 
automatic loading, a second non-invasive prototype (V) was designed and 
tested. Here, a glass fiber with ten OFSs in series was embedded into the 
surface of a metal plate. The metal plate was placed underneath the samples 
during lyophilization. Exemplarily, the temperature profile of a 5% mannitol 
sample obtained with this OFS plate in comparison to the profile obtained with a 
TC is displayed in Figure 8-11. 
This optical fiber system prototype rendered temperature profiles which were 
highly adopted to the temperature of the shelf. But still this setup allowed for an 
endpoint detection of primary drying that was in very good agreement with the 
one obtained with the TC or with Pirani/capacitance manometry, and also to 
detect the endpoint of secondary drying reaching the plateau simultaneously 
with the TC. 
In general, such a setup with more than 100 sensor points could be easily 
integrated directly in the surface of each shelf in a freeze-drier, even without the 
prerequisite of a plate between the samples and the shelf.   
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Figure 8-11: Exemplary temperature profiles of one 4 mL 5% [m/V] mannitol samples in 6R vials 
obtained with a conventional thermocouple (TC) or the prototype V of the optical fiber sensors 
(OFS Plate) during a complete freeze-drying cycle with comparative Pirani/capacitance (CM) 
manometry. 
Thus, drying performance and drying heterogeneities of edge vials or other 
outliers with a large number of sample points in a batch could be easily 
monitored without the necessity of any sensor placement. In combination with a 
suitable mathematical model in order to calculate the “real” product temperature 
or other process parameters from the obtained “external” temperature date in 
analogy to Barresi et al. [55-56], this setup could be a highly advantageous PAT 
tool. Moreover, this setup could be easily applied in any laboratory and 
manufacturing scale freeze-drier and therefore used in order to facilitate a 
transfer from laboratory to production scale. In addition, the setup would also 
allow for monitoring of the shelf-temperature (“shelf-mapping”) with and without 
load during lyophilization cycles. 
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4 Conclusion 
In this study, it was the first time that OFSs based on FBGs were used for 
temperature measurements during lyophilization. We could show that data 
obtained with the optical fiber systems were in good comparison to data 
obtained by conventional TCs or Pirani/capacitance manometry. 
The chemically inert and sterilizable OFSs are simple and easy in handling due 
to less cable and the fixation of the sensors in center bottom position. The 
OFSs showed significantly higher sensitivity, faster response and better 
resolution compared to conventional TCs. This allowed for the monitoring of 
further physico-chemical events such as crystallization. It was found that force 
effects were responsible for temperature shifts of the unshielded OFSs. 
However with metal shielding this effect could be eliminated. On the other hand 
the force effects on unshielded sensors enable to detect non-temperature but 
viscosity related events like glass transition, which is not possible with 
conventional TCs.  
By using an OFS helix three-dimensional temperature profiles at ten sensor 
points could be experimentally obtained. This helix setup allowed for the first 
time for the experimental detection of the three-dimensional freezing behavior of 
a sample. Moreover, temperature data obtained with the OFS helix during 
primary drying supported the theory that the ice-vapor interface follows a curved 
geometry, where drying is finished somewhere in the center of the vial.  
Non-invasive temperature measurements showed similar temperature 
characteristics (with a small temperature gradient) to TC data and could be 
used for reasonable endpoint detection without the necessity of any sensor 
placement inside the sample. The integration of a OFS glass fiber with multiple 
sensor points on the surface of a plate or the shelf itself enables automatic 
loading, allows for non-invasive product temperatures of many vials at the same 
time, enables automatic loading and could also be used for “shelf-mapping”.  
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In conclusion, the novel optical fiber systems exhibit several substantial 
advantages compared to other process monitoring tools and thus could be 
developed into highly attractive new PAT tools. 
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Chapter 9 
Summary of the thesis 
The general goal of the thesis was the lyophilization of cationic polymer-based 
nucleic acid nanoparticles. Here, the main focus was set on the development of 
lyophilized, long-term stable pDNA or siRNA polyplex formulations. Moreover, 
the underlying stabilization mechanism of polyplexes during freezing was 
investigated and a novel optical fiber system for advanced monitoring of the 
lyophilization process was evaluated. 
 
In the general introduction the major steps of the lyophilization process and the 
essential components as well as their function in a freeze-drier were 
summarized in brief. Moreover, recent advances and further challenges in 
lyophilization were discussed. Special attention was drawn to the lyophilization 
of nucleic acid based pharmaceuticals. At first, a brief overview on the basic 
concepts of pDNA and siRNA delivery in gene therapy was given. The clinical 
practicability of nucleic acid nanoparticles is limited due to their instability in 
aqueous suspension raising the demand for lyophilized, long-term stable 
formulations. However, at that time, neither pDNA nor siRNA polyplexes have 
been successfully lyophilized without limitations. 
 
In a first step, a micro-mixer method had to be established for the preparation of 
pDNA/LPEI polyplexes in order to guarantee their defined quality. Here, the 
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plasmid and LPEI solutions were mixed at the junction of a T-connector using 
two syringe drivers and the mixing speed was controlled by plunger speed 
and/or syringe size. It was found that the z-average diameter and polydispersity 
index of the polyplexes could be controlled via the mixing speed and were 
influenced by the pDNA concentration. This micro-mixer method could also be 
successfully transferred to up-scale the preparation of defined siRNA/oligo-
aminoamide polyplexes. Hence, the micro-mixer method is a highly valuable 
method for the reproducible preparation of large, standardized batches of 
homogeneous, well-defined, and transfection-competent polyplexes.  
 
For the development of a lyophilized, long-term stable pDNA/LPEI polyplex 
formulation, the initial HBG buffer was changed to the more acidic L-histidine 
buffer in order to improve homogeneity and stability of the polyplexes. In a first 
freeze-thaw study, high concentrations of the commonly used disaccharides, 
sucrose or trehalose, were required to maintain particle size, greatly exceeding 
isotonicity levels and indicating the prerequisite of a critical ratio of stabilizer to 
polyplex (~4000). Here, higher molecular weight excipients, such as 
lactosucrose, hydroxypropylbetadex (HP-β-CD), or povidone (PVP), were 
beneficial for sufficient particle stabilization at low osmotic pressure during 
freezing and drying. Using isotonic formulations with 14% lactosucrose, 10% 
HP-β-CD/6.5% sucrose, or 10% PVP/6.3% sucrose polyplex size was far better 
preserved (< 170 nm) upon lyophilization and storage over 6 weeks up to 40 °C 
compared to previous studies. Only PVP/sucrose samples showed decreased 
transfection efficiency and metabolic activity. Thus, by using lactosucrose or 
CD/sucrose formulations, pDNA/LPEI polyplexes could be the first time 
lyophilized with only a marginal increase in size and preserved biological activity 
at high pharmaceutical quality.  
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Plasmid/LPEI polyplexes are highly sensitive to freezing induced stresses 
unless formulated at a sufficient stabilizer/DNA mass ratio, but underlying 
stabilization mechanisms were still not fully understood. Thus, the effect of 
freezing on the stability of plasmid/LPEI polyplexes was thoroughly investigated 
by the aid of a controlled ice nucleation method. It was found that particle 
stability is not only dependent on the stabilizer/DNA ratio of the formulation but 
also on the freezing process. Ice nucleation temperature only affected particle 
stability at low DNA concentrations. For both, low and high DNA concentrations, 
particle size drastically increased when frozen at decreased shelf-ramp rates. 
Particle stability was markedly affected during the initial part of freezing down to 
temperatures of ~−3 °C. In this temperature range the maximum in bimolecular 
reaction rates was observed as freeze-concentration is highly advanced at still 
low sample viscosities. Below a critical temperature (~≤ −18 °C) no further 
particle aggregation occurred as particle mobility is completely inhibited due to 
high sample viscosities even in the absence of vitrification. The initial 
sucrose/DNA ratio defined the maximum level of bimolecular reaction rates. In 
summary, the time span that the particles spend in the low viscous state after 
ice nucleation, determined by initial sample viscosity and applied freezing rate, 
is the predominant factor in the stabilization of nucleic acid nanoparticles during 
freezing. 
 
In a next step, lyophilized, long-term stable formulations for siRNA/oligoamino-
amide polyplexes based on two different oligomers had to be developed. In 
contrast to pDNA/LPEI polyplexes, siRNA polyplexes maintained particle size 
and gene silencing efficiency in absence or the presence of only low amounts 
(mass ratio of ~700) of stabilizers after freeze-thawing or lyophilization, 
depending on the polymer. Sucrose, trehalose, or lactosucrose exhibited similar 
good stabilizing potential. Only cyclodextrin had a destabilizing effect on siRNA 
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polyplexes. Freeze-thawing experiments using polyplexes based on oligomer 
analogs showed that the presence of cysteines, which internally stabilize 
polyplexes by disulfide formation, was not responsible for the difference in 
colloidal stability of the two siRNA polyplexes. The concentration of the siRNA 
polyplexes could be easily increased by reconstitution of the lyophilisates with 
reduced volume without affecting particle size or gene silencing efficiency. 
Long-term stability of both siRNA polyplexes over 6 months up to 40 °C was 
demonstrated when formulated with 5% or 10% sucrose or 7% lactosucrose. 
Thus, in this thesis, it was the first time that lyophilized stable siRNA polyplex 
formulations were achieved which showed excellent physicochemical and 
transfection stability.  
 
Finally, a further objective of the thesis was the implementation and evaluation 
of an optical fiber system (OFSs) as novel process monitoring tool during 
lyophilization. The OFSs, which allowed easy sensor handling, showed 
significantly higher sensitivity, faster response, and better resolution in 
comparison to conventional thermocouples. This allowed for the monitoring of 
additional physico-chemical events such as crystallization or viscosity related 
glass transition. The detection of the latter event could be ascribed to force 
effects on unshielded sensors. By using an OFS helix, information on three-
dimensional freezing and drying behavior could be gained. Non-invasive 
temperature measurements showed slightly shifted temperature characteristics, 
still appropriate for reasonable endpoint detection. The integration of a glass 
fiber with several OFSs into the surface of a plate or the shelf allows for non-
invasive temperature measurements allowing for automatic loading. These 
advantages turn the novel optical fiber systems into a highly attractive 
monitoring tool during lyophilization.  
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In conclusion, in this thesis it was shown that an up-scaled preparation method 
in combination with subsequent lyophilization is a promising approach to 
reproducibly achieve long-term stable pDNA or siRNA polyplexes maintaining 
particle size and biological activity at pharmaceutically defined high quality. The 
results demonstrated that formulation development, highly dependent on the 
used type of polymer or nucleic acid, and process development in combination 
with appropriate process monitoring needs always to be performed hand in 
hand. All in all, this thesis makes an essential contribution in order to move 
closer from a promising biotechnological approach towards clinic-friendly drugs.
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